Document And Entity Information
Document And Entity Information - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Apr. 16, 2018 | Jun. 30, 2017 | |
Document Information [Line Items] | |||
Entity Registrant Name | AMYRIS, INC. | ||
Entity Central Index Key | 1,365,916 | ||
Trading Symbol | amrs | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Filer Category | Smaller Reporting Company | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Common Stock, Shares Outstanding (in shares) | 49,694,705 | ||
Entity Public Float | $ 50.9 | ||
Document Type | 10-K/A | ||
Document Period End Date | Dec. 31, 2017 | ||
Document Fiscal Year Focus | 2,017 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | true | ||
Amendment Description | This Amendment No. 2 on Form 10-K/A (this "Amendment") amends the Annual Report on Form 10-K of Amyris, Inc. (the "Company") for the fiscal year ended December 31, 2017 (the "Form 10-K"), as filed with the Securities and Exchange Commission (the "SEC") on April 17, 2018 (the "Original Filing Date") and as previously amended by the Amendment No. 1 on Form 10-K/A filed with the SEC on April 18, 2018. This Amendment is being filed solely to correct two discrete administrative errors in the content of the Report of Independent Registered Public Accounting Firm of PricewaterhouseCoopers LLP (the "PwC Report"), the Company's prior independent registered public accounting firm, contained in Part II, Item 8 of the Form 10-K. The PwC Report in the Form 10-K referenced the balance sheet of the Company at December 31, 2016 and December 31, 2015. Although PricewaterhouseCoopers LLP did audit the Company's financial position at December 31, 2015, such balance sheet was not required to be included, and was not included, in the Form 10-K. Accordingly, the PwC Report was amended to remove the extraneous reference. In addition, the PwC Report was updated to reference the reverse stock-split disclosed in Note 1 to the financial statements and the fact that the impact of the reverse stock-split on comparative periods was not audited by PricewaterhouseCoopers LLP. No other changes have been made to the Form 10-K. This Amendment speaks as of the Original Filing Date and does not reflect events that may have occurred subsequent to the Original Filing Date, and, except as expressly set forth herein, does not modify or update in any way the disclosures made in the Form 10-K. Pursuant to Rule 12b-15 promulgated under the Securities Exchange Act of 1934 (the "Exchange Act"), this Amendment sets forth the complete text of Part II, Item 8 of the Form 10-K as amended hereby. Part IV, Item 15 of this Amendment reflects a new consent of PricewaterhouseCoopers LLP as well as new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Section 906 of the Sarbanes-Oxley Act of 2002, each of which is attached hereto. |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Assets | ||
Cash and cash equivalents | $ 57,059 | $ 27,150 |
Restricted cash | 2,994 | 4,326 |
Short-term investments | 1,374 | |
Accounts receivable, net of allowance of $642 and $501, respectively | 33,621 | 13,977 |
Inventories | 5,408 | 6,213 |
Prepaid expenses and other current assets | 5,525 | 6,083 |
Total current assets | 104,607 | 59,123 |
Property, plant and equipment, net | 13,892 | 53,735 |
Unbilled receivable | 7,940 | |
Restricted cash, noncurrent | 959 | 957 |
Recoverable taxes from Brazilian government entities | 1,445 | 13,723 |
Other assets | 22,640 | 2,335 |
Total assets | 151,483 | 129,873 |
Liabilities, Mezzanine Equity and Stockholders' Deficit | ||
Accounts payable | 15,921 | 15,315 |
Accrued and other current liabilities | 29,402 | 30,110 |
Deferred revenue | 4,880 | 5,288 |
Debt, current portion | 36,924 | 25,853 |
Related party debt, current portion | 20,019 | 33,302 |
Total current liabilities | 107,146 | 109,868 |
Long-term debt, net of current portion | 61,893 | 128,744 |
Related party debt, net of current portion | 46,541 | 39,144 |
Derivative liabilities | 119,978 | 6,894 |
Other noncurrent liabilities | 10,632 | 23,731 |
Total liabilities | 346,190 | 308,381 |
Commitments and contingencies (Note 9) | ||
Stockholders’ deficit: | ||
Preferred stock - $0.0001 par value, 5,000,000 shares authorized as of December 31, 2017 and 2016, and 22,171 and 0 shares issued and outstanding as of December 31, 2017 and December 31, 2016, respectively | ||
Common stock - $0.0001 par value, 250,000,000 and 500,000,000 shares authorized as of December 31, 2017 and 2016, respectively; 45,637,433 and 18,273,921 shares issued and outstanding as of December 31, 2017 and December 31, 2016, respectively | 5 | 2 |
Additional paid-in capital - common stock and other | 1,048,274 | 990,895 |
Accumulated other comprehensive loss | (42,156) | (40,904) |
Accumulated deficit | (1,206,767) | (1,134,438) |
Total Amyris, Inc. stockholders’ deficit | (200,644) | (184,445) |
Noncontrolling interest | 937 | 937 |
Total stockholders' deficit | (199,707) | (183,508) |
Total liabilities, mezzanine equity and stockholders' deficit | 151,483 | 129,873 |
Contingently Redeemable Common Stock [Member] | ||
Liabilities, Mezzanine Equity and Stockholders' Deficit | ||
Mezzanine Equity | $ 5,000 | $ 5,000 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - $ / shares | Dec. 31, 2017 | Dec. 31, 2016 |
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares issued (in shares) | 22,171 | 0 |
Preferred stock, shares outstanding (in shares) | 22,171 | 0 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 250,000,000 | 500,000,000 |
Common stock, shares issued (in shares) | 45,637,433 | 18,273,921 |
Common stock, shares outstanding (in shares) | 45,637,433 | 18,273,921 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Revenue | |||
Renewable products (includes related party revenue of $1,291, $1,562 and $865, respectively) | $ 42,370,000 | $ 25,510,000 | $ 14,506,000 |
Licenses and royalties (includes related party revenue of $57,972, $0 and $0, respectively) | 64,477,000 | 15,839,000 | 390,000 |
Grants and collaborations (includes related party revenue of $1,679, $0 and $0, respectively) | 36,598,000 | 25,843,000 | 19,257,000 |
Total revenue | 143,445,000 | 67,192,000 | 34,153,000 |
Cost and operating expenses | |||
Cost of products sold | 62,713,000 | 56,678,000 | 37,374,000 |
Research and development | 56,956,000 | 51,412,000 | 44,636,000 |
Sales, general and administrative | 63,291,000 | 47,721,000 | 56,262,000 |
Impairment of property, plant and equipment | 7,305,000 | 34,166,000 | |
Withholding tax related to conversion of related party notes | 4,723,000 | ||
Impairment of intangible assets | 5,525,000 | ||
Total cost and operating expenses | 182,960,000 | 163,116,000 | 182,686,000 |
Loss from operations | (39,515,000) | (95,924,000) | (148,533,000) |
Other income (expense) | |||
Gain on divestiture | 5,732,000 | ||
Interest expense | (34,032,000) | (37,629,000) | (78,854,000) |
Gain (loss) from change in fair value of derivative instruments | (1,742,000) | 41,355,000 | 16,287,000 |
Loss upon extinguishment of debt | (1,521,000) | (4,146,000) | (1,141,000) |
Other expense, net | (956,000) | (437,000) | (1,159,000) |
Total other expense, net | (32,519,000) | (857,000) | (64,867,000) |
Loss before income taxes and loss from investments in affiliates | (72,034,000) | (96,781,000) | (213,400,000) |
Provision for income taxes | (295,000) | (553,000) | (468,000) |
Net loss before loss from investments in affiliates | (72,329,000) | (97,334,000) | (213,868,000) |
Loss from investments in affiliates | (4,184,000) | ||
Net loss | (72,329,000) | (97,334,000) | (218,052,000) |
Net loss attributable to noncontrolling interest | 100,000 | ||
Net loss attributable to Amyris, Inc. | (72,329,000) | (97,334,000) | (217,952,000) |
Less deemed dividend on capital distribution to related parties | (8,648,000) | ||
Less deemed dividend related to beneficial conversion feature on Series A preferred stock | (562,000) | ||
Less deemed dividend related to beneficial conversion feature on Series B preferred stock | (634,000) | ||
Less deemed dividend related to beneficial conversion feature on Series D preferred stock | (5,757,000) | ||
Less cumulative dividends on Series A and Series B preferred stock | (5,439,000) | ||
Net loss attributable to Amyris, Inc. common stockholders | $ (93,369,000) | $ (97,334,000) | $ (217,952,000) |
Net loss per share attributable to Amyris, Inc. common stockholders: | |||
Basic (in dollars per share) | $ (2.89) | $ (6.12) | $ (26.20) |
Diluted (in dollars per share) | $ (2.89) | $ (6.55) | $ (26.20) |
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock: | |||
Basic (in shares) | 32,253,570 | 15,896,014 | 8,464,106 |
Diluted (in shares) | 32,253,570 | 17,642,965 | 8,464,106 |
Consolidated Statements of Ope5
Consolidated Statements of Operations (Parentheticals) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Renewable products, related party | $ 1,291 | $ 1,562 | $ 865 |
Licenses and royalties, related party | 57,972 | 0 | 0 |
Grants and collaborations, related party | $ 1,679 | $ 0 | $ 0 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Comprehensive loss: | |||
Net loss | $ (72,329) | $ (97,334) | $ (218,052) |
Foreign currency translation adjustment, net of tax | (1,252) | 6,294 | (16,901) |
Total comprehensive loss | (73,581) | (91,040) | (234,953) |
Net loss attributable to noncontrolling interest | 100 | ||
Foreign currency translation adjustment attributable to noncontrolling interest | (320) | ||
Comprehensive loss attributable to Amyris, Inc. | $ (73,581) | $ (91,040) | $ (235,173) |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands | Series A Preferred Stock [Member]Preferred Stock [Member] | Series A Preferred Stock [Member]Common Stock [Member] | Series A Preferred Stock [Member]Preferred Stock Including Additional Paid in Capital [Member] | Series A Preferred Stock [Member]AOCI Attributable to Parent [Member] | Series A Preferred Stock [Member]Retained Earnings [Member] | Series A Preferred Stock [Member]Noncontrolling Interest [Member] | Series A Preferred Stock [Member]Mezzanine Equity, Common Stock [Member] | Series A Preferred Stock [Member]Mezzanine Equity, Preferred Stock [Member] | Series A Preferred Stock [Member] | Series B Preferred Stock [Member]Preferred Stock [Member] | Series B Preferred Stock [Member]Common Stock [Member] | Series B Preferred Stock [Member]Preferred Stock Including Additional Paid in Capital [Member] | Series B Preferred Stock [Member]AOCI Attributable to Parent [Member] | Series B Preferred Stock [Member]Retained Earnings [Member] | Series B Preferred Stock [Member]Noncontrolling Interest [Member] | Series B Preferred Stock [Member]Mezzanine Equity, Common Stock [Member] | Series B Preferred Stock [Member]Mezzanine Equity, Preferred Stock [Member] | Series B Preferred Stock [Member] | Series D Preferred Stock [Member]Preferred Stock [Member] | Series D Preferred Stock [Member]Common Stock [Member] | Series D Preferred Stock [Member]Preferred Stock Including Additional Paid in Capital [Member] | Series D Preferred Stock [Member]AOCI Attributable to Parent [Member] | Series D Preferred Stock [Member]Retained Earnings [Member] | Series D Preferred Stock [Member]Noncontrolling Interest [Member] | Series D Preferred Stock [Member]Mezzanine Equity, Common Stock [Member] | Series D Preferred Stock [Member]Mezzanine Equity, Preferred Stock [Member] | Series D Preferred Stock [Member] | Deemed Dividend on Capital Distribution to Related Parties [Member]Preferred Stock [Member] | Deemed Dividend on Capital Distribution to Related Parties [Member]Common Stock [Member] | Deemed Dividend on Capital Distribution to Related Parties [Member]Preferred Stock Including Additional Paid in Capital [Member] | Deemed Dividend on Capital Distribution to Related Parties [Member]AOCI Attributable to Parent [Member] | Deemed Dividend on Capital Distribution to Related Parties [Member]Retained Earnings [Member] | Deemed Dividend on Capital Distribution to Related Parties [Member]Noncontrolling Interest [Member] | Deemed Dividend on Capital Distribution to Related Parties [Member]Mezzanine Equity, Common Stock [Member] | Deemed Dividend on Capital Distribution to Related Parties [Member]Mezzanine Equity, Preferred Stock [Member] | Deemed Dividend on Capital Distribution to Related Parties [Member] | Preferred Stock [Member] | Common Stock [Member] | Preferred Stock Including Additional Paid in Capital [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] | Noncontrolling Interest [Member] | Mezzanine Equity, Common Stock [Member] | Mezzanine Equity, Preferred Stock [Member] | Total |
Balance (in shares) at Dec. 31, 2014 | 5,281,459 | ||||||||||||||||||||||||||||||||||||||||||||
Balance at Dec. 31, 2014 | $ 1 | $ 724,676 | $ (29,977) | $ (819,152) | $ (611) | $ (125,063) | |||||||||||||||||||||||||||||||||||||||
Issuance of common stock in private placement, net of issuance costs (in shares) | 1,068,377 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock in private placement, net of issuance costs | 24,626 | 24,626 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon conversion of debt (in shares) | 4,146,148 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon conversion of debt | $ 1 | 96,621 | 96,622 | ||||||||||||||||||||||||||||||||||||||||||
Issuance of warrants on conversion of debt | 51,704 | 51,704 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon exercise of warrants (in shares) | 3,158,832 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon exercise of warrants | 19,194 | 19,194 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock from restricted stock settlement (in shares) | 60,592 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock from restricted stock settlement | (333) | (333) | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon ESPP purchase (in shares) | 25,727 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon ESPP purchase | 595 | 595 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon exercise of stock options (in shares) | 884 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon exercise of stock options | 18 | 18 | |||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation | 9,134 | 9,134 | |||||||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment | (17,221) | 320 | (16,901) | ||||||||||||||||||||||||||||||||||||||||||
Net loss | (217,952) | (100) | (218,052) | ||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Dec. 31, 2015 | 13,742,019 | ||||||||||||||||||||||||||||||||||||||||||||
Balance at Dec. 31, 2015 | $ 2 | 926,235 | (47,198) | (1,037,104) | (391) | (158,456) | |||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon conversion of debt (in shares) | 1,048,601 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon conversion of debt | 14,366 | 14,366 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of warrants on conversion of debt | 4,387 | 4,387 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon exercise of warrants (in shares) | 666,667 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon exercise of warrants | 10,435 | 10,435 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock from restricted stock settlement (in shares) | 120,234 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock from restricted stock settlement | (254) | (254) | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon ESPP purchase (in shares) | 22,405 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon ESPP purchase | 180 | 180 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon exercise of stock options (in shares) | 9 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation | 7,325 | 7,325 | |||||||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment | 6,294 | 6,294 | |||||||||||||||||||||||||||||||||||||||||||
Net loss | (97,334) | (97,334) | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock for settlement of debt principal payments (in shares) | 2,381,588 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock for settlement of debt principal payments | 17,414 | 17,414 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of contingently redeemable common stock (in shares) | 292,398 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of contingently redeemable common stock | 5,000 | ||||||||||||||||||||||||||||||||||||||||||||
Contribution upon restructuring of Total Amyris BioSolutions B.V. | 4,252 | 4,252 | |||||||||||||||||||||||||||||||||||||||||||
Acquisitions of noncontrolling interests | (2,508) | 391 | (2,117) | ||||||||||||||||||||||||||||||||||||||||||
Disposal of noncontrolling interest in Aprinnova LLC | 9,063 | 937 | 10,000 | ||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Dec. 31, 2016 | 18,273,921 | ||||||||||||||||||||||||||||||||||||||||||||
Balance at Dec. 31, 2016 | $ 2 | 990,895 | (40,904) | (1,134,438) | 937 | 5,000 | (183,508) | ||||||||||||||||||||||||||||||||||||||
Issuance of common stock in private placement, net of issuance costs (in shares) | 2,826,711 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock in private placement, net of issuance costs | $ 5,476 | $ 1,300 | $ 5,476 | $ 6,197 | $ 6,197 | ||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon conversion of debt (in shares) | 2,257,786 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon conversion of debt | 6,417 | $ 6,417 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon exercise of warrants (in shares) | 3,148,097 | (3,103,278) | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon exercise of warrants | 9,557 | $ 9,557 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock from restricted stock settlement (in shares) | 156,104 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock from restricted stock settlement | (385) | (385) | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon ESPP purchase (in shares) | 47,058 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon ESPP purchase | |||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon exercise of stock options (in shares) | 134 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon exercise of stock options | |||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation | 6,265 | 6,265 | |||||||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment | (1,252) | (1,252) | |||||||||||||||||||||||||||||||||||||||||||
Net loss | (72,329) | (72,329) | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock for settlement of debt principal payments (in shares) | 1,246,165 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock for settlement of debt principal payments | 10,708 | 10,708 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of preferred stock for cash (in shares) | 22,140 | 55,700 | 12,958 | ||||||||||||||||||||||||||||||||||||||||||
Issuance of Series B preferred stock upon conversion of debt, net of issuance costs of $0 (in shares) | 40,204 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of Series B preferred stock upon conversion of debt, net of issuance costs of $0 | 11,530 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock due to rounding from reverse stock split (in shares) | 6,473 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock due to rounding from reverse stock split | |||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock for cash | 5,527 | 5,527 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon conversion of preferred stock (in shares) | (108,831) | 17,274,017 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon conversion of preferred stock | $ 3 | (1) | 2 | ||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock for settlement of debt interest payments (in shares) | 400,967 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock for settlement of debt interest payments | 3,436 | 3,436 | |||||||||||||||||||||||||||||||||||||||||||
Beneficial conversion feature of preferred stock | 562 | 562 | 634 | 634 | 5,757 | 5,757 | |||||||||||||||||||||||||||||||||||||||
Deemed dividend | $ (562) | $ (562) | $ (634) | $ (634) | $ (5,757) | $ (5,757) | $ (8,648) | $ (8,648) | |||||||||||||||||||||||||||||||||||||
Reclassification from mezzanine equity to permanent equity | 12,830 | (12,830) | 12,830 | ||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Dec. 31, 2017 | 22,171 | 45,637,433 | |||||||||||||||||||||||||||||||||||||||||||
Balance at Dec. 31, 2017 | $ 5 | $ 1,048,274 | $ (42,156) | $ (1,206,767) | $ 937 | $ 5,000 | $ (199,707) |
Consolidated Statements of Sto8
Consolidated Statements of Stockholders' Deficit (Parentheticals) - Retained Earnings [Member] | 12 Months Ended |
Dec. 31, 2017USD ($) | |
Series A Preferred Stock [Member] | |
Issuance costs | $ 562,000 |
Series B Preferred Stock [Member] | |
Issuance costs | 562 |
Series D Preferred Stock [Member] | |
Issuance costs | $ 176,000 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Operating activities | |||
Net loss | $ (72,329,000) | $ (97,334,000) | $ (218,052,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Gain on divestiture | (5,732,000) | ||
Depreciation and amortization | 11,358,000 | 11,374,000 | 12,920,000 |
Loss on impairment of property, plant and equipment | 7,305,000 | 34,166,000 | |
Impairment of intangible assets | 5,525,000 | ||
Withholding tax related to conversion of related party notes | 4,723,000 | ||
Loss from investments in affiliates | 4,184,000 | ||
Loss (gain) on disposal of property, plant and equipment | 142,000 | (161,000) | 154,000 |
Stock-based compensation | 6,265,000 | 7,325,000 | 9,134,000 |
Amortization of debt discount | 12,490,000 | 14,445,000 | 58,559,000 |
Loss upon extinguishment of debt | 1,521,000 | 4,146,000 | 1,141,000 |
Receipt of noncash consideration in connection with license revenue | (8,046,000) | ||
Receipt of equity in connection with collaboration arrangements revenue | (2,661,000) | ||
Loss (gain) from change in fair value and extinguishment of derivative instruments | 1,742,000 | (41,355,000) | (16,287,000) |
(Gain) loss on foreign currency exchange rates | (1,230,000) | 557,000 | 1,328,000 |
Other non-cash expenses | 442,000 | (1,741,000) | |
Changes in assets and liabilities: | |||
Accounts receivable | (19,647,000) | (8,959,000) | 4,271,000 |
Inventories | (3,126,000) | 5,686,000 | 4,470,000 |
Prepaid expenses and other assets | (19,336,000) | (4,913,000) | (4,297,000) |
Unbilled receivable | (7,940,000) | ||
Accounts payable | 5,858,000 | 6,442,000 | 4,373,000 |
Accrued and other liabilities | 7,295,000 | 11,919,000 | 10,386,000 |
Deferred revenue | (7,241,000) | 714,000 | (89,000) |
Net cash used in operating activities | (100,617,000) | (82,367,000) | (85,132,000) |
Investing activities | |||
Proceeds from divestiture | 54,827,000 | ||
Purchase of short-term investments | (11,786,000) | (5,559,000) | (2,759,000) |
Maturities of short-term investments | 12,403,000 | 6,187,000 | 2,321,000 |
Sale of short-term investments | 95,000 | ||
Purchases of property, plant and equipment | (4,412,000) | (922,000) | (3,367,000) |
Proceeds on disposal of noncontrolling interest | 10,000,000 | ||
Change in restricted cash | 865,000 | (4,040,000) | 240,000 |
Loan to affiliate | (1,579,000) | ||
Change in restricted stock | (24,000) | ||
Net cash provided by (used in) investing activities | 51,992,000 | 5,642,000 | (5,144,000) |
Financing activities | |||
Proceeds from issuance of common stock in private placements, net of issuance costs | 24,625,000 | ||
Proceeds from debt issued | 18,925,000 | 63,911,000 | 66,931,000 |
Proceeds from debt issued to related parties | 29,699,000 | 10,850,000 | |
Principal payments on debt | (37,500,000) | (9,759,000) | (40,819,000) |
Payment on early redemption of debt | (1,909,000) | ||
Proceeds from issuance of contingently redeemable common stock | 5,000,000 | ||
Proceeds from exercise of warrants | 5,000,000 | 285,000 | |
Proceeds from exercises of common stock options, net of repurchases | 160,000 | 180,000 | 614,000 |
Principal payments on capital leases | (1,579,000) | (729,000) | |
Change in restricted cash related to contingently redeemable common stock | 1,046,000 | ||
Payment of swap termination | (3,113,000) | ||
Employees' taxes paid upon vesting of restricted stock units | (385,000) | (253,000) | (333,000) |
Net cash provided by financing activities | 78,348,000 | 92,199,000 | 61,424,000 |
Effect of exchange rate changes on cash and cash equivalents | 186,000 | (316,000) | (1,203,000) |
Net increase (decrease) in cash and cash equivalents | 29,909,000 | 15,158,000 | (30,055,000) |
Cash and cash equivalents at beginning of period | 27,150,000 | 11,992,000 | 42,047,000 |
Cash and cash equivalents at end of period | 57,059,000 | 27,150,000 | 11,992,000 |
Supplemental disclosures of cash flow information: | |||
Cash paid for interest | 11,539,000 | 9,983,000 | 9,425,000 |
Supplemental disclosures of non-cash investing and financing activities: | |||
Acquisition of property, plant and equipment under accounts payable, accrued liabilities and notes payable | 221,000 | (1,252,000) | (465,000) |
Financing of equipment | 2,136,000 | 613,000 | |
Acquisition of noncontrolling interest in Glycotech via debt | 3,906,000 | ||
Financing of insurance premium under note payable | (467,000) | (123,000) | 53,000 |
Issuance of debt in exchange for prepaid royalties | 6,847,000 | ||
Issuance of note payable in exchange for debt extinguishment with third party | 16,954,000 | ||
Settlement of debt principal by a related party | (25,000,000) | ||
Issuance of common stock for settlement of debt principal and interest payments | 3,436,000 | 17,410,000 | |
Issuance of convertible preferred stock upon conversion of debt | 40,204,000 | ||
Issuance of common stock upon conversion of debt | 28,702,000 | 14,364,000 | |
Receipt of antidilution warrants | 9,549,000 | ||
Deemed dividend on capital distribution to related parties | 8,648,000 | ||
Accrued interest added to debt principal | 2,816,000 | 3,147,000 | 6,354,000 |
Revenue recognized from noncash consideration received | 2,661,000 | ||
Cancellation of debt and accrued interest on disposal of interest in affiliate | 4,252,000 | ||
May 2017 Offerings [Member] | |||
Financing activities | |||
Proceeds from sale of convertible, net of issuance costs | 50,411,000 | ||
August 2017, Vivo Offering [Member] | |||
Financing activities | |||
Proceeds from sale of convertible, net of issuance costs | 24,768,000 | ||
August 2017 DSM Offering [Member] | |||
Financing activities | |||
Proceeds from sale of convertible, net of issuance costs | $ 25,945,000 |
Note 1 - Basis of Presentation
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 1. Business Description Amyris, Inc. (Amyris or the Company) is a leading industrial biotechnology company that applies its technology platform to engineer, manufacture and sell high performance, natural, sustainably sourced products into the Health & Wellness, Clean Skincare, and Flavors & Fragrances markets. The Company's proven technology platform enables the Company to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. The Company's biotechnology platform and industrial fermentation process replace existing complex and expensive manufacturing processes. The Company has successfully used its technology to develop and produce five The Company believes that industrial synthetic biology represents a third On December 28, 2017, 1 $33.0 $12.6 $56.9 $5.7 Concurrent with the sale of Amyris Brasil, the Company and DSM entered into a series of commercial agreements including (i) a license agreement to DSM of its farnesene product for DSM to use in the Vitamin E, lubricant, and flavor and fragrance markets; (ii) a value share agreement that DSM will pay the Company specified royalties representing a portion of the profit on the sale of Vitamin E produced from farnesene under the Nenter Supply Agreement assigned to DSM; (iii) a performance agreement for the Company to perform research and development to optimize farnesene for production and sale of farnesene products; and (iv) a transition services agreement for the Company to provide finance, legal, logistics, and human resource services to support the Brotas 1 six six $27.5 $15.0 2018 2019. $17.8 10, $25.0 4, Liquidity The Company has incurred significant operating losses since its inception and expects to continue to incur losses and negative cash flows from operations for at least the next 12 December 31, 2017, $59.6 $77.9 December 31, 2016 $1.2 As of December 31, 2017, $30.4 $165.4 $56.9 $21.8 April 17, 2019 $129.3 $12.9 Cash and cash equivalents of $57.1 December 31, 2017 April 12, 2018 ( 18 not March 31, 2019. one not 2018 December 31, 2017, first 2018, 2 may may not Basis of Consolidation The accompanying consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States (U.S. GAAP). The consolidated financial statements include the accounts of Amyris, Inc. and its wholly-owned and partially-owned subsidiaries in which the Company has a controlling interest after elimination of all significant intercompany accounts and transactions. Investments and joint venture arrangements are assessed to determine whether the terms provide economic or other control over the entity requiring consolidation of the entity. Entities controlled by means other than a majority voting interest are referred to as variable-interest entities (VIEs) and are consolidated when Amyris has both the power to direct the activities of the VIE that most significantly impact its economic performance and the obligation to absorb losses or the right to receive benefits that could potentially be significant to the entity. For any investment or joint venture in which (i) the Company does not not not not Sale of Subsidiary and Entry into Commercial Agreements On December 28, 2017, 1 $5.7 not not $29.7 not 2 10, 11, 13, Use of Estimates and Judgements The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may Reverse Stock Split On June 5, 2017, 1 15 $0.0001 500,000,000 250,000,000. first first may The par value, number of shares outstanding and number of authorized shares of preferred stock were not Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation in the Company’s consolidated financial statements and the accompanying notes to the consolidated financial statements. The consolidated statements of operations previously presented license fee revenue in combination with grants and collaborations revenue, and royalties (formerly referred to as “value share”) were previously presented in combination with renewable products revenue. Licenses and royalties revenue is presented as a separate line within the consolidated statements of operations. The reclassifications reflect the growth in the Company’s business model to license its technology and earn royalties from customers utilizing the Company’s technology in the products it produces and sells. The reclassifications had no Significant Accounting Policies Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original or remaining maturity of three Inventories Inventories, which consist of farnesene-derived products and flavors and fragrances ingredients, are stated at the lower of cost or net realizable value and are categorized as finished goods, work in process or raw material inventories. The Company evaluates the recoverability of its inventories based on assumptions about expected demand and net realizable value. If the Company determines that the cost of inventories exceeds their estimated net realizable value, the Company records a write-down equal to the difference between the cost of inventories and the estimated net realizable value. If actual net realizable values are less favorable than those projected by management, additional inventory write-downs may may first first Property, Plant and Equipment, Net Property and equipment are recorded at cost. Depreciation and amortization are computed straight-line based on the estimated useful lives of the related assets, ranging from 3 15 15 The Company expenses costs for maintenance and repairs and capitalizes major replacements, renewals and betterments. For assets retired or otherwise disposed, both cost and accumulated depreciation are eliminated from the asset and accumulated depreciation accounts, and gains or losses related to the disposal are recorded in the statement of operations for the period. Impairment of Long-Lived Assets Long-lived assets that are held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not Recoverable Taxes from Brazilian Government Entities Recoverable taxes from Brazilian government entities represent value-added taxes paid on purchases in Brazil, which are reclaimable from the Brazilian tax authorities, net of reserves for amounts estimated not Fair Value Measurements The Company measures certain financial assets and liabilities at fair value based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. Where available, fair value is based on or derived from observable market prices or other observable inputs. Where observable prices or inputs are not The carrying amounts of certain financial instruments, such as cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The fair values of loans payable, convertible notes and credit facilities are based on the present value of expected future cash flows and assumptions about current interest rates and the creditworthiness of the Company. The loans payable, convertible notes and credit facilities are carried on the consolidated balance sheet on a historical cost basis, because the Company has not July 29, 2015; 4, Changes in the inputs into these valuation models have a significant impact on the estimated fair value of the embedded and freestanding derivatives. For example, a decrease (increase) in the estimated credit spread for the Company results in an increase (decrease) in the estimated fair value of the embedded derivatives. Conversely, a decrease (increase) in the stock price results in a decrease (increase) in the estimated fair value of the embedded derivatives. The changes during 2017, 2016 2015 Derivatives The Company has made limited use of derivative instruments, including cross-currency interest rate swap agreements, to manage the Company's exposure to foreign currency exchange rate fluctuations and interest rate fluctuations related to the Company's Banco Pine S.A. loan, which the Company repaid in full in December 2017; 4, December 31, 2017, Embedded derivatives that are required to be bifurcated from the underlying debt instrument (i.e., host) are accounted for and valued as separate financial instruments. The Company evaluated the terms and features of its convertible notes payable and convertible preferred stock and identified compound embedded derivatives requiring bifurcation and accounting at fair value because the economic and contractual characteristics of the embedded derivatives met the criteria for bifurcation and separate accounting due to the instruments containing conversion options, “make-whole interest” provisions, down round conversion price adjustment provisions and conversion rate adjustments. Cash and anti-dilution warrants issued in conjunction with the convertible debt and equity financings are freestanding financial instruments which are also classified as derivative liabilities. Noncontrolling Interest Noncontrolling interests represent the portion of the Company's net income (loss), net assets and comprehensive income (loss) that is not Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and accounts receivable. The Company places its cash equivalents and investments (primarily certificates of deposits) with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one may not The Company performs ongoing credit evaluation of its customers, does not Customers representing 10% As of December 31, 2017 2016 Customer A (related party) 38 % * Customer B 10 % 33 % Customer C ** 22 % Customer E 15 % ** ______________ ** Less than 10% Customers representing 10% Years Ended December 31, 2017 2016 2015 Customer A (related party) 42 % * * Customer B 12 % 27 % 37 % Customer C 10 % ** * Customer D ** 22 % * Customer E ** 14 % ** Customer G ** ** 10 % ______________ * Not ** Less than 10% Revenue Recognition The Company recognizes revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants and collaborative research and development services. Revenue is recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable, and collectability is reasonably assured. If sales arrangements contain multiple elements, the Company evaluates whether the components of each arrangement represent separate units of accounting. Renewable Product Sales The Company’s renewable product sales do not not two March 31, 2012, not Licenses and Royalties License fees for intellectual property transferred to other parties, representing non-refundable payments received at the time of signature of license agreements, are recognized as revenue upon signature of the license agreements when the Company has no Royalties from intellectual property licenses that allow Amyris's customers to use the Company’s intellectual property to produce and sell their products in which the Company shares in the profits are recognized in the period the royalty report is received. Grants and Collaborative Research and Development Services Revenues from collaborative research and development services are recognized as the services are performed consistent with the performance requirements of the contract. In cases where the planned levels of research and development services fluctuate over the research term, the Company recognizes revenues using the proportional performance method based upon actual efforts to date relative to the amount of expected effort to be incurred by us. When up-front payments are received and the planned levels of research and development services do not Grants are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. Revenues from grants are recognized in the period during which the related costs are incurred, provided that the conditions under which the grants were provided have been met and only perfunctory obligations are outstanding. Cost of Products Sold Cost of products sold includes the production costs of renewable products, which include the cost of raw materials, amounts paid to contract manufacturers and period costs including inventory write-downs resulting from applying lower of cost or net realizable value inventory adjustments. Cost of products sold also includes certain costs related to the scale-up of production. Shipping and handling costs charged to customers are recorded as revenues. Outbound shipping costs incurred are included in cost of products sold. Such charges were not Research and Development Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements and government grants, including internal research. Research and development costs consist of direct and indirect internal costs related to specific projects, as well as fees paid to others that conduct certain research activities on the Company’s behalf. Debt Extinguishment The Company accounts for the income or loss from extinguishment of debt in accordance with ASC 470, Debt, Stock-based Compensation The Company accounts for stock-based employee compensation plans under the fair value recognition and measurement provisions of U.S. GAAP. Those provisions require all stock-based payments to employees, including grants of stock options and restricted stock units (RSUs), to be measured using the grant-date fair value of each award. The Company recognizes stock-based compensation expense net of expected forfeitures over each award's requisite service period, which is generally the vesting term. Expected forfeiture rates are based on the Company's historical experience. Stock-based compensation plans are described more fully in Note 12, Income Taxes The Company is subject to income taxes in the United States and foreign jurisdictions and uses estimates to determine its provisions for income taxes. The Company uses the asset and liability method of accounting for income taxes, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect for the year in which the differences are expected to affect taxable income. Recognition of deferred tax assets is appropriate when realization of such assets is more likely than not. not The Company applies the provisions of Financial Accounting Standards Board (FASB) guidance on accounting for uncertainty in income taxes. The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability, and the tax benefit to be recognized is measured at the largest amount of benefit that is greater than 50 may Foreign Currency Translation The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at each balance sheet date, and revenue and expense amounts are translated at average rates during each period, with resulting foreign currency translation adjustments recorded in other comprehensive loss, net of tax, in the consolidated statements of stockholders’ deficit. As of December 31, 2017 2016, $42.2 $40.9 Where the U.S. dollar is the functional currency, remeasurement adjustments are recorded in other income (expense), net in the accompanying consolidated statements of operations. Net losses resulting from foreign exchange transactions were $0.4 $0.6 $1.3 December 31, 2017, 2016, 2015, Recently Adopted Accounting Standards During the year ended December 31, 2017 • ASU 2015 11, Inventory (Topic 330 2015 11, • ASU 2016 06 , Derivatives and Hedging (Topic 815 not one January 1, 2017, • ASU 2016 09, Compensation–Stock Compensation (Topic 718 2016 09 $40.1 None Recently Issued Accounting Standards Not Revenue Recognition In May 2014, No. 2014 09, Revenue from Contracts with Customers 2014 09 first 2018. 2014 09 March 2016, April 2016, May 2016 December 2016 2016 08, Revenue from Contracts with Customers: Principal versus Agent Considerations 2016 10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing 2016 12, Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients 2016 20, Technical Corrections and Improvements to Topic 606, The Company is adopting these standards using the modified retrospective approach applied only to contracts that are not January 1, 2018. January 1, 2018. January 1, 2018 $1.0 $2.0 first 2018. Financial Instruments In January 2016, 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01 not 2016 01 January 1, 2018, 2016 01 2016 01, In February 2018, 2018 03, Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities 2018 03 no 2018 03 not 2018 03 December 15, 2017, June 15, 2018, may 2016 01. The Company will be adopting ASU 2016 01 2018 03 January 1, 2018. not Leases In February 2016, 2016 02, Leases (Topic 842 first 2019 Classification of Cash Flow Elements In August 2016, 2016 15, 230 Classification of Certain Cash Receipts and Cash Payments zero 2016 15 January 1, 2018 Income Tax Consequences of Intra-Entity Transfers of Assets Other Than Inventory In October 2016, 2016 16, Income Taxes (Topic 740 January 1, 2018, not December 31, 2017, 2016 16 Restricted Cash in Statement of Cash Flows In November 2016, 2016 18, 230 Restricted Cash one no one 2016 18 January 1, 2018 not Derecognition of Nonfinancial Assets In February 2017, 2017 05, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610 20 606 not 1 not not not 2 not first 2018 Financial Instruments with "Down Round" Features In July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 no first 2019 |
Note 2 - Balance Sheet Details
Note 2 - Balance Sheet Details | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Supplemental Balance Sheet Disclosures [Text Block] | 2. Accounts Receivable, Net December 31, 2017 2016 Accounts receivable $ 19,572 $ 13,673 Related party accounts receivable 14,691 805 34,263 14,478 Less: allowance for doubtful accounts (642 ) (501 ) Total accounts receivable, net $ 33,621 $ 13,977 Inventories December 31, 2017 2016 Raw materials $ 819 $ 3,159 Work in process 364 1,848 Finished goods 4,225 1,206 Total inventories $ 5,408 $ 6,213 Property, Plant and Equipment, net December 31, (In thousands) 2017 2016 Machinery and equipment $ 49,277 $ 82,688 Leasehold improvements 40,036 38,785 Computers and software 9,555 9,585 Buildings — 4,699 Furniture and office equipment, vehicles and land 3,415 2,957 Construction in progress 17,438 2,216 119,721 140,930 Less: accumulated depreciation and amortization (105,829 ) (87,195 ) Total property, plant and equipment, net $ 13,892 $ 53,735 Property, plant and equipment, net includes $4.2 $3.1 December 31, 2017 2016, $1.6 $0.6 December 31, 2017 2016, Depreciation and amortization expense, including amortization of assets under capital leases, was $11.4 $11.4 $12.9 December 31, 2017, 2016 2015, Losses (gains) on disposal of property, plant and equipment were $0.1 0.2 $0.2 December 31, 2017, 2016 2015, In December 2017, 13, In 2016, $7.3 Other Assets December 31, 2017 2016 Contingent consideration $ 8,151 $ — Prepaid royalty 7,409 — Cost-method investment in SweeGen 3,233 — Deposits 2,462 409 Goodwill 560 560 Other 825 1,366 Total other assets $ 22,640 $ 2,335 Accrued and Other Current Liabilities December 31, 2017 2016 Accrued interest $ 8,213 $ 4,847 Payroll and related expenses 7,238 6,344 Tax-related liabilities 5,837 2,610 SMA relocation accrual 3,587 3,641 Other 2,633 5,792 Professional services 1,894 6,876 Total accrued and other current liabilities $ 29,402 $ 30,110 Other Noncurrent Liabilities December 31, 2017 2016 Deferred rent, net of current portion $ 7,818 $ 8,906 Deferred revenue, net of current portion 383 6,650 Capital lease obligation, net of current portion 217 334 Accrued interest, net of current portion — 5,542 Other liabilities 2,214 2,299 Total other noncurrent liabilities $ 10,632 $ 23,731 |
Note 3 - Fair Value Measurement
Note 3 - Fair Value Measurement | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Financial Instruments Disclosure [Text Block] | 3. Assets and liabilities are measured and reported at fair value per related accounting standards that define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. An asset's or liability's level is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are valued and disclosed in one three • 1: • 2: • 3: not As of December 31, 2017 2016, December 31, 2017 2016 Level Level Level Total Level Level Level Total Assets Money market funds $ 53,199 $ — $ — $ 53,199 $ 1,549 $ — $ — $ 1,549 Certificates of deposit 7,813 — — 7,813 1,373 — — 1,373 Total assets measured and recorded at fair value $ 61,012 $ — $ — $ 61,012 $ 2,922 $ — $ — $ 2,922 Liabilities Embedded derivatives in connection with issuance of debt and equity instruments $ — $ — $ 4,203 $ 4,203 $ — $ — $ 2,283 $ 2,283 Freestanding derivative instruments in connection with issuance of equity instruments — — $ 115,775 $ 115,775 — — 1,852 1,852 Cross-currency interest rate swap derivative liability (1) — — — — 3,343 — 3,343 Total liabilities measured and recorded at fair value $ — $ — $ 119,978 $ 119,978 $ — $ 3,343 $ 4,135 $ 7,478 ______________ ( 1 The balance of the cross-currency interest rate swap derivative liability at December 31, 2017 December 2017 There were no 2017 2016. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgements and consider factors specific to the asset or liability. The fair values of money market funds and certificates of deposit are based on fair values of identical assets. The fair values of the loans payable, convertible notes, credit facilities and cross-currency interest rate swap are based on the present value of expected future cash flows and assumptions about current interest rates and the creditworthiness of the Company. The method of determining the fair value of the compound embedded derivative liabilities is described subsequently in this note. Market risk associated with the fixed and variable rate long-term loans payable, credit facilities and convertible notes relates to the potential reduction in fair value and negative impact to future earnings, from an increase in interest rates. Market risk associated with the compound embedded derivative liabilities relates to the potential reduction in fair value and negative impact to future earnings from a decrease in interest rates. At December 31, 2017 December 31, 2016, Derivative Instruments The following table provides a reconciliation of the beginning and ending liability balances associated with both freestanding and compound embedded derivatives measured at fair value using significant unobservable inputs (Level 3 (in thousands) 2017 2016 Balance at January 1 $ 4,135 $ 46,430 Additions 130,957 2,050 (Gain) loss from change in fair value of derivative liabilities 31,600 (41,459 ) Derecognition upon conversion or extinguishment (46,714 ) (2,886 ) Balance at December 31 $ 119,978 $ 4,135 The liabilities associated with freestanding and compound embedded derivatives represent the fair value of the equity conversion options, make-whole provisions, down round conversion price or conversion rate adjustment provisions and antidilution provisions in some of the Company's debt, preferred stock, cash warrants and antidilution warrants; see Note 4, 6, no A Monte Carlo simulation valuation model combines expected cash outflows with market-based assumptions regarding risk-adjusted yields, stock price volatility, probability of a change of control and the trading information of the Company's common stock into which the notes are or may two one A lattice model was used to determine if a convertible note or share of convertible preferred stock would be converted, called or held at each decision point. Within the lattice model, the following assumptions are made: (i) the convertible note or share of convertible preferred stock will be converted early if the conversion value is greater than the holding value and (ii) the convertible note or share of convertible preferred stock will be called if the holding value is greater than both (a) redemption price and (b) the conversion value at the time. If the convertible note or share of convertible preferred stock is called, the holder will maximize their value by finding the optimal decision between ( 1 2 not The market-based assumptions and estimates used in valuing the compound embedded and freestanding derivative liabilities include amounts in the following ranges/amounts: December 31, 2017 2016 Risk-free interest rate 1.68% - 2.40% 0.55% - 1.31% Risk-adjusted yields 18.40% - 28.53% 12.80% - 22.93% Stock price volatility 45% - 80% 45% Probability of change in control 5% 5% Stock price $3.75 $10.95 Credit spread 16.63% - 26.70% 11.59% - 21.64% Estimated conversion dates 2018 - 2025 2017 - 2019 Changes in valuation assumptions can have a significant impact on the valuation of the embedded and freestanding derivative liabilities. For example, all other things being equal, a decrease/increase in the Company’s stock price, probability of change of control, credit spread, term to maturity/conversion or stock price volatility decreases/increases the valuation of the liabilities, whereas a decrease/increase in risk adjusted yields or risk-free interest rates increases/decreases the valuation of the liabilities. Certain of the convertible notes and shares of convertible preferred stock also include conversion price adjustment features and, for example, certain issuances of common stock by the Company at prices lower than the current conversion price result in a reduction of the conversion price of such notes or convertible preferred stock, which increases the value of the embedded and freestanding derivative liabilities; see Note 4, In June 2012, R$22.0 $6.6 December 31, 2017 4, 3.94%. December 31, 2017, On July 29, 2015, "August 2013 4, $70 4, may not 815 40 15 Initial recognition Expected dividend yield — % Risk-free interest rate 2 % Expected term (in years) 10.0 Expected volatility 74 % The Company recognized a derivative liability for the Temasek Funding Warrant of $19.4 July 29, 2015. December 15, 2015, $0.1 $18.9 12.7 February May 2016, 4, 164,169 May 2017 August 2017 ( 6, 4, 1,125,755 600,062 The May 2017 August 2017 August 2017 6, May 2017 May 2017 August 2017 August 2017 $123.0 December 31, 2017 $120.0 $1.1 2017 6, Derivative instruments measured at fair value on a recurring basis as of December 31, 2017 2016, December 31, 2017 2016 Swap obligation, at fair market value: Current portion $ — $ 584 Noncurrent portion — 2,759 Total swap obligation — 3,343 Freestanding or compound embedded derivative liabilities, at fair value 119,978 4,135 Total derivative liabilities $ 119,978 $ 7,478 Assets and Liabilities Recorded at Carrying Value Financial Assets and Liabilities The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Loans payable, credit facilities and convertible notes are recorded at carrying value, which is representative of fair value at the date of acquisition. The Company estimates the fair value of loans payable and credit facilities using observable market-based inputs (Level 2 3 December 31, 2017 $165.4 December 31, 2017 $156.9 27%. Cost-method Investment In April 2017, 850,115 December 2016. $3.2 40%. |
Note 4 - Debt
Note 4 - Debt | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 4. December 31, 2017 2016 Principal Unamortized Debt (Discount) Premium Net Principal Unamortized Debt (Discount) Premium Net Convertible notes payable 2015 Rule 144A convertible notes $ 37,887 $ (6,872 ) $ 31,015 $ 40,478 $ (17,712 ) $ 22,766 2014 Rule 144A convertible notes 24,004 (3,170 ) 20,834 27,404 (5,399 ) 22,005 December 2016, April 2017, June 2017 and December 2017 convertible notes 5,000 (25 ) 4,975 10,000 (78 ) 9,922 August 2013 financing convertible notes 4,009 (2,918 ) 1,091 13,826 (4,579 ) 9,247 Fidelity notes — — — 15,309 (326 ) 14,983 70,900 (12,985 ) 57,915 107,017 (28,094 ) 78,923 Related party convertible notes payable August 2013 financing convertible notes 21,711 897 22,608 19,781 2,033 21,814 2014 Rule 144A convertible notes 24,705 (3,784 ) 20,921 24,705 (7,380 ) 17,325 R&D note 3,700 (18 ) 3,682 3,700 (80 ) 3,620 50,116 (2,905 ) 47,211 48,186 (5,427 ) 42,759 Loans payable and credit facilities Senior secured loan facility 28,566 (253 ) 28,313 28,566 (908 ) 27,658 Ginkgo notes 12,000 (4,983 ) 7,017 8,500 — 8,500 Nossa Caixa and Banco Pine notes — — — 11,135 — 11,135 Other loans payable 6,463 (1,277 ) 5,186 8,305 (1,361 ) 6,944 Guanfu credit facility — — — 25,000 (5,436 ) 19,564 Other credit facilities 381 — 381 1,869 — 1,869 47,410 (6,513 ) 40,897 83,375 (7,705 ) 75,670 Related party loans payable DSM note 25,000 (8,039 ) 16,961 — — — February 2016 private placement 2,000 — 2,000 20,000 (1,309 ) 18,691 Other DSM loan 393 — 393 — — — June and October 2016 private placements — — — 11,000 — 11,000 27,393 (8,039 ) 19,354 31,000 (1,309 ) 29,691 Total debt $ 195,819 $ (30,442 ) 165,377 $ 269,578 $ (42,535 ) 227,043 Less: current portion (56,943 ) (59,155 ) Long-term debt, net of current portion $ 108,434 $ 167,888 Future minimum payments under the debt agreements as of December 31, 2017 Years Ending December 31, Convertible Related Loans Related Total 2018 $ 11,060 $ 20,835 $ 36,465 $ 5,423 $ 73,783 2019 69,334 35,238 1,704 2,500 108,776 2020 — — 1,627 2,500 4,127 2021 — — 1,627 27,500 29,127 2022 — — 13,417 — 13,417 Thereafter — — 2,528 — 2,528 Total future minimum payments (1) 80,394 56,073 57,368 37,923 231,758 Less: amount representing interest (2) (22,479 ) (8,862 ) (16,471 ) (18,569 ) (66,381 ) Present value of minimum debt payments 57,915 47,211 40,897 19,354 165,377 Less: current portion (4,932 ) (17,626 ) (31,992 ) (2,393 ) (56,943 ) Noncurrent portion of debt $ 52,983 $ 29,585 $ 8,905 $ 16,961 $ 108,434 ______________ ( 1 Including $5.8 2018 $5 may $25.0 2018 2019 no ( 2 Including net debt discount of $30.4 Convertible Notes Payable 2015 144A In October 2015, $57.6 9.50% 2019 2015 144A $54.4 $18.3 $22.9 2014 144A 2015 144A 9.50% April 15 October 15 2015 144A 92.5% April 15, 2016 2017 October 15, 2016 2017 2015 144A April 15, 2019 The 2015 144A 58.2076 $1,000 2015 144A $17.18 December 31, 2017. 2015 144A April 15, 2019, 0.75%. may 92.5% December 31, 2017, In January 2017, $19.1 2015 144A 2015 144A $15.3 2015 144A 2015 144A 3,652,935 2015 144A $0.1 December 31, 2017. In May 2017, $3.7 2015 144A 17.38% 6, $2.0 December 31, 2017. 2014 144A In May 2014, $75.0 6.50% 2019 2014 144A $72.0 $9.7 2014 144A $24.7 2014 144A 2014 144A 6.5%, May 15 November 15 2014 144A May 15, 2019, The 2014 144A 17.8073 $1,000 2014 144A $56.16 December 31, 2017. 2014 144A In May 2017, $3.4 2014 144A 17.38% 6, $1.8 December 31, 2017. Maturity Treatment Agreement In July 2015, 2015 $71.0 $70.0 $34.50 2015 2015 July 29, 2015, 2014 144A not 2015 not May 2017, 2014 144A $9.7 December 31, 2017 $10.0 December 31, 2017 no December 31, 2017, not $21.8 2015 $200 50% $125 30% $5 not December 2016, April 2017, June 2017 December 2017 In December 2016, December 2016 $10.0 December 2016 $9.9 December 2016 May 2017, no In April 2017, April 2017 $15.0 April 2017 April 2017, April 2017 $7.0 $6.9 May 2017, $1.4 December 31, 2017. In May 2017, April 2017 December 2016 December 2016 April 2017 April 2017 may 20% 70% No May 2017. In June 2017, April 2017 $3.0 $3.0 August 2017, $0.5 In December 2017, April 2017 April 2017 $5.0 $5 $5.0 April 2017 December 2016 June 1, 2018 $5 $5 April 2017 $5 118% $5 not 50% $200,000. $5 118% $5 $28.50 December 31, 2017 $5 $5 4.99% not 9.99%, not 61 $5 3,645,118 $5 $5 may not April 2017 $5 $5 may December 31, 2017, $5.0 August 2013 In August 2013, August 2013 $73.0 August 2013 August 2013 August 2013 two sixty October 16, 2018). 5% six December 31, 2017, may six The Tranche II Notes are due sixty January 15, 2019). 10% December 31, 2017, The conversion price of the Tranche Notes is $5.2977 December 31, 2017 August 2013 $200 50% $125 30% one $20.0 may Fidelity Notes In 2012, $25.0 March 1, 2017 3.0% $106.02 October 2015, $57.6 2015 144A $8.8 $9.7 January 2017, $19.1 2015 144A $15.3 1:1.25 $1.00 $1.25 2015 144A not $0.1 December 31, 2017. Related Party Convertible Notes Payable August 2013 Certain of the August 2013 11, 2014 144A Certain of the 2014 144A 11, R&D Note In March 2016, $3.7 $105.0 2012. February 2017, March 1, 2017 May 15, 2017. May 2017, May 15, 2017 March 31, 2018, ( 1.5% 12.0%, May 16, 2017, December 31, 2017 March 2018, March 31, 2018 May 31, 2018, March 31, 2018 May 31, 2018. $46.20 December 31, 2017 10 $200 50% $125 30% may Loans Payable and Credit Facilities Senior Secured Loan Facility In March 2014, $25.0 June 2014, March 2015 November 2015 $31.0 $16.0 $1.5 In June 2016, 50% October 2016, fourth $1 In January 2017, October 15, 2018 No January 2017, 7, fifth $3 In December 2017, 13, sixth October 15, 2018 July 15, 2018 ( $1.3 January 2018 $5.5 March 2018, July 15, 2018 65% 100% sixth No On March 30, 2018, $5.5 March 31, 2018 May 31, 2018. April 1, 2018 $5.5 5.0%. Certain of the loans under the Senior Secured Loan Facility bear interest at a rate per annum equal to the greater of (i) the prime rate reported in the Wall Street Journal plus 6.25% 9.50%, 5.25% 8.5%, may 101% $3.3 $425,000 December 31, 2017 $450,000 7, first may Ginkgo Notes In November 2017, $12.0 November 2017 10, November 2017 10.5% October 19, 2022. November 2017 2017. $6.8 $5.2 November 2017 may November 2017 may In October 2016, $8.5 April 2017, $3.0 13.50% May 15, 2017. no Nossa Caixa and Banco Pine Notes In July 2012, July 2012 Under the July 2012 R$52.0 $15.7 December 31, 2017 July 2012 R$52.0 $15.7 December 31, 2017 R$68.0 $20.6 December 31, 2017 July 15, 2022 5.5% As of December 31, 2017, Other Loans Payable Salisbury Note: December 2016, $3.5 5.0% 13 January 1, 2017 January 2017, No Nikko Note: December 2016, 7, $3.9 5% 13 January 1, 2017 first 10% $400,000 $100,000 January 1, 2017, February 1, 2017, March 1, 2017 April 1, 2017 fourth may may Aprinnova Working Capital Loans: February 2017, $1.5 $375,000 May 1, 2017, August 1, 2017, November 1, 2017 February 1, 2018. February 2018. August 2017, second $1.5 July 31, 2018, 2.75% Guanfu Credit Facility In October 2016, $25.0 December 31, 2016, $25.0 five 10% March 31, 2017. December 2017, Other Credit Facilities FINEP Credit Facility: November 2010, R$6.4 $1.9 December 31, 2017). 5% R$6.4 December 31, 2017, BNDES Credit Facility: December 2011, R$22.4 U.S.6.8 December 31, 2017). 7% R$19.1 December 2017. Related Party Loans Payable DSM Note In December 2017, $25.0 December 28, 2017, $25.0 $8.0 The DSM Note (i) is an unsecured obligation of the Company, (ii) matures on December 31, 2021 December 28, 2017 10% December 31, 2017. may 10, may February 2016 In February 2016, $20.0 February 2016 190,477 $0.15 December 31, 2017 February 2016 $20.0 $16.0 February 2016 152,381 $2.0 February 2016 19,048 $2.0 February 2016 19,048 The February 2016 13.50% May 15, 2017. May 2017, February 2016 17.38% 6, In May 2017, February 2016 November 15, 2017, November 13, 2017, December 31, 2017. January 2, 2018. The February 2016 five February 2016 December 31, 2017, $0.1 December 31, 2017, none February 2016 June October 2016 In June October 2016, $11.0 13.50% May 15, 2017. May 2017, 17.38% 6, not Letters of Credit In June 2012, $1.0 $1.0 December 31, 2017 2016. |
Note 5 - Mezzanine Equity
Note 5 - Mezzanine Equity | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Mezzanine Equity Disclosure [Text Block] | 5. Mezzanine equity at December 31, 2017 2016 May 10, 2016 April 8, 2016, 292,398 $17.10, twenty April 7, 2016, $5.0 In connection with the entry into the Securities Purchase Agreement, on April 8, 2016, not 2017. third $17.10 10%. |
Note 6 - Stockholders' Deficit
Note 6 - Stockholders' Deficit | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 6. May 2017 In May 2017, 22,140 70,904 7,384,190 $7.80 7,384,190 $9.30 May 2017 May 2017 The May 2017 $50.7 May 2017 $22.1 May 2017 $30.7 $40.2 $33.1 Series A Prefer red Stock Each share of Series A Preferred Stock has a stated value of $1,000 $17.25 not October 9, 2017, 90th May 2017 Dividends, at a rate per year equal to 17.38% tenth October 15 April 15, October 15, 2017, tenth $1,738 $1,000 not first Unless and until converted into common stock in accordance with its terms, the Series A Preferred Stock has no Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series A Preferred Stock shall be entitled to receive out of the assets of the Company the same amount that a holder of Common Stock would receive if the Series A Preferred Stock were fully converted to common stock immediately prior to such liquidation, dissolution or winding-up (without regard to whether such Series A Preferred Stock is convertible at such time), which amount shall be paid pari passu The conversion of the Series A Preferred Stock is subject to a beneficial ownership limitation of 4.99% not 9.99%, not 61 May 2017 July 2017 not 3,792,778 May 2017 The Series A Preferred Stock is classified as permanent equity, as the Company controls all actions or events required to settle the optional and mandatory conversion feature in shares. The Make-Whole Payment was determined to be an embedded derivative requiring bifurcation and separate recognition as a derivative liability recognized at its fair value as of the issuance date with subsequent changes in fair value recorded in earnings until the Series A Preferred Stock is converted into common stock and the Make-Whole Payment is paid or until the Make-Whole Payment is paid through declared dividends or cash. A derivative liability was recognized at fair value on the date of issuance for the Make-Whole Payment in the amount of $11.0 $0.6 $0. As of December 31, 2017, 22,140 and zero December 31, 2017, $10.5 in fair value of the derivative liabilities in connection with the 22,140 Series B Preferred Stock The Series B Preferred Stock has substantially identical terms to the Series A Preferred Stock, except that (i) the conversion of the Series B Preferred Stock was subject to the July 2017 May 2017 not December 31, 2017, June 30, 2017. “July 2017 July 2017 May 2017 July 2017 $12.8 The investors that purchased shares of the Series B Preferred Stock included related parties affiliated with members of the Board: Foris exchanged an aggregate principal amount of $27.0 30,729 May 2017 4,877,386 $2.0 2,333 May 2017 370,404 $8.6 The investors that purchased shares of the Series B Preferred Stock also included non-related party holders of the Company's 2014 144A 2015 144A $3.4 2014 144A $3.7 2015 144A May 2017 May 2017 $1.9 Upon the closing of the May 2017 The Series B Preferred Stock issued to DSM in the May 2017 three September 30, 2017 July 2017 $0.6 not As of December 31, 2017, 86,691 August 2017 9,213 $34.7 December 31, 2017 $1.2 $0.2 May 2017 December 31, 2017, $26.7 86,691 May 2017 Warrants The Company issued to each investor in the May 2017 100% 14,768,380 May 2017 May 2017 three May 2017 May 2017 December 31, 2017, May 2017 $4.40 December 31, 2017, no May 2017 In addition, the Company issued to each investor a warrant, with an exercise price of $0.0015 December 31, 2017 May 2017 May 2017 $6.30, December 31, 2017, May 2017 6,377,466 3,103,278 $9.6 The May 2017 five July 2017 May 2017 May 2017 May 2017 May 2017 $39.5 December 31, 2017, May 2017 $34.1 third December 31, 2017, $5.4 May 2017 May 2017 July 2022. The full-ratchet anti-dilution protection of the May 2017 $4.4 December 31, 2017, May 2017 $40.6 December 31, 2017, $45.7 July 2022. July 2017 Stockholder Approval In May 2017 May 2017 May 2017 July 2017 July 10, 2017, July 2017 May 2017 July 7, 2017. August 2017 On August 7, 2017, in a private placement (the August 2017 • 25,000 August 2017 $1,000 • a warrant to purchase 3,968,116 $6.30 five August 2017 • the August 2017 Net proceeds to the Company were $25.9 The exercise price of the August 2017 three August 7, 2017 ( August 2017 The August 2017 $6.30, $0.10 August 2017 five The effectiveness of the anti-dilution adjustment provision of the August 2017 August 2017 August 2017 December 31, 2017, August 2017 not August 2017 not In connection with the August 2017 not October 31, 2017, ( May 11, 2018 In connection with the August 2017 May 11, 2017 ( one 4.5%, not May 2017 May 2018 three no not, 33% one 1933, May 2017 second 10%, August 2017 In addition, pursuant to the Amended and Restated DSM Stockholder Agreement, the Company and DSM agreed to negotiate in good faith regarding an agreement concerning the development of certain products in the Health and Nutrition field and, in the event that the parties did not 90 August 2017 August 2017 first August 2017 $5.0 not $25.0 September 2017, August 2017 In connection with the August 2017 $25.9 $9.0 October 28, 2017, 2018. $7.1 $34.0 August 2017 August 2017 August 2017 3 August 2017 $5.5 $0.2 $9.9 August 2017 August 2017 $10.6 August 2017 August 2017 December 31, 2017 $2.4 December 31, 2017. December 31, no August 2017 None August 2017 August 2017 December 31, 2017. zero December 31, 2017 $9.9 The DSM Credit Letter was reported as deferred revenue and its fair value was determined based on the assumptions that DSM would realize its credit over the next 18 4 50% 90% 8.6% $34.0 $0.7 December 31, 2017. December 2017, $7.3 10, August 2017 On August 3, 2017, August 2017 • 2,826,711 $4.26 • 12,958 $1,000 • warrants to purchase an aggregate of 5,575,118 $6.39 five August 2017 • the August 2017 Net proceeds to the Company were $24.8 Each share of Series D Preferred Stock has a stated value of $1,000 August 2017 $4.26 The 9.99% August 2017 may 61 Prior first $0.0001 no December 31, 2017. Unless no The Series D Preferred Stock is classified as permanent equity, as the Company controls all actions or events required to settle the optional conversion feature in shares. The August 2017 August 2017 which have been recorded as derivative liabilities. These warrants have been recognized at their fair value of $13.0 third 3 from the date of issuance through December 31, 2017 $3.1 December 31, 2017. $12.0 $5.5 August 2017 $6.2 $0.2 $5.8 $12.0 $6.2 In the event of a Fundamental Transaction, the holders of the Series D Preferred Stock will have the right to receive the consider pari passu one 50% 50% Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series D Preferred Stock shall be entitled to receive out of the assets of the Company the same amount that a holder of common stock would receive if the Series D Preferred Stock were fully converted to common stock immediately prior to such liquidation, dissolution or winding-up (without regard to whether such Series D Preferred Stock is convertible at such time), which amount shall be paid pari passu The exercise price of the August 2017 three August 3, 2017 ( August 2017 The August 2017 $4.26, August 2017 five The effectiveness of the anti-dilution adjustment provision of the August 2017 August 2017 August 2017 December 31, 2017, none August 2017 August 2017 not In connection with the August 2017 not In connection with the August 2017 4.5%, one . Furthermore, Vivo will have the right to purchase additional shares of capital stock of the Company in connection with a sale of equity or equity-linked securities by the Company in a capital raising transaction for cash, subject to certain exceptions, to maintain its proportionate ownership percentage in the Company. Vivo agreed not August 2017 August 2018 . three August 2017 three no not, 33% one August 2017 August 2017 Au gust 2017 The may August 2017 August 2017 August 2017 August 2017 August 2017 2018 August 2017 may, 90 2018 not August 2017 four August 2017 August 2017 August 2017 August 2017 August 2017 August 2017 no August 2017 may not August 2017 August 2017 August 2017 August 2017 August 2017 Warrants in Connection with May August 2017 Warrant activity and balances in connection with the May August 2017 Issued Exercised Warrants May and August 2017 Cash Warrants May 2017 14,768,380 — 14,768,380 August 2017 9,543,234 — 9,543,234 24,311,614 — 24,311,614 May and August 2017 Dilution Warrants May 2017 6,377,466 (3,103,278 ) 3,274,188 August 2017 — — — 6,377,466 (3,103,278 ) 3,274,188 30,689,080 (3,103,278 ) 27,585,802 May 2017 Exchange of Common Stock for Series C Convertible Preferred Stock In May 2017, May 2017 1,394,706 20,921 $0.0001 not July 2017 Each share of Series C Preferred Stock has a stated value of $1,000 $15.00 The Series C Preferred Stock is entitled to participate with the common stock on an as-converted basis with respect to any dividends or other distributions to holders of common stock. The Series C Preferred Stock shall vote together as one Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series C Preferred stock shall be entitled to receive out of the assets of the Company an amount equal to the greater of (i) the par value of each share of Series C Preferred Stock, plus any accrued and unpaid dividends or other amounts due on such Series C Preferred Stock, prior to any distribution or payment to the holders of common stock or (ii) the amount that a holder would receive if the Series C Preferred Stock were fully converted to common stock immediately prior to such liquidation, dissolution or winding-up (without regard to whether such Series C Preferred Stock is convertible at such time), which amount shall be paid pari passu The shares of Series C Preferred Stock automatically converted to common stock on June 6, 2017 May 2017 no Exchange Agreement Warrants Under 2015 2015 • Total received a warrant to purchase 1,261,613 December 31, 2017. • Total received a warrant to purchase 133,334 March 1, 2017, March 1, 2017, not March 1, 2017 December 31, 2017, not • Temasek received a warrant to purchase 978,525 December 31, 2017. • Temasek received a warrant exercisable for that number of shares of common stock equal to 58,690 133,334 December 31, 2017, not • Temasek received a warrant exercisable for that number of shares of common stock equal to ( 1 may 2015 133,334, 30.6% 69.4% 2 2014 144A may 13.3% 86.7% December 31, 2017, 846,683 1,889,986 The 2015 five 2015 ten $0.15 December 31, 2017. In 2015 66,667 October 2013 2015 December 31, 2017 2016, July 2015 In July 2015, 1,068,379 $23.40 $25.0 July 29, 2015. $0.15 December 31, 2017, 10% September 17, 2015. December 31, 2017, 25,643 81,197 At M arket Issuance Sales Agreement On March 8, 2016, may $50.0 3 No. 333 203216 April 15, 2015. 415 one may not 3.0% no During December 31, 2017 December 31, 2016, not December 31, 2017, $50.0 Evergreen Shares for 2010 2010 In January 2017, 2010 548,214. 3.0% 18,273,921 December 31, 2016. January 1, 2017. 8 October 1, 2010 ( No. 333 169715 8 April 17, 2017 No. 333 217345 January 1, 2017. not 2010 2017. Right of First Investment to Certain Investors In connection with investments in Amyris, the Company has granted certain investors, including Total and DSM, a right of first may first may |
Note 7 - Variable-interest Enti
Note 7 - Variable-interest Entities and Unconsolidated Investments | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Variable Interest Entity Disclosure [Text Block] | 7. Consolidated Variable-interest Entity Aprinnova, LLC (Aprinnova JV) In December 2016, not third Nikko purchased a 50% December 2016 $10.0 three $10.0 Pursuant to the Aprinnova JV Agreement, the Company and Nikko agreed to make working capital loans to the Aprinnova JV in the amounts of $0.5 $1.5 Under the Aprinnova JV Agreement, in the event of a merger, acquisition, sale or other similar reorganization, or a bankruptcy, dissolution, insolvency or other similar event, of the Company, on the one first The Aprinnova JV operates under an agreement (the Aprinnova Operating Agreement) under which the Aprinnova JV is managed by a Board of Directors that consists of four two two 810, Consolidation, 810. Under the Aprinnova Operating Agreement, profits from the operations of the Aprinnova JV, if any, are distributed as follows: (i) first, to the Company and Nikko (the Members) in proportion to their respective unreturned capital contribution balances, until each Member’s unreturned capital contribution balance equals zero 50%/50% In connection with the contribution of the Leland Facility by the Company to the Aprinnova JV, at the closing of the formation of the Aprinnova JV, Nikko made a loan to the Company in the principal amount of $3.9 4, Purchase of North Carolina Manufacturing Facility and Transfer to Aprinnova JV In December 2016, $4.4 $3.5 4, December 2016, The following presents the carrying amounts of the Aprinnova JV’s assets and liabilities included in the accompanying consolidated balance sheets. Assets presented below are restricted for settlement of the Aprinnova JV's obligations and all liabilities presented below can only be settled using the Aprinnova JV resources. December 31, 2017 2016 Assets $ 36,781 $ 30,778 Liabilities $ 3,187 $ 333 The Aprinnova JV's assets and liabilities are primarily comprised of inventory, property, plant and equipment, accounts payable and debt, which are classified in the same categories in the Company's consolidated balance sheets. The change in noncontrolling interest for the Aprinnova JV for the years ended December 31, 2017 2016 (In thousands) 2017 2016 Balance at January 1 $ (937 ) $ 391 Income attributable to noncontrolling interest — (1,328 ) Balance at December 31 $ (937 ) $ (937 ) Unconsolidated Investments Equity-method Investments Novvi LLC (Novvi) Novvi is a U.S.-based joint venture among the Company, Cosan US, Inc. (Cosan U.S.), American Refining Group, Inc. (ARG), Chevron U.S.A. Inc. (Chevron) and H&R Group US, Inc. (H&R). Novvi's purpose is to develop, produce and commercialize base oils, additives and lubricants derived from Biofene for use in the automotive, commercial and industrial lubricants markets. In July 2016, $10.0 one third seven December 31, 2017, three one third two In November 2016, $1.0 3% 25% may, In October 2017, $10.0 24.39% December 31, 2017, 24.39% 2.44%. Additional funding requirements to finance the ongoing operations of Novvi are expected to occur through revolving credit or other loan facilities provided by unrelated parties (i.e., such as financial institutions); cash advances or other credit or loan facilities provided by Novvi’s members or their affiliates; or additional capital contributions by the existing Novvi members or new investors. The Company has identified Novvi as a VIE and determined that the power to direct activities which most significantly impact the economic success of the joint venture (i.e., continuing research and development, marketing, sales, distribution and manufacturing of Novvi products) are shared among the Company, Cosan U.S., ARG and H&R. Accordingly, The Company accounts for its investment in Novvi under the equity method of accounting, having determined that (i) Novvi is a VIE, (ii) the Company is not zero December 31, 2017 2016 Total Amyris BioSolutions B.V. (TAB) TAB is a joint venture formed in November 2013 not December 31, 2017, 25% 75% not December 31, 2017 $0. Cost-method Investment In April 2017, 850,115 December 2016. $3.2 40%. |
Note 8 - Net Loss Per Share Att
Note 8 - Net Loss Per Share Attributable to Common Stockholders | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 8. The Company computes net loss per share in accordance with ASC 260, 2015 December 31, 2017 2015, The following table presents the calculation of basic and diluted net loss per share of common stock attributable to Amyris, Inc. common stockholders: Years Ended December 31, 2017 2016 2015 Numerator: Net income (loss) attributable to Amyris, Inc. $ (72,329 ) $ (97,334 ) $ (217,952 ) Less deemed dividend on capital distribution to related parties (8,648 ) — — Less deemed dividend related to beneficial conversion feature on Series A preferred stock (562 ) — — Less deemed dividend related to beneficial conversion feature on Series B preferred stock (634 ) — — Less deemed dividend related to beneficial conversion feature on Series D preferred stock (5,757 ) — — Less cumulative dividends on Series A and Series B preferred stock (5,439 ) — — Net loss attributable to Amyris, Inc. common stockholders, basic (93,369 ) (97,334 ) (217,952 ) Adjustment to exclude fair value gain on liability classified warrants (1) — — (3,825 ) Net loss attributable to Amyris, Inc. common stockholders for basic net loss per share (93,369 ) (97,334 ) (221,777 ) Interest on convertible debt — 4,428 — Accretion of debt discount — 2,889 — Gain from change in fair value of derivative instruments — (25,630 ) — Net loss attributable to Amyris, Inc. common stockholders, diluted $ (93,369 ) $ (115,647 ) $ (221,777 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic 32,253,570 15,896,014 8,464,106 Basic loss per share $ (2.89 ) $ (6.12 ) $ (26.20 ) Weighted-average shares of common stock outstanding 32,253,570 15,896,014 8,464,106 Effective of dilutive convertible promissory notes — 1,746,951 — Weighted-average common stock equivalents used in computing net loss per share of common stock, diluted 32,253,570 17,642,965 8,464,106 Diluted loss per share $ (2.89 ) $ (6.55 ) $ (26.20 ) ______________ ( 1 The amount represents a net gain related to a change in the fair value of a liability classified common stock warrant included in the Company’s consolidated statement of operations for the year ended December 31, 2015. 2015. The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive: Years Ended December 31, 2017 2016 2015 Period-end common stock warrants 29,921,844 334,740 193,462 Convertible promissory notes (1) 8,040,828 2,395,596 4,835,821 Period-end stock options to purchase common stock 1,338,367 899,179 862,008 Period-end restricted stock units 685,007 466,076 370,323 Total potentially dilutive securities excluded from computation of diluted net loss per share 39,986,046 4,095,591 6,261,614 ______________ ( 1 The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of December 31, 2017. |
Note 9 - Commitments and Contin
Note 9 - Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Contingencies Disclosure [Text Block] | 9. Lease Obligations The Company leases certain facilities and finances certain equipment under operating and capital leases, respectively. Operating leases include leased facilities and capital leases include leased equipment (see Note 2, February 2031. $5.1 $5.3 $5.5 December 31, 2017, 2016 2015, Future minimum payments under the Company's lease obligations as of December 31, 2017, Years Ending December 31 Capital Operating Total Lease 2018 $ 755 $ 10,127 $ 10,882 2019 185 8,760 8,945 2020 39 7,018 7,057 2021 — 7,242 7,242 2022 — 7,415 7,415 Thereafter — 3,545 3,545 Total future minimum payments 979 $ 44,107 $ 45,086 Less: amount representing interest (38 ) Present value of minimum lease payments 941 Less: current portion (724 ) Long-term portion $ 217 Sublease Arrangements The Company subleases certain of its facilities to two December 31, 2017 $0.4 Guarantor Arrangements The Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officer or director is serving in his or her official capacity. The indemnification period remains enforceable for the officer's or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future payments. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no December 31, 2017 2016. The Company entered into the FINEP Credit Facility to finance a research and development project on sugarcane-based biodiesel; see Note 4, R$6.0 $1.8 December 31, 2017 January 2018. The Company entered into the BNDES Credit Facility to finance a production site in Brazil; see Note 4, December 2017 first R$24.9 $7.5 December 31, 2017 In 2012, R$52.0 $15.7 December 31, 2017 4, December 31, 2017, two December 2017, 13, January 2018 The Company has a financing agreement with Banco Safra for $1.0 one June 2018 The Senior Secured Loan Facility (see Note 4, first 4, first 10% Purchase Obligations As of December 31, 2017, $18.3 $9.0 Production Cost Commitment As of December 31, 2017, not no Other Matters Certain conditions may may one may If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not not In April 2017, March 2, 2017 April 17, 2017. March 2, 2017 12b 25 April 3, 2017. September 21, 2017, Subsequent to the filing of the securities class action complaint described above, four No. 4:17 04719, August 15, 2017, No. 3:17 04927, August 24, 2017. September 19, 2017, No. 2:15 04719, November 3, 2017. November 3, 2017, December 21, 2017, March 9, 2018, March 29, 2018, two No. 665782, June 20, 2017, No. 17865966, June 29, 2017, August 31, 2017, RG17876383. not The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not not may not one |
Note 10 - Significant Revenue A
Note 10 - Significant Revenue Agreements | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Collaborative Arrangement Disclosure [Text Block] | 10. For the years ended December 31, 2017 2016 and 2015, Years Ended December 31, (In thousands) 2017 2016 2015 Renewable Licenses Grants and TOTAL Renewable Licenses Grants and TOTAL Renewable Licenses Grants and TOTAL Revenue from significant revenue agreements with: DSM (related party) $ — $ 57,972 $ 1,679 $ 59,651 $ — $ — $ — $ — $ — $ — $ — $ — Firmenich 9,621 1,199 5,803 16,623 9,660 745 7,513 17,918 1,425 259 11,000 12,684 Nenter & Co., Inc. 12,057 2,633 — 14,690 6,236 — — 6,236 — — — — DARPA — — 12,333 12,333 — — 9,697 9,697 — — 80 80 Ginkgo — — — — — 15,000 — 15,000 — — — — Subtotal revenue from significant revenue agreements 21,678 61,804 19,815 103,297 15,896 15,745 17,210 48,851 1,425 259 11,080 12,764 Revenue from all other customers 20,692 2,673 16,783 40,148 9,614 94 8,633 18,341 13,081 131 8,177 21,389 Total revenue from all customers $ 42,370 $ 64,477 $ 36,598 $ 143,445 $ 25,510 $ 15,839 $ 25,843 $ 67,192 $ 14,506 $ 390 $ 19,257 $ 34,153 Renewable Products Firmenich Agreements In 2013, 2014, Firmenich Supply Agreement (the F In July 2017, the 70/30 70% two 70/30 70% $15.0 50/50 not Pursuant to the Firmenich Collaboration Agreement, the Company agreed to pay a one $2.5 not December 31, 2017. one 10 3 December 31, 2017 $0.3 one that has been recorded as a reduction to the associated collaboration revenue. Nenter Agreements In April 2016, December 31, 2020 five In December 2017, 1 13, In October 2016, cooperation agreement. In May 2017, $2.5 December 31, 2017. Licenses and Royalties DSM Agreements DSM July September 2017 In July September 2017, three three In $9.0 one In addition, in connection with the entry into the DSM Collaboration Agreements, the Company and DSM entered into the DSM Credit Letter, pursuant to which the Company granted a credit to DSM in an aggregate amount of $12.0 not $6.0 2018. DSM Credit Letter was $7.1 three December 31, 2017, $12.0 The Company received $34.0 August 2017 first $33.3 August 2017 August 2017 August 2017 $0.7 December 31, 2017, $7.1 December 2017 DSM Value Sharing Agreement In December 2017, 1 13, first three December 2017 first three 4, December 2027, March 2018, 2018 2018. DSM Performance Agreement In December 2017, 1 13, 1 not $1.8 December 2020, DSM November 2017 In November 2017, 1 13, 1 November 2017 December 2017, $27.5 $57.3 Ginkgo Agreements Ginkgo Initial Strategic Partnership Agreement and Collaboration Agreement In June 2016, $20.0 two 10% first $15.0 2016. not second $5.0 In addition, pursuant to the Initial Ginkgo Agreement, (i) the Company and Ginkgo agreed to pursue the negotiation and execution of a detailed definitive partnership and license agreement setting forth the terms of a commercial partnership and collaboration arrangement between the parties (Ginkgo Collaboration), (ii) the Company agreed to issue to Ginkgo a warrant to purchase 333,334 $7.50, one October 31, 2016 4, x In August 2016, August 2017 In September 2016, third not March 30, 2017, $5.0 not second Under the Ginkgo Collaboration Agreement, subject to certain exceptions, including excluded or refused products and cost savings initiatives, the profit on the sale of products subject to the Ginkgo Collaboration Agreement as well as cost-sharing, milestone and “value-creation” payments associated with the development and production of such products would be shared equally between the parties. The parties also agreed to provide each other with a license and other rights to certain intellectual property necessary to support the development and manufacture of the products under the Ginkgo Collaboration, and also to provide each other with access to certain other intellectual property useful in connection with the activities to be undertaken under the Ginkgo Collaboration Agreement, subject to certain carve-outs. The initial term of the Ginkgo Collaboration Agreement was three $15.0 July 2016. $5.0 not Ginkgo Partnership Agreement In November 2017, • to continue to collaborate on limited research and development; • to provide each other licenses (with royalties) to specified intellectual property for limited purposes; • for the Company to pay Ginkgo quarterly fees of $0.8 December 31, 2018 September 30, 2022; • to share profit margins from sales of a certain product to be developed under the Ginkgo Partnership Agreement on a 50/50 November 2017 4, • for the Company to pay Ginkgo $0.5 The Ginkgo Partnership Agreement provides for an initial term of two one Collaborations DARPA Technology Investment Agreement In September 2015, $35.0 four $15.5 four |
Note 11 - Related Party Transac
Note 11 - Related Party Transactions | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 11. Related Party Divestiture See Note 13, December 2017. Related Party Debt See Note 4, • August 2013 • 2014 144A • 18, • 13, • February 2016 • June 2016 October 2016 • Related party debt was as follows: December 31, 2017 2016 Principal Unamortized Net Principal Unamortized Net Total R&D note $ 3,700 $ (18 ) $ 3,682 $ 3,700 $ (80 ) $ 3,620 August 2013 financing convertible notes 21,711 897 22,608 19,781 2,033 21,814 2014 Rule 144A convertible notes 9,705 (1,538 ) 8,167 9,705 (2,986 ) 6,719 35,116 (659 ) 34,457 33,186 (1,033 ) 32,153 DSM DSM note 25,000 (8,039 ) 16,961 — — — Other DSM loan 393 — 393 — — — 25,393 (8,039 ) 17,354 — — — Biolding February 2016 private placement 2,000 — 2,000 2,000 (131 ) 1,869 Foris 2014 Rule 144A convertible notes 5,000 (660 ) 4,340 5,000 (1,316 ) 3,684 February 2016 private placement — — — 16,000 (1,047 ) 14,953 June and October 2016 private placements — — — 11,000 — 11,000 5,000 (660 ) 4,340 32,000 (2,363 ) 29,637 Naxyris February 2016 private placement — — — 2,000 (131 ) 1,869 Temasek 2014 Rule 144A convertible notes 10,000 (1,586 ) 8,414 10,000 (3,078 ) 6,922 $ 77,509 $ (10,944 ) $ 66,565 $ 79,186 $ (6,736 ) $ 72,450 The fair value of the derivative liabilities related to the related party R&D Note, related party August 2013 2014 144A December 31, 2017 2016 $0.2 $0.8 $0.6 $7.6 $10.5 December 31, 2017, 2016 2015, 3, Related Party Revenue The Company recognized revenue from related parties and from all other customers as follows: Years Ended December 31, (In thousands) 2017 2016 2015 Renewable Licenses Grants and TOTAL Renewable Licenses Grants and TOTAL Renewable Licenses Grants and TOTAL Revenue from related parties: DSM $ — $ 57,972 $ 1,679 $ 59,651 $ — $ — $ — $ — $ — $ — $ — $ — Novvi 1,491 — — 1,491 1,390 — — 1,390 — — — — Total (200 ) — — (200 ) 172 — — 172 865 — — 865 Subtotal revenue from related parties 1,291 57,972 1,679 60,942 1,562 — — 1,562 865 — — 865 Revenue from all other customers 41,079 6,505 34,919 82,503 23,948 15,839 25,843 65,630 13,641 390 19,257 33,288 Total revenue from all customers $ 42,370 $ 64,477 $ 36,598 $ 143,445 $ 25,510 $ 15,839 $ 25,843 $ 67,192 $ 14,506 $ 390 $ 19,257 $ 34,153 See Note 10, Related Party Accounts Receivable Related party accounts receivable was as follows: December 31, 2017 2016 DSM $ 12,823 $ — Novvi $ 1,607 $ — Total $ 238 $ 805 Related party accounts receivable, net $ 14,668 $ 805 In addition to the amounts shown above, there was a $7.9 December 31, 2017. Related Party Joint Ventures See Note 7, • • Pilot Plant and Secondee Agreements The Company and Total are parties to the following agreements: • $0.4 $0.4 $0.9 December 31, 2017, 2016 2015, • $0.8 $0.9 December 31, 2017, 2016 2015, In February 2017, not May 1, 2016, two $1.4 $2.2 December 31, 2017 2016, December 31, 2017, April 2019. Office Sublease The Company subleases certain office space to Novvi, for which the Company charged Novvi $0.5 $0.4 $0.4 $0.7 December 31, 2017, 2016 2015, |
Note 12 - Stock-based Compensat
Note 12 - Stock-based Compensation | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | 12. Stock-based Compensation Expense Related to All Plans Stock-based compensation expense related to all employee stock compensation plans, including options, restricted stock units and ESPP, was as follows: Years Ended December 31, (In thousands) 2017 2016 2015 Research and development $ 2,204 $ 1,948 $ 2,306 Sales, general and administrative 4,061 5,377 6,828 Total stock-based compensation expense $ 6,265 $ 7,325 $ 9,134 Plans 2010 The Company's 2010 2010 September 28, 2010 2020. 2010 2010 may may may no 2,000,000 2010 2010 may ten ten may not 100% 10% may not 110% four five As of December 31, 2017 2016, 1,255,045 770,761 2010 $26.29 $45.76, December 31, 2017 2016, 683,554 454,923 2010 December 31, 2017 2016, 252,107 552,392 may 2010 The number of shares reserved for issuance under the 2010 January 1 January 1, 2011, 5% December 31. 2005 In 2005, 2005 2005 2005 2005 All options issued under the 2005 ten 2005 not 100% 10% not 110% 5 As of December 31, 2017 2016, 79,322 100,260 2005 2010 zero 2005 2005 December 31, 2017 2016 $144.58 $127.58, 2010 The 2010 2010 September 28, 2010. 2010 2010 May 16 November 16, one two six 2010 85% first 11,241 2010 2010 January 1 January 1, 2011, 1% December 31. No 666,666 may 2010 no may Stock Option Activity Stock option activity is summarized as follows: Year ended December 31, 2017 2016 2015 Options granted 661,094 239,012 314,686 Weighted-average grant-date fair value per share $ 3.26 $ 8.85 $ 18.15 Compensation expense related to stock options (in millions) $ 3.3 $ 3.5 $ 6.0 Unrecognized compensation costs as of December 31 (in millions) $ 2.7 $ 4.4 $ 8.0 The Company expects to recognize the December 31, 2017 2.5 Stock-based compensation expense for stock options and employee stock purchase plan rights is estimated at the grant date and offering date, respectively, based on the fair-value using the Black-Scholes option pricing model. The fair value of employee stock options is amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following weighted-average assumptions: Years Ended December 31, 2017 2016 2015 Expected dividend yield — % — % — % Risk-free interest rate 2.1 % 1.4 % 1.8 % Expected term (in years) 6.12 6.16 6.08 Expected volatility 84 % 73 % 74 % The Company uses third The expected life of options is based primarily on historical share option exercise experience of the employees for options granted by the Company. All options are treated as a single group in the determination of expected life, as the Company does not no Stock-based compensation expense associated with options is based on awards ultimately expected to vest. At the time of an option grant, the Company estimates the expected future rate of forfeitures based on historical experience. These estimates are revised, if necessary, in subsequent periods if actual forfeiture rates differ from those estimates. If the actual forfeiture rate is lower than estimated the Company will record additional expense and if the actual forfeiture is higher than estimated the Company will record a recovery of prior expense. The Company’s stock option activity and related information for the year ended December 31, 2017 Number of Weighted- Weighted-average (in years) Aggregate Outstanding - December 31, 2016 875,021 $ 55.20 6.70 $ 443 Options granted 661,094 $ 4.56 Options exercised - $ - Options forfeited or expired (197,748 ) $ 33.46 Outstanding - December 31, 2017 1,338,367 $ 33.40 7.71 $ 97 Vested or expected to vest after December 31, 2017 1,257,439 $ 33.40 7.62 $ 81 Exercisable at December 31, 2017 925,778 $ 43.48 7.18 $ 27 The aggregate intrinsic value of options exercised under all option plans was zero December 31, 2017, 2016 2015, Restricted Stock Units Activity and Expense During the years ended December 31, 2017, 2016 2015, 523,167, 326,523 332,569 $5.51, $9.15 $27.30, $2.8 $3.6 $2.8 December 31, 2017, 2016 2015 December 31, 2017 2016, $5.0 $5.4 Stock-based compensation expense for RSUs is measured based on the closing fair market value of the Company's common stock on the date of grant. The Company’s RSU and restricted stock activity and related information for the year ended December 31, 2017 Number of Weighted- Weighted-average Outstanding - December 31, 2016 454,923 $ 17.48 1.4 Awarded 523,167 $ 5.51 Vested (191,844 ) $ 18.71 Forfeited (102,692 ) $ 13.00 Outstanding - December 31, 2017 683,554 $ 8.66 1.4 Vested or expected to vest after December 31, 2017 533,670 $ 8.92 1.3 ESPP Activity and Expense During the years ended December 31, 2017 2016, 47,045 22,405 2010 December 31, 2017 2016, 80,594 127,669 2010 During the years ended December 31, 2017, 2016 2015, 2010 $0.1 $0.1 $0.3 The valuation of employee stock purchase rights and the related assumptions are for the employee stock purchases made during the respective fiscal years. |
Note 13 - Divestiture
Note 13 - Divestiture | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] | 13. On December 28, 2017, 1 $33.0 $12.6 $56.9 $5.7 Concurrent with the sale of Amyris Brasil, the Company and DSM entered into a series of commercial agreements including (i) a license agreement to DSM of its farnesene product for DSM to use in the Vitamin E, lubricant, and flavor and fragrance markets; (ii) a value share agreement that DSM will pay the Company specified royalties representing a portion of the profit on the sale of Vitamin E produced from farnesene under the Nenter Supply Agreement assigned to DSM; (iii) a performance agreement for the Company to perform research and development to optimize farnesene for production and sale of farnesene products; and (iv) a transition services agreement for the Company to provide finance, legal, logistics, and human resource services to support the Brotas 1 six six $27.5 $15.0 2018 2019. $17.8 10, $25.0 4, The Company accounted for the sale of Amyris Brasil as a sale of a business. The agreements entered into concurrently with the sale of Amyris Brasil including the license agreement, value share agreement, performance agreement, transition services agreement, and credit agreement contain various elements and, as such, are deemed to be an arrangement with multiple deliverables as defined under U.S. GAAP. The Company performed an analysis to determine the fair value for all elements in the agreements with DSM and separated the elements between the non-revenue and revenue elements. After allocating the total fair value of the non-revenue elements from the fixed and determinable consideration received, the Company allocated the remaining fixed and determinable consideration to the revenue elements based on relative fair value. As such, the Company recognized $57.3 $2.1 December 31, 2017. Results from the operations of Amyris Brasil are included in our Consolidated Statements of Operations for 2017, 2016 2015 not not not |
Note 14 - Goodwill
Note 14 - Goodwill | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Goodwill Disclosure [Text Block] | 14. At December 31, 2017 December 31, 2016, $0.6 |
Note 15 - Income Taxes
Note 15 - Income Taxes | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 15. The components of loss before income taxes, loss from investments in affiliates and net loss attributable to noncontrolling interest are as follows: Years Ended December 31, 2017 2016 2015 United States $ (68,777 ) $ (101,210 ) $ (188,943 ) Foreign (3,257 ) 4,429 (24,457 ) Loss before income taxes and loss from investments in affiliates $ (72,034 ) $ (96,781 ) $ (213,400 ) The components of the provision for income taxes are as follows: Years Ended December 31, 2017 2016 2015 Current: Federal $ — $ — $ — State — — — Foreign 964 553 468 Total current provision 964 553 468 Deferred: Federal (669 ) — — State — — — Foreign — — — Total deferred provision (benefit) (669 ) — — Total provision for income taxes $ 295 $ 553 $ 468 A reconciliation between the statutory federal income tax and the Company’s effective tax rates as a percentage of loss before income taxes and loss from investments in affiliates is as follows: Years Ended December 31, 2017 2016 2015 Statutory tax rate (34.0 )% (34.0 )% (34.0 )% State taxes, net of federal tax benefit — % — % (0.3 )% Stock-based compensation 0.1 % — % 0.1 % Federal R&D credit (1.0 )% (0.8 )% (0.6 )% Derivative liabilities 1.7 % 1.4 % 3.6 % Nondeductible interest 6.2 % 5.0 % 5.5 % Other (0.4 )% (3.2 )% 0.1 % Foreign losses 17.6 % 0.5 % (1.2 )% Change in U.S. federal tax rate 57.0 % — % — % IRC Section 382 limitation 5.0 % — % — % Change in valuation allowance (51.9 )% 31.7 % 27.1 % Effective income tax rate 0.3 % 0.6 % 0.3 % Temporary differences and carryforwards that gave rise to significant portions of deferred taxes are as follows: December 31, 2017 2016 2015 Net operating loss carryforwards $ 23,877 $ 236,741 $ 207,241 Property, plant and equipment 4,195 12,917 10,519 Research and development credits 10,702 17,348 16,612 Foreign tax credit 2,669 2,452 1,899 Accruals and reserves 10,754 30,303 26,366 Stock-based compensation 11,417 17,184 19,048 Capitalized start-up costs — 9,182 9,568 Capitalized research and development costs 34,973 65,962 63,339 Intangible and others 3,932 6,714 9,999 Total deferred tax assets 102,519 398,803 364,591 Debt discount and derivative (6,616 ) (11,936 ) (4,402 ) Total deferred tax liabilities (6,616 ) (11,936 ) (4,402 ) Net deferred tax assets prior to valuation allowance 95,903 386,867 360,189 Less: valuation allowance (95,903 ) (386,867 ) (360,189 ) Net deferred tax assets $ — $ — $ — Recognition of deferred tax assets is appropriate when realization of such assets is more likely than not. not not December 31, 2017, 2016 2015. $291.0 December 31, 2017 $26.7 $47.9 December 31, 2016 2015, On January 1, 2017, 2016 09, 2016 09 not $40.1 On December 22, 2017, 2017 not 35% 21% December 31, 2017, one December 31, 2017. The Company has calculated its best estimate of the impact of the Act in its year-end income tax provision in accordance with its understanding of the Act and guidance available as of the date of this filing. The provisional amount related to the remeasurement of certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future was approximately $37.7 December 31, 2017. not one On December 22, 2017, No. 118 118 not 118, December 31, 2017. not not not not Given that the Company is still in the transition period for the accounting for income tax effects of the Act, the current assessment on deferred tax assets is based on currently available information and guidance. If in the future any element of the tax reform changes the related accounting guidance for income tax, such change could affect the Company’s income tax position, and the Company might need to adjust the provision for income taxes accordingly. As of December 31, 2017, $136.5 $111.7 1986, may 382 382 may may one not 50% three December 31, 2017, 50%. $438.1 $14.2 As of December 31, 2017, $0.7 $12.7 If not 2025, 2028. 2038 not During the year ended December 31, 2015, $8.5 no A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In thousands) Balance at December 31, 2014 $ 17,081 Decreases in tax positions for prior period (9,404 ) Increases in tax positions during current period 957 Balance at December 31, 2015 8,634 Decreases in tax positions for prior period (314 ) Increases in tax positions during current period 781 Balance at December 31, 2016 9,101 Increases in tax positions for prior period 50 Increases in tax positions during current period 8,029 Balance at December 31, 2017 $ 17,180 The Company’s policy is to include interest and penalties related to unrecognized tax benefits within the provision for income taxes. The Company determined that no December 31, 2017, 2016 2015. None not 12 The Company’s primary tax jurisdiction is the United States. For United States federal and state tax purposes, returns for tax years 2005 2010 As of December 31, 2017, 2008 no 2008, may |
Note 16 - Geographical Informat
Note 16 - Geographical Information | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | 16. The chief operating decision maker is the Company's Chief Executive Officer, who makes resource allocation decisions and assesses performance based on financial information presented on a consolidated basis. There are no Revenue by geography is based on the location of the customer. The following tables set forth revenue and property, plant and equipment by geographic area: Revenue Years Ended December 31, 2017 2016 2015 United States $ 94,060 $ 30,942 $ 7,122 Europe 23,823 23,612 16,049 Asia 23,290 12,055 5,907 Brazil 2,159 488 5,004 Other 113 95 71 $ 143,445 $ 67,192 $ 34,153 Property, Plant and Equipment December 31, 2017 2016 2015 United States $ 10,357 $ 9,342 $ 18,401 Brazil 3,357 44,153 41,093 Europe 178 240 303 $ 13,892 $ 53,735 $ 59,797 |
Note 17 - Quarterly Results of
Note 17 - Quarterly Results of Operations Data (Unaudited)* | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Quarterly Financial Information [Text Block] | 17. Years Ended December 31, 2017 2016 Fourth Third Second First Fourth Third Second First Revenue Renewable products $ 13,445 $ 10,996 $ 9,892 $ 8,037 $ 11,215 $ 6,619 $ 4,711 $ 2,965 Licenses and royalties 57,703 1,022 5,497 255 252 15,201 211 175 Grants and collaborations 9,440 12,179 10,291 4,688 10,771 4,724 4,677 5,671 Total revenue $ 80,588 $ 24,197 $ 25,680 $ 12,980 $ 22,238 $ 26,544 $ 9,599 $ 8,811 Gross profit (loss) from product sales $ (1,584 ) $ (6,641 ) $ (7,387 ) $ (4,731 ) $ (11,290 ) $ (8,056 ) $ (2,969 ) $ (8,038 ) Net income (loss) $ (1,717 ) $ (33,861 ) $ 620 $ (37,371 ) $ (48,755 ) $ (19,705 ) $ (13,566 ) $ (15,308 ) Net loss attributable to Amyris, Inc. common stockholders: For basic loss per share $ (2,914 ) $ (42,819 ) $ (10,265 ) $ (37,371 ) $ (48,755 ) $ (19,705 ) $ (13,566 ) $ (15,308 ) For diluted loss per share $ (2,914 ) $ (42,819 ) $ (10,265 ) $ (37,371 ) $ (48,755 ) $ (19,705 ) $ (29,245 ) $ (30,273 ) Net loss per share attributable to common stockholders: Basic $ (0.06 ) $ (1.14 ) $ (0.44 ) $ (1.93 ) $ (2.67 ) $ (1.19 ) $ (0.91 ) $ (1.11 ) Diluted $ (0.06 ) $ (1.14 ) $ (0.44 ) $ (1.93 ) $ (2.67 ) $ (1.19 ) $ (1.67 ) $ (1.74 ) Weighted-average shares of common stock outstanding used in computing net loss per share of common stock: Basic 47,895,238 37,529,694 23,155,874 19,335,948 18,227,100 16,612,690 14,874,135 13,813,305 Diluted 47,895,238 37,529,694 23,155,874 19,335,948 18,227,100 16,612,690 17,526,410 17,395,474 ______________ * Certain amounts rounded to reconcile to year-to-date amounts previously reported in Quarterly Reports on Form 10 may not |
Note 18 - Subsequent Events
Note 18 - Subsequent Events | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 18. R&D Note Extension On March 30, 2018, March 31, 2018 May 31, 2018, March 31, 2018 May 31, 2018. Senior Secured Loan Facility Extension On March 30, 2018, $5.5 March 31, 2018 May 31, 2018. April 1, 2018 $5.5 5.0%. DSM Value Sharing Agreement Amendment On March 30, 2018, 2018 2018. Warrants Exchange and Exercise On April 12, 2018, 3,616,174 $7.00 fifteen May 2017 6, May 2017 3,616,174 $15.9 May 2017 not May 2017 not six no not not 30% thirty |
Schedule II - Valuation and Qua
Schedule II - Valuation and Qualifying Accounts | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] | SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS (In thousands) Balance at Provisions Recoveries Balance at Allowance for doubtful accounts: Year Ended December 31, 2017 501 141 — 642 Year Ended December 31, 2016 969 — (468 ) 501 Year Ended December 31, 2015 479 490 — 969 (In thousands) Balance at Additions Reductions/ Balance at Deferred tax assets valuation allowance: Year Ended December 31, 2017 386,867 13,567 (294,877 ) 105,557 Year Ended December 31, 2016 360,189 26,678 — 386,867 Year Ended December 31, 2015 312,323 47,866 — 360,189 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2017 | |
Accounting Policies [Abstract] | |
Liquidity [Policy Text Block] | Liquidity The Company has incurred significant operating losses since its inception and expects to continue to incur losses and negative cash flows from operations for at least the next 12 December 31, 2017, $59.6 $77.9 December 31, 2016 $1.2 As of December 31, 2017, $30.4 $165.4 $56.9 $21.8 April 17, 2019 $129.3 $12.9 Cash and cash equivalents of $57.1 December 31, 2017 April 12, 2018 ( 18 not March 31, 2019. one not 2018 December 31, 2017, first 2018, 2 may may not |
Basis of Accounting, Policy [Policy Text Block] | Basis of Consolidation The accompanying consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States (U.S. GAAP). The consolidated financial statements include the accounts of Amyris, Inc. and its wholly-owned and partially-owned subsidiaries in which the Company has a controlling interest after elimination of all significant intercompany accounts and transactions. Investments and joint venture arrangements are assessed to determine whether the terms provide economic or other control over the entity requiring consolidation of the entity. Entities controlled by means other than a majority voting interest are referred to as variable-interest entities (VIEs) and are consolidated when Amyris has both the power to direct the activities of the VIE that most significantly impact its economic performance and the obligation to absorb losses or the right to receive benefits that could potentially be significant to the entity. For any investment or joint venture in which (i) the Company does not not not not |
Sale of Subsidiary and Entry Into Commercial Agreements, Policy [Policy Text Block] | Sale of Subsidiary and Entry into Commercial Agreements On December 28, 2017, 1 $5.7 not not $29.7 not 2 10, 11, 13, |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates and Judgements The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may |
Reverse Stock Split [Policy Text Block] | Reverse Stock Split On June 5, 2017, 1 15 $0.0001 500,000,000 250,000,000. first first may The par value, number of shares outstanding and number of authorized shares of preferred stock were not |
Reclassification, Policy [Policy Text Block] | Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation in the Company’s consolidated financial statements and the accompanying notes to the consolidated financial statements. The consolidated statements of operations previously presented license fee revenue in combination with grants and collaborations revenue, and royalties (formerly referred to as “value share”) were previously presented in combination with renewable products revenue. Licenses and royalties revenue is presented as a separate line within the consolidated statements of operations. The reclassifications reflect the growth in the Company’s business model to license its technology and earn royalties from customers utilizing the Company’s technology in the products it produces and sells. The reclassifications had no |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original or remaining maturity of three |
Inventory, Policy [Policy Text Block] | Inventories Inventories, which consist of farnesene-derived products and flavors and fragrances ingredients, are stated at the lower of cost or net realizable value and are categorized as finished goods, work in process or raw material inventories. The Company evaluates the recoverability of its inventories based on assumptions about expected demand and net realizable value. If the Company determines that the cost of inventories exceeds their estimated net realizable value, the Company records a write-down equal to the difference between the cost of inventories and the estimated net realizable value. If actual net realizable values are less favorable than those projected by management, additional inventory write-downs may may first first |
Property, Plant and Equipment, Policy [Policy Text Block] | Property, Plant and Equipment, Net Property and equipment are recorded at cost. Depreciation and amortization are computed straight-line based on the estimated useful lives of the related assets, ranging from 3 15 15 The Company expenses costs for maintenance and repairs and capitalizes major replacements, renewals and betterments. For assets retired or otherwise disposed, both cost and accumulated depreciation are eliminated from the asset and accumulated depreciation accounts, and gains or losses related to the disposal are recorded in the statement of operations for the period. |
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] | Impairment of Long-Lived Assets Long-lived assets that are held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not |
Recoverable Taxes from Brazilian Government Entities [Policy Text Block] | Recoverable Taxes from Brazilian Government Entities Recoverable taxes from Brazilian government entities represent value-added taxes paid on purchases in Brazil, which are reclaimable from the Brazilian tax authorities, net of reserves for amounts estimated not |
Fair Value Measurement, Policy [Policy Text Block] | Fair Value Measurements The Company measures certain financial assets and liabilities at fair value based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. Where available, fair value is based on or derived from observable market prices or other observable inputs. Where observable prices or inputs are not The carrying amounts of certain financial instruments, such as cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The fair values of loans payable, convertible notes and credit facilities are based on the present value of expected future cash flows and assumptions about current interest rates and the creditworthiness of the Company. The loans payable, convertible notes and credit facilities are carried on the consolidated balance sheet on a historical cost basis, because the Company has not July 29, 2015; 4, Changes in the inputs into these valuation models have a significant impact on the estimated fair value of the embedded and freestanding derivatives. For example, a decrease (increase) in the estimated credit spread for the Company results in an increase (decrease) in the estimated fair value of the embedded derivatives. Conversely, a decrease (increase) in the stock price results in a decrease (increase) in the estimated fair value of the embedded derivatives. The changes during 2017, 2016 2015 |
Derivatives, Policy [Policy Text Block] | Derivatives The Company has made limited use of derivative instruments, including cross-currency interest rate swap agreements, to manage the Company's exposure to foreign currency exchange rate fluctuations and interest rate fluctuations related to the Company's Banco Pine S.A. loan, which the Company repaid in full in December 2017; 4, December 31, 2017, Embedded derivatives that are required to be bifurcated from the underlying debt instrument (i.e., host) are accounted for and valued as separate financial instruments. The Company evaluated the terms and features of its convertible notes payable and convertible preferred stock and identified compound embedded derivatives requiring bifurcation and accounting at fair value because the economic and contractual characteristics of the embedded derivatives met the criteria for bifurcation and separate accounting due to the instruments containing conversion options, “make-whole interest” provisions, down round conversion price adjustment provisions and conversion rate adjustments. Cash and anti-dilution warrants issued in conjunction with the convertible debt and equity financings are freestanding financial instruments which are also classified as derivative liabilities. |
Noncontrolling Interest [Policy Text Block] | Noncontrolling Interest Noncontrolling interests represent the portion of the Company's net income (loss), net assets and comprehensive income (loss) that is not |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and accounts receivable. The Company places its cash equivalents and investments (primarily certificates of deposits) with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one may not The Company performs ongoing credit evaluation of its customers, does not Customers representing 10% As of December 31, 2017 2016 Customer A (related party) 38 % * Customer B 10 % 33 % Customer C ** 22 % Customer E 15 % ** ______________ ** Less than 10% Customers representing 10% Years Ended December 31, 2017 2016 2015 Customer A (related party) 42 % * * Customer B 12 % 27 % 37 % Customer C 10 % ** * Customer D ** 22 % * Customer E ** 14 % ** Customer G ** ** 10 % ______________ * Not ** Less than 10% |
Revenue Recognition, Policy [Policy Text Block] | Revenue Recognition The Company recognizes revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants and collaborative research and development services. Revenue is recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable, and collectability is reasonably assured. If sales arrangements contain multiple elements, the Company evaluates whether the components of each arrangement represent separate units of accounting. Renewable Product Sales The Company’s renewable product sales do not not two March 31, 2012, not Licenses and Royalties License fees for intellectual property transferred to other parties, representing non-refundable payments received at the time of signature of license agreements, are recognized as revenue upon signature of the license agreements when the Company has no Royalties from intellectual property licenses that allow Amyris's customers to use the Company’s intellectual property to produce and sell their products in which the Company shares in the profits are recognized in the period the royalty report is received. Grants and Collaborative Research and Development Services Revenues from collaborative research and development services are recognized as the services are performed consistent with the performance requirements of the contract. In cases where the planned levels of research and development services fluctuate over the research term, the Company recognizes revenues using the proportional performance method based upon actual efforts to date relative to the amount of expected effort to be incurred by us. When up-front payments are received and the planned levels of research and development services do not Grants are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. Revenues from grants are recognized in the period during which the related costs are incurred, provided that the conditions under which the grants were provided have been met and only perfunctory obligations are outstanding. |
Cost of Sales, Policy [Policy Text Block] | Cost of Products Sold Cost of products sold includes the production costs of renewable products, which include the cost of raw materials, amounts paid to contract manufacturers and period costs including inventory write-downs resulting from applying lower of cost or net realizable value inventory adjustments. Cost of products sold also includes certain costs related to the scale-up of production. Shipping and handling costs charged to customers are recorded as revenues. Outbound shipping costs incurred are included in cost of products sold. Such charges were not |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements and government grants, including internal research. Research and development costs consist of direct and indirect internal costs related to specific projects, as well as fees paid to others that conduct certain research activities on the Company’s behalf. |
Debt, Policy [Policy Text Block] | Debt Extinguishment The Company accounts for the income or loss from extinguishment of debt in accordance with ASC 470, Debt, |
Compensation Related Costs, Policy [Policy Text Block] | Stock-based Compensation The Company accounts for stock-based employee compensation plans under the fair value recognition and measurement provisions of U.S. GAAP. Those provisions require all stock-based payments to employees, including grants of stock options and restricted stock units (RSUs), to be measured using the grant-date fair value of each award. The Company recognizes stock-based compensation expense net of expected forfeitures over each award's requisite service period, which is generally the vesting term. Expected forfeiture rates are based on the Company's historical experience. Stock-based compensation plans are described more fully in Note 12, |
Income Tax, Policy [Policy Text Block] | Income Taxes The Company is subject to income taxes in the United States and foreign jurisdictions and uses estimates to determine its provisions for income taxes. The Company uses the asset and liability method of accounting for income taxes, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect for the year in which the differences are expected to affect taxable income. Recognition of deferred tax assets is appropriate when realization of such assets is more likely than not. not The Company applies the provisions of Financial Accounting Standards Board (FASB) guidance on accounting for uncertainty in income taxes. The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability, and the tax benefit to be recognized is measured at the largest amount of benefit that is greater than 50 may |
Foreign Currency Transactions and Translations Policy [Policy Text Block] | Foreign Currency Translation The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at each balance sheet date, and revenue and expense amounts are translated at average rates during each period, with resulting foreign currency translation adjustments recorded in other comprehensive loss, net of tax, in the consolidated statements of stockholders’ deficit. As of December 31, 2017 2016, $42.2 $40.9 Where the U.S. dollar is the functional currency, remeasurement adjustments are recorded in other income (expense), net in the accompanying consolidated statements of operations. Net losses resulting from foreign exchange transactions were $0.4 $0.6 $1.3 December 31, 2017, 2016, 2015, |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Adopted Accounting Standards During the year ended December 31, 2017 • ASU 2015 11, Inventory (Topic 330 2015 11, • ASU 2016 06 , Derivatives and Hedging (Topic 815 not one January 1, 2017, • ASU 2016 09, Compensation–Stock Compensation (Topic 718 2016 09 $40.1 None Recently Issued Accounting Standards Not Revenue Recognition In May 2014, No. 2014 09, Revenue from Contracts with Customers 2014 09 first 2018. 2014 09 March 2016, April 2016, May 2016 December 2016 2016 08, Revenue from Contracts with Customers: Principal versus Agent Considerations 2016 10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing 2016 12, Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients 2016 20, Technical Corrections and Improvements to Topic 606, The Company is adopting these standards using the modified retrospective approach applied only to contracts that are not January 1, 2018. January 1, 2018. January 1, 2018 $1.0 $2.0 first 2018. Financial Instruments In January 2016, 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01 not 2016 01 January 1, 2018, 2016 01 2016 01, In February 2018, 2018 03, Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities 2018 03 no 2018 03 not 2018 03 December 15, 2017, June 15, 2018, may 2016 01. The Company will be adopting ASU 2016 01 2018 03 January 1, 2018. not Leases In February 2016, 2016 02, Leases (Topic 842 first 2019 Classification of Cash Flow Elements In August 2016, 2016 15, 230 Classification of Certain Cash Receipts and Cash Payments zero 2016 15 January 1, 2018 Income Tax Consequences of Intra-Entity Transfers of Assets Other Than Inventory In October 2016, 2016 16, Income Taxes (Topic 740 January 1, 2018, not December 31, 2017, 2016 16 Restricted Cash in Statement of Cash Flows In November 2016, 2016 18, 230 Restricted Cash one no one 2016 18 January 1, 2018 not Derecognition of Nonfinancial Assets In February 2017, 2017 05, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610 20 606 not 1 not not not 2 not first 2018 Financial Instruments with "Down Round" Features In July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 no first 2019 |
Note 1 - Basis of Presentatio30
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] | As of December 31, 2017 2016 Customer A (related party) 38 % * Customer B 10 % 33 % Customer C ** 22 % Customer E 15 % ** Years Ended December 31, 2017 2016 2015 Customer A (related party) 42 % * * Customer B 12 % 27 % 37 % Customer C 10 % ** * Customer D ** 22 % * Customer E ** 14 % ** Customer G ** ** 10 % |
Note 2 - Balance Sheet Details
Note 2 - Balance Sheet Details (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] | December 31, 2017 2016 Accounts receivable $ 19,572 $ 13,673 Related party accounts receivable 14,691 805 34,263 14,478 Less: allowance for doubtful accounts (642 ) (501 ) Total accounts receivable, net $ 33,621 $ 13,977 |
Schedule of Inventory, Current [Table Text Block] | December 31, 2017 2016 Raw materials $ 819 $ 3,159 Work in process 364 1,848 Finished goods 4,225 1,206 Total inventories $ 5,408 $ 6,213 |
Property, Plant and Equipment [Table Text Block] | December 31, (In thousands) 2017 2016 Machinery and equipment $ 49,277 $ 82,688 Leasehold improvements 40,036 38,785 Computers and software 9,555 9,585 Buildings — 4,699 Furniture and office equipment, vehicles and land 3,415 2,957 Construction in progress 17,438 2,216 119,721 140,930 Less: accumulated depreciation and amortization (105,829 ) (87,195 ) Total property, plant and equipment, net $ 13,892 $ 53,735 |
Schedule of Other Assets, Noncurrent [Table Text Block] | December 31, 2017 2016 Contingent consideration $ 8,151 $ — Prepaid royalty 7,409 — Cost-method investment in SweeGen 3,233 — Deposits 2,462 409 Goodwill 560 560 Other 825 1,366 Total other assets $ 22,640 $ 2,335 |
Schedule of Accrued and Other Current Liabilities [Table Text Block] | December 31, 2017 2016 Accrued interest $ 8,213 $ 4,847 Payroll and related expenses 7,238 6,344 Tax-related liabilities 5,837 2,610 SMA relocation accrual 3,587 3,641 Other 2,633 5,792 Professional services 1,894 6,876 Total accrued and other current liabilities $ 29,402 $ 30,110 |
Other Liabilities [Table Text Block] | December 31, 2017 2016 Deferred rent, net of current portion $ 7,818 $ 8,906 Deferred revenue, net of current portion 383 6,650 Capital lease obligation, net of current portion 217 334 Accrued interest, net of current portion — 5,542 Other liabilities 2,214 2,299 Total other noncurrent liabilities $ 10,632 $ 23,731 |
Note 3 - Fair Value Measureme32
Note 3 - Fair Value Measurement (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | December 31, 2017 2016 Level Level Level Total Level Level Level Total Assets Money market funds $ 53,199 $ — $ — $ 53,199 $ 1,549 $ — $ — $ 1,549 Certificates of deposit 7,813 — — 7,813 1,373 — — 1,373 Total assets measured and recorded at fair value $ 61,012 $ — $ — $ 61,012 $ 2,922 $ — $ — $ 2,922 Liabilities Embedded derivatives in connection with issuance of debt and equity instruments $ — $ — $ 4,203 $ 4,203 $ — $ — $ 2,283 $ 2,283 Freestanding derivative instruments in connection with issuance of equity instruments — — $ 115,775 $ 115,775 — — 1,852 1,852 Cross-currency interest rate swap derivative liability (1) — — — — 3,343 — 3,343 Total liabilities measured and recorded at fair value $ — $ — $ 119,978 $ 119,978 $ — $ 3,343 $ 4,135 $ 7,478 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | (in thousands) 2017 2016 Balance at January 1 $ 4,135 $ 46,430 Additions 130,957 2,050 (Gain) loss from change in fair value of derivative liabilities 31,600 (41,459 ) Derecognition upon conversion or extinguishment (46,714 ) (2,886 ) Balance at December 31 $ 119,978 $ 4,135 |
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] | December 31, 2017 2016 Risk-free interest rate 1.68% - 2.40% 0.55% - 1.31% Risk-adjusted yields 18.40% - 28.53% 12.80% - 22.93% Stock price volatility 45% - 80% 45% Probability of change in control 5% 5% Stock price $3.75 $10.95 Credit spread 16.63% - 26.70% 11.59% - 21.64% Estimated conversion dates 2018 - 2025 2017 - 2019 Initial recognition Expected dividend yield — % Risk-free interest rate 2 % Expected term (in years) 10.0 Expected volatility 74 % |
Schedule of Derivative Liabilities at Fair Value [Table Text Block] | December 31, 2017 2016 Swap obligation, at fair market value: Current portion $ — $ 584 Noncurrent portion — 2,759 Total swap obligation — 3,343 Freestanding or compound embedded derivative liabilities, at fair value 119,978 4,135 Total derivative liabilities $ 119,978 $ 7,478 |
Note 4 - Debt (Tables)
Note 4 - Debt (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | December 31, 2017 2016 Principal Unamortized Debt (Discount) Premium Net Principal Unamortized Debt (Discount) Premium Net Convertible notes payable 2015 Rule 144A convertible notes $ 37,887 $ (6,872 ) $ 31,015 $ 40,478 $ (17,712 ) $ 22,766 2014 Rule 144A convertible notes 24,004 (3,170 ) 20,834 27,404 (5,399 ) 22,005 December 2016, April 2017, June 2017 and December 2017 convertible notes 5,000 (25 ) 4,975 10,000 (78 ) 9,922 August 2013 financing convertible notes 4,009 (2,918 ) 1,091 13,826 (4,579 ) 9,247 Fidelity notes — — — 15,309 (326 ) 14,983 70,900 (12,985 ) 57,915 107,017 (28,094 ) 78,923 Related party convertible notes payable August 2013 financing convertible notes 21,711 897 22,608 19,781 2,033 21,814 2014 Rule 144A convertible notes 24,705 (3,784 ) 20,921 24,705 (7,380 ) 17,325 R&D note 3,700 (18 ) 3,682 3,700 (80 ) 3,620 50,116 (2,905 ) 47,211 48,186 (5,427 ) 42,759 Loans payable and credit facilities Senior secured loan facility 28,566 (253 ) 28,313 28,566 (908 ) 27,658 Ginkgo notes 12,000 (4,983 ) 7,017 8,500 — 8,500 Nossa Caixa and Banco Pine notes — — — 11,135 — 11,135 Other loans payable 6,463 (1,277 ) 5,186 8,305 (1,361 ) 6,944 Guanfu credit facility — — — 25,000 (5,436 ) 19,564 Other credit facilities 381 — 381 1,869 — 1,869 47,410 (6,513 ) 40,897 83,375 (7,705 ) 75,670 Related party loans payable DSM note 25,000 (8,039 ) 16,961 — — — February 2016 private placement 2,000 — 2,000 20,000 (1,309 ) 18,691 Other DSM loan 393 — 393 — — — June and October 2016 private placements — — — 11,000 — 11,000 27,393 (8,039 ) 19,354 31,000 (1,309 ) 29,691 Total debt $ 195,819 $ (30,442 ) 165,377 $ 269,578 $ (42,535 ) 227,043 Less: current portion (56,943 ) (59,155 ) Long-term debt, net of current portion $ 108,434 $ 167,888 |
Schedule of Long-term Debt Instruments [Table Text Block] | Years Ending December 31, Convertible Related Loans Related Total 2018 $ 11,060 $ 20,835 $ 36,465 $ 5,423 $ 73,783 2019 69,334 35,238 1,704 2,500 108,776 2020 — — 1,627 2,500 4,127 2021 — — 1,627 27,500 29,127 2022 — — 13,417 — 13,417 Thereafter — — 2,528 — 2,528 Total future minimum payments (1) 80,394 56,073 57,368 37,923 231,758 Less: amount representing interest (2) (22,479 ) (8,862 ) (16,471 ) (18,569 ) (66,381 ) Present value of minimum debt payments 57,915 47,211 40,897 19,354 165,377 Less: current portion (4,932 ) (17,626 ) (31,992 ) (2,393 ) (56,943 ) Noncurrent portion of debt $ 52,983 $ 29,585 $ 8,905 $ 16,961 $ 108,434 |
Note 6 - Stockholders' Deficit
Note 6 - Stockholders' Deficit (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Issued Exercised Warrants May and August 2017 Cash Warrants May 2017 14,768,380 — 14,768,380 August 2017 9,543,234 — 9,543,234 24,311,614 — 24,311,614 May and August 2017 Dilution Warrants May 2017 6,377,466 (3,103,278 ) 3,274,188 August 2017 — — — 6,377,466 (3,103,278 ) 3,274,188 30,689,080 (3,103,278 ) 27,585,802 |
Note 7 - Variable-interest En35
Note 7 - Variable-interest Entities and Unconsolidated Investments (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedule of Variable Interest Entities [Table Text Block] | December 31, 2017 2016 Assets $ 36,781 $ 30,778 Liabilities $ 3,187 $ 333 |
Noncontrolling Interest [Table Text Block] | (In thousands) 2017 2016 Balance at January 1 $ (937 ) $ 391 Income attributable to noncontrolling interest — (1,328 ) Balance at December 31 $ (937 ) $ (937 ) |
Note 8 - Net Loss Per Share A36
Note 8 - Net Loss Per Share Attributable to Common Stockholders (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Years Ended December 31, 2017 2016 2015 Numerator: Net income (loss) attributable to Amyris, Inc. $ (72,329 ) $ (97,334 ) $ (217,952 ) Less deemed dividend on capital distribution to related parties (8,648 ) — — Less deemed dividend related to beneficial conversion feature on Series A preferred stock (562 ) — — Less deemed dividend related to beneficial conversion feature on Series B preferred stock (634 ) — — Less deemed dividend related to beneficial conversion feature on Series D preferred stock (5,757 ) — — Less cumulative dividends on Series A and Series B preferred stock (5,439 ) — — Net loss attributable to Amyris, Inc. common stockholders, basic (93,369 ) (97,334 ) (217,952 ) Adjustment to exclude fair value gain on liability classified warrants (1) — — (3,825 ) Net loss attributable to Amyris, Inc. common stockholders for basic net loss per share (93,369 ) (97,334 ) (221,777 ) Interest on convertible debt — 4,428 — Accretion of debt discount — 2,889 — Gain from change in fair value of derivative instruments — (25,630 ) — Net loss attributable to Amyris, Inc. common stockholders, diluted $ (93,369 ) $ (115,647 ) $ (221,777 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic 32,253,570 15,896,014 8,464,106 Basic loss per share $ (2.89 ) $ (6.12 ) $ (26.20 ) Weighted-average shares of common stock outstanding 32,253,570 15,896,014 8,464,106 Effective of dilutive convertible promissory notes — 1,746,951 — Weighted-average common stock equivalents used in computing net loss per share of common stock, diluted 32,253,570 17,642,965 8,464,106 Diluted loss per share $ (2.89 ) $ (6.55 ) $ (26.20 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Years Ended December 31, 2017 2016 2015 Period-end common stock warrants 29,921,844 334,740 193,462 Convertible promissory notes (1) 8,040,828 2,395,596 4,835,821 Period-end stock options to purchase common stock 1,338,367 899,179 862,008 Period-end restricted stock units 685,007 466,076 370,323 Total potentially dilutive securities excluded from computation of diluted net loss per share 39,986,046 4,095,591 6,261,614 |
Note 9 - Commitments and Cont37
Note 9 - Commitments and Contingencies (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedule Of Future Minimum Payments For Lease Obligations [Table Text Block] | Years Ending December 31 Capital Operating Total Lease 2018 $ 755 $ 10,127 $ 10,882 2019 185 8,760 8,945 2020 39 7,018 7,057 2021 — 7,242 7,242 2022 — 7,415 7,415 Thereafter — 3,545 3,545 Total future minimum payments 979 $ 44,107 $ 45,086 Less: amount representing interest (38 ) Present value of minimum lease payments 941 Less: current portion (724 ) Long-term portion $ 217 |
Note 10 - Significant Revenue38
Note 10 - Significant Revenue Agreements (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Revenue in Connection with Significant Revenue Agreement [Table Text Block] | Years Ended December 31, (In thousands) 2017 2016 2015 Renewable Licenses Grants and TOTAL Renewable Licenses Grants and TOTAL Renewable Licenses Grants and TOTAL Revenue from significant revenue agreements with: DSM (related party) $ — $ 57,972 $ 1,679 $ 59,651 $ — $ — $ — $ — $ — $ — $ — $ — Firmenich 9,621 1,199 5,803 16,623 9,660 745 7,513 17,918 1,425 259 11,000 12,684 Nenter & Co., Inc. 12,057 2,633 — 14,690 6,236 — — 6,236 — — — — DARPA — — 12,333 12,333 — — 9,697 9,697 — — 80 80 Ginkgo — — — — — 15,000 — 15,000 — — — — Subtotal revenue from significant revenue agreements 21,678 61,804 19,815 103,297 15,896 15,745 17,210 48,851 1,425 259 11,080 12,764 Revenue from all other customers 20,692 2,673 16,783 40,148 9,614 94 8,633 18,341 13,081 131 8,177 21,389 Total revenue from all customers $ 42,370 $ 64,477 $ 36,598 $ 143,445 $ 25,510 $ 15,839 $ 25,843 $ 67,192 $ 14,506 $ 390 $ 19,257 $ 34,153 |
Note 11 - Related Party Trans39
Note 11 - Related Party Transactions (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedule of Related Party Debt [Table Text Block] | December 31, 2017 2016 Principal Unamortized Net Principal Unamortized Net Total R&D note $ 3,700 $ (18 ) $ 3,682 $ 3,700 $ (80 ) $ 3,620 August 2013 financing convertible notes 21,711 897 22,608 19,781 2,033 21,814 2014 Rule 144A convertible notes 9,705 (1,538 ) 8,167 9,705 (2,986 ) 6,719 35,116 (659 ) 34,457 33,186 (1,033 ) 32,153 DSM DSM note 25,000 (8,039 ) 16,961 — — — Other DSM loan 393 — 393 — — — 25,393 (8,039 ) 17,354 — — — Biolding February 2016 private placement 2,000 — 2,000 2,000 (131 ) 1,869 Foris 2014 Rule 144A convertible notes 5,000 (660 ) 4,340 5,000 (1,316 ) 3,684 February 2016 private placement — — — 16,000 (1,047 ) 14,953 June and October 2016 private placements — — — 11,000 — 11,000 5,000 (660 ) 4,340 32,000 (2,363 ) 29,637 Naxyris February 2016 private placement — — — 2,000 (131 ) 1,869 Temasek 2014 Rule 144A convertible notes 10,000 (1,586 ) 8,414 10,000 (3,078 ) 6,922 $ 77,509 $ (10,944 ) $ 66,565 $ 79,186 $ (6,736 ) $ 72,450 |
Schedule of Related Party Revenues [Table Text Block] | Years Ended December 31, (In thousands) 2017 2016 2015 Renewable Licenses Grants and TOTAL Renewable Licenses Grants and TOTAL Renewable Licenses Grants and TOTAL Revenue from related parties: DSM $ — $ 57,972 $ 1,679 $ 59,651 $ — $ — $ — $ — $ — $ — $ — $ — Novvi 1,491 — — 1,491 1,390 — — 1,390 — — — — Total (200 ) — — (200 ) 172 — — 172 865 — — 865 Subtotal revenue from related parties 1,291 57,972 1,679 60,942 1,562 — — 1,562 865 — — 865 Revenue from all other customers 41,079 6,505 34,919 82,503 23,948 15,839 25,843 65,630 13,641 390 19,257 33,288 Total revenue from all customers $ 42,370 $ 64,477 $ 36,598 $ 143,445 $ 25,510 $ 15,839 $ 25,843 $ 67,192 $ 14,506 $ 390 $ 19,257 $ 34,153 |
Schedule of Related Party Accounts Receivables [Table Text Block] | December 31, 2017 2016 DSM $ 12,823 $ — Novvi $ 1,607 $ — Total $ 238 $ 805 Related party accounts receivable, net $ 14,668 $ 805 |
Note 12 - Stock-based Compens40
Note 12 - Stock-based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | Years Ended December 31, (In thousands) 2017 2016 2015 Research and development $ 2,204 $ 1,948 $ 2,306 Sales, general and administrative 4,061 5,377 6,828 Total stock-based compensation expense $ 6,265 $ 7,325 $ 9,134 |
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] | Year ended December 31, 2017 2016 2015 Options granted 661,094 239,012 314,686 Weighted-average grant-date fair value per share $ 3.26 $ 8.85 $ 18.15 Compensation expense related to stock options (in millions) $ 3.3 $ 3.5 $ 6.0 Unrecognized compensation costs as of December 31 (in millions) $ 2.7 $ 4.4 $ 8.0 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Years Ended December 31, 2017 2016 2015 Expected dividend yield — % — % — % Risk-free interest rate 2.1 % 1.4 % 1.8 % Expected term (in years) 6.12 6.16 6.08 Expected volatility 84 % 73 % 74 % |
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block] | Number of Weighted- Weighted-average (in years) Aggregate Outstanding - December 31, 2016 875,021 $ 55.20 6.70 $ 443 Options granted 661,094 $ 4.56 Options exercised - $ - Options forfeited or expired (197,748 ) $ 33.46 Outstanding - December 31, 2017 1,338,367 $ 33.40 7.71 $ 97 Vested or expected to vest after December 31, 2017 1,257,439 $ 33.40 7.62 $ 81 Exercisable at December 31, 2017 925,778 $ 43.48 7.18 $ 27 |
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] | Number of Weighted- Weighted-average Outstanding - December 31, 2016 454,923 $ 17.48 1.4 Awarded 523,167 $ 5.51 Vested (191,844 ) $ 18.71 Forfeited (102,692 ) $ 13.00 Outstanding - December 31, 2017 683,554 $ 8.66 1.4 Vested or expected to vest after December 31, 2017 533,670 $ 8.92 1.3 |
Note 15 - Income Taxes (Tables)
Note 15 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] | Years Ended December 31, 2017 2016 2015 United States $ (68,777 ) $ (101,210 ) $ (188,943 ) Foreign (3,257 ) 4,429 (24,457 ) Loss before income taxes and loss from investments in affiliates $ (72,034 ) $ (96,781 ) $ (213,400 ) |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | Years Ended December 31, 2017 2016 2015 Current: Federal $ — $ — $ — State — — — Foreign 964 553 468 Total current provision 964 553 468 Deferred: Federal (669 ) — — State — — — Foreign — — — Total deferred provision (benefit) (669 ) — — Total provision for income taxes $ 295 $ 553 $ 468 |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | Years Ended December 31, 2017 2016 2015 Statutory tax rate (34.0 )% (34.0 )% (34.0 )% State taxes, net of federal tax benefit — % — % (0.3 )% Stock-based compensation 0.1 % — % 0.1 % Federal R&D credit (1.0 )% (0.8 )% (0.6 )% Derivative liabilities 1.7 % 1.4 % 3.6 % Nondeductible interest 6.2 % 5.0 % 5.5 % Other (0.4 )% (3.2 )% 0.1 % Foreign losses 17.6 % 0.5 % (1.2 )% Change in U.S. federal tax rate 57.0 % — % — % IRC Section 382 limitation 5.0 % — % — % Change in valuation allowance (51.9 )% 31.7 % 27.1 % Effective income tax rate 0.3 % 0.6 % 0.3 % |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | December 31, 2017 2016 2015 Net operating loss carryforwards $ 23,877 $ 236,741 $ 207,241 Property, plant and equipment 4,195 12,917 10,519 Research and development credits 10,702 17,348 16,612 Foreign tax credit 2,669 2,452 1,899 Accruals and reserves 10,754 30,303 26,366 Stock-based compensation 11,417 17,184 19,048 Capitalized start-up costs — 9,182 9,568 Capitalized research and development costs 34,973 65,962 63,339 Intangible and others 3,932 6,714 9,999 Total deferred tax assets 102,519 398,803 364,591 Debt discount and derivative (6,616 ) (11,936 ) (4,402 ) Total deferred tax liabilities (6,616 ) (11,936 ) (4,402 ) Net deferred tax assets prior to valuation allowance 95,903 386,867 360,189 Less: valuation allowance (95,903 ) (386,867 ) (360,189 ) Net deferred tax assets $ — $ — $ — |
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] | (In thousands) Balance at December 31, 2014 $ 17,081 Decreases in tax positions for prior period (9,404 ) Increases in tax positions during current period 957 Balance at December 31, 2015 8,634 Decreases in tax positions for prior period (314 ) Increases in tax positions during current period 781 Balance at December 31, 2016 9,101 Increases in tax positions for prior period 50 Increases in tax positions during current period 8,029 Balance at December 31, 2017 $ 17,180 |
Note 16 - Geographical Inform42
Note 16 - Geographical Information (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] | Years Ended December 31, 2017 2016 2015 United States $ 94,060 $ 30,942 $ 7,122 Europe 23,823 23,612 16,049 Asia 23,290 12,055 5,907 Brazil 2,159 488 5,004 Other 113 95 71 $ 143,445 $ 67,192 $ 34,153 |
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] | December 31, 2017 2016 2015 United States $ 10,357 $ 9,342 $ 18,401 Brazil 3,357 44,153 41,093 Europe 178 240 303 $ 13,892 $ 53,735 $ 59,797 |
Note 17 - Quarterly Results o43
Note 17 - Quarterly Results of Operations Data (Unaudited)* (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Quarterly Financial Information [Table Text Block] | Years Ended December 31, 2017 2016 Fourth Third Second First Fourth Third Second First Revenue Renewable products $ 13,445 $ 10,996 $ 9,892 $ 8,037 $ 11,215 $ 6,619 $ 4,711 $ 2,965 Licenses and royalties 57,703 1,022 5,497 255 252 15,201 211 175 Grants and collaborations 9,440 12,179 10,291 4,688 10,771 4,724 4,677 5,671 Total revenue $ 80,588 $ 24,197 $ 25,680 $ 12,980 $ 22,238 $ 26,544 $ 9,599 $ 8,811 Gross profit (loss) from product sales $ (1,584 ) $ (6,641 ) $ (7,387 ) $ (4,731 ) $ (11,290 ) $ (8,056 ) $ (2,969 ) $ (8,038 ) Net income (loss) $ (1,717 ) $ (33,861 ) $ 620 $ (37,371 ) $ (48,755 ) $ (19,705 ) $ (13,566 ) $ (15,308 ) Net loss attributable to Amyris, Inc. common stockholders: For basic loss per share $ (2,914 ) $ (42,819 ) $ (10,265 ) $ (37,371 ) $ (48,755 ) $ (19,705 ) $ (13,566 ) $ (15,308 ) For diluted loss per share $ (2,914 ) $ (42,819 ) $ (10,265 ) $ (37,371 ) $ (48,755 ) $ (19,705 ) $ (29,245 ) $ (30,273 ) Net loss per share attributable to common stockholders: Basic $ (0.06 ) $ (1.14 ) $ (0.44 ) $ (1.93 ) $ (2.67 ) $ (1.19 ) $ (0.91 ) $ (1.11 ) Diluted $ (0.06 ) $ (1.14 ) $ (0.44 ) $ (1.93 ) $ (2.67 ) $ (1.19 ) $ (1.67 ) $ (1.74 ) Weighted-average shares of common stock outstanding used in computing net loss per share of common stock: Basic 47,895,238 37,529,694 23,155,874 19,335,948 18,227,100 16,612,690 14,874,135 13,813,305 Diluted 47,895,238 37,529,694 23,155,874 19,335,948 18,227,100 16,612,690 17,526,410 17,395,474 |
Schedule II - Valuation and Q44
Schedule II - Valuation and Qualifying Accounts (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Summary of Valuation Allowance [Table Text Block] | (In thousands) Balance at Provisions Recoveries Balance at Allowance for doubtful accounts: Year Ended December 31, 2017 501 141 — 642 Year Ended December 31, 2016 969 — (468 ) 501 Year Ended December 31, 2015 479 490 — 969 (In thousands) Balance at Additions Reductions/ Balance at Deferred tax assets valuation allowance: Year Ended December 31, 2017 386,867 13,567 (294,877 ) 105,557 Year Ended December 31, 2016 360,189 26,678 — 386,867 Year Ended December 31, 2015 312,323 47,866 — 360,189 |
Note 1 - Basis of Presentatio45
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) $ / shares in Units, $ in Thousands | Dec. 28, 2017USD ($) | Jun. 05, 2017$ / sharesshares | Dec. 31, 2017USD ($)$ / sharesshares | Dec. 31, 2016USD ($)$ / sharesshares | Dec. 31, 2015USD ($) |
Proceeds from Divestiture of Businesses | $ 54,827 | ||||
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal | 5,732 | ||||
Working Capital | (59,600) | (77,900) | |||
Retained Earnings (Accumulated Deficit) | (1,206,767) | (1,134,438) | |||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | 30,400 | ||||
Long-term Debt | 165,377 | 227,043 | |||
Long-term Debt, Current Maturities, Including Due to Related Parties | 56,943 | 59,155 | |||
Convertible Debt | 21,800 | ||||
Long-term Debt, Maturities, Repayments of Principal and Interest in Next 15 Months | 129,300 | ||||
Long-term Debt, Maturities, Repayments of Interest in Next 15 Months | 12,900 | ||||
Cash, Cash Equivalents, and Short-term Investments | 57,100 | ||||
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax | $ (42,200) | $ (40,900) | |||
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||
Common Stock, Shares Authorized | shares | 250,000,000 | 250,000,000 | 500,000,000 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 12 years | ||||
Foreign Currency Transaction Gain (Loss), before Tax | $ 1,230 | $ (557) | (1,328) | ||
Deferred Tax Assets, Gross | 102,519 | 398,803 | 364,591 | ||
Accounting Standards Update 2016-09 [Member] | |||||
Deferred Tax Assets, Gross | 40,100 | ||||
Other Expense, Net [Member] | |||||
Foreign Currency Transaction Gain (Loss), before Tax | (400) | $ (600) | $ (1,300) | ||
Minimum [Member] | Accounting Standards Update 2014-09 [Member] | |||||
Cumulative Effect on Retained Earnings, Net of Tax | 1,000 | ||||
Maximum [Member] | Accounting Standards Update 2014-09 [Member] | |||||
Cumulative Effect on Retained Earnings, Net of Tax | $ 2,000 | ||||
Machinery, Equipment, and Fixtures [Member] | Minimum [Member] | |||||
Property, Plant and Equipment, Useful Life | 3 years | ||||
Machinery, Equipment, and Fixtures [Member] | Maximum [Member] | |||||
Property, Plant and Equipment, Useful Life | 15 years | ||||
Building [Member] | |||||
Property, Plant and Equipment, Useful Life | 15 years | ||||
Reverse Stock Split [Member] | |||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 15 | ||||
DSM [Member] | |||||
Disposal Group, Including Discontinued Operation, Consideration | $ 17,800 | ||||
License and Services Revenue | 27,500 | ||||
Line of Credit Facility, Maximum Borrowing Capacity | 25,000 | ||||
Royalty Revenue | 15,000 | ||||
Future Minimum Annual Royalty Payments Receivable, Fair Value | 17,800 | ||||
Amyris Brasil [Member] | |||||
Proceeds from Divestiture of Businesses | 33,000 | ||||
Repayments of Debt | 12,600 | ||||
Disposal Group, Including Discontinued Operation, Consideration | 56,900 | ||||
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal | 5,700 | ||||
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax | $ 29,700 |
Note 1 - Basis of Presentatio46
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) - Customer Concentration Risk [Member] | 12 Months Ended | |||||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | ||||
Accounts Receivable [Member] | Customer B [Member] | ||||||
Customer A (related party) | 38.00% | |||||
Accounts Receivable [Member] | Customer C [Member] | ||||||
Customer A (related party) | 10.00% | 33.00% | ||||
Accounts Receivable [Member] | Customer E [Member] | ||||||
Customer A (related party) | 22.00% | |||||
Accounts Receivable [Member] | Customer F [Member] | ||||||
Customer A (related party) | 15.00% | |||||
Revenues [Member] | Customer B [Member] | ||||||
Customer A (related party) | 12.00% | 27.00% | 37.00% | |||
Revenues [Member] | Customer A [Member] | ||||||
Customer A (related party) | 42.00% | |||||
Revenues [Member] | Customer C [Member] | ||||||
Customer A (related party) | 10.00% | [1] | [2] | |||
Revenues [Member] | Customer E [Member] | ||||||
Customer A (related party) | [1] | 14.00% | [1] | |||
Revenues [Member] | Customer D [Member] | ||||||
Customer A (related party) | [1] | 22.00% | [2] | |||
Revenues [Member] | Customer G [Member] | ||||||
Customer A (related party) | [1] | [1] | 10.00% | |||
[1] | Less than 10% | |||||
[2] | Not a customer |
Note 2 - Balance Sheet Detail47
Note 2 - Balance Sheet Details (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Property, Plant and Equipment, Net | $ 13,892 | $ 53,735 | |
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | 105,829 | 87,195 | |
Depreciation, Depletion and Amortization | 11,358 | 11,374 | $ 12,920 |
Impairment of Long-Lived Assets Held-for-use | 7,305 | 34,166 | |
Other Expense, Net [Member] | |||
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property | 100 | (200) | 200 |
Property, Plant and Equipment, Including Capital Leases [Member] | |||
Depreciation, Depletion and Amortization | 11,400 | 11,400 | $ 12,900 |
Capital Lease Obligations [Member] | |||
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | 1,600 | 600 | |
Capital Lease Obligations [Member] | Machinery and Equipment, Furniture and Office Equipment Under Capital Lease [Member] | |||
Property, Plant and Equipment, Net | $ 4,200 | $ 3,100 |
Note 2 - Balance Sheet Detail48
Note 2 - Balance Sheet Details - Accounts Receivable (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Accounts receivable | $ 19,572 | $ 13,673 |
Related party accounts receivable | 14,691 | 805 |
34,263 | 14,478 | |
Less: allowance for doubtful accounts | (642) | (501) |
Total accounts receivable, net | $ 33,621 | $ 13,977 |
Note 2 - Balance Sheet Detail49
Note 2 - Balance Sheet Details - Inventory, Current (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Raw materials | $ 819 | $ 3,159 |
Work in process | 364 | 1,848 |
Finished goods | 4,225 | 1,206 |
Total inventories | $ 5,408 | $ 6,213 |
Note 2 - Balance Sheet Detail50
Note 2 - Balance Sheet Details - Property, Plant and Equipment (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Property, plant and equipment | $ 119,721 | $ 140,930 |
Less: accumulated depreciation and amortization | (105,829) | (87,195) |
Total property, plant and equipment, net | 13,892 | 53,735 |
Machinery and Equipment [Member] | ||
Property, plant and equipment | 49,277 | 82,688 |
Leasehold Improvements [Member] | ||
Property, plant and equipment | 40,036 | 38,785 |
Computer Equipment and Software [Member] | ||
Property, plant and equipment | 9,555 | 9,585 |
Building [Member] | ||
Property, plant and equipment | 4,699 | |
Furniture and Office Equipment, Vehicles and Land [Member] | ||
Property, plant and equipment | 3,415 | 2,957 |
Construction in Progress [Member] | ||
Property, plant and equipment | $ 17,438 | $ 2,216 |
Note 2 - Balance Sheet Detail51
Note 2 - Balance Sheet Details - Other Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Contingent consideration | $ 8,151 | |
Prepaid royalty | 7,409 | |
Cost-method investment in SweeGen | 3,233 | |
Deposits | 2,462 | 409 |
Goodwill | 560 | 560 |
Other | 825 | 1,366 |
Total other assets | $ 22,640 | $ 2,335 |
Note 2 - Balance Sheet Detail52
Note 2 - Balance Sheet Details - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Accrued interest | $ 8,213 | $ 4,847 |
Payroll and related expenses | 7,238 | 6,344 |
Tax-related liabilities | 5,837 | 2,610 |
SMA relocation accrual | 3,587 | 3,641 |
Other | 2,633 | 5,792 |
Professional services | 1,894 | 6,876 |
Total accrued and other current liabilities | $ 29,402 | $ 30,110 |
Note 2 - Balance Sheet Detail53
Note 2 - Balance Sheet Details - Other Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Deferred rent, net of current portion | $ 7,818 | $ 8,906 |
Deferred revenue, net of current portion | 383 | 6,650 |
Capital lease obligation, net of current portion | 217 | 334 |
Accrued interest, net of current portion | 5,542 | |
Other liabilities | 2,214 | 2,299 |
Total other noncurrent liabilities | $ 10,632 | $ 23,731 |
Note 3 - Fair Value Measureme54
Note 3 - Fair Value Measurement (Details Textual) R$ in Millions | Dec. 15, 2015USD ($)shares | Jul. 29, 2015USD ($) | Aug. 31, 2017USD ($)shares | May 31, 2017shares | Apr. 30, 2017USD ($)shares | May 31, 2016shares | Dec. 31, 2017USD ($) | Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($) | Dec. 31, 2017BRL (R$) |
Derivative Liability | $ 119,978,000 | $ 7,478,000 | ||||||||
Proceeds from Warrant Exercises | 5,000,000 | $ 285,000 | ||||||||
Gain (Loss) on Derivative Instruments, Net, Pretax | (1,742,000) | 41,355,000 | $ 16,287,000 | |||||||
Long-term Debt | 165,377,000 | 227,043,000 | ||||||||
Long-term Debt, Fair Value | $ 156,900,000 | |||||||||
Cost of Capital, Weighted Average | 27.00% | 27.00% | ||||||||
Fair Value Inputs, Discount Rate | 8.60% | |||||||||
SweeGen Common Stock [Member] | ||||||||||
Equity Method Investment, Aggregate Cost | $ 3,200,000 | |||||||||
Fair Value Inputs, Discount Rate | 40.00% | |||||||||
Blue California [Member] | Intellectual Property License and Strain Access Agreement [Member] | SweeGen Common Stock [Member] | ||||||||||
Shares Received in Satisfaction of Payment Obligation | shares | 850,115 | |||||||||
Temasek Funding Warrant [Member] | ||||||||||
Derivative Liability | $ 18,900,000 | $ 19,400,000 | ||||||||
Proceeds from Warrant Exercises | $ 100,000 | |||||||||
Stock Issued During Period, Shares, New Issues | shares | 12,700,000 | |||||||||
Class of Warrant or Right, Modification, Additional Shares Called by Warrants or Rights | shares | 600,062 | 1,125,755 | 164,169 | |||||||
Total [Member] | ||||||||||
Debt Conversion, Original Debt, Amount | $ 70,000,000 | |||||||||
Interest Rate Swap [Member] | ||||||||||
Derivative Liability | $ 3,343,000 | |||||||||
May 2017 warrants , May 2017 Offering Make Whole Provision [Member] | ||||||||||
Derivative Liability | $ 123,000,000 | |||||||||
Derivative, Fair Value, Net | 120,000,000 | |||||||||
DSM Offering and Make Whole Provision [Member] | ||||||||||
Gain (Loss) on Derivative Instruments, Net, Pretax | 1.10 | |||||||||
Banco Pine July 2012 Loan Agreement [Member] | Interest Rate Swap [Member] | ||||||||||
Derivative, Notional Amount | $ 6,600,000 | R$ 22 | ||||||||
Derivative, Fixed Interest Rate | 3.94% | 3.94% |
Note 3 - Fair Value Measureme55
Note 3 - Fair Value Measurement - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 | |
Money market funds | $ 53,199 | $ 1,549 | |
Certificates of deposit | 7,813 | 1,373 | |
Total assets measured and recorded at fair value | 61,012 | 2,922 | |
Embedded derivatives in connection with issuance of debt and equity instruments | 4,203 | 2,283 | |
Freestanding derivative instruments in connection with issuance of equity instruments | 115,775 | 1,852 | |
Cross-currency interest rate swap derivative liability(1) | [1] | 3,343 | |
Total liabilities measured and recorded at fair value | 119,978 | 7,478 | |
Fair Value, Inputs, Level 1 [Member] | |||
Money market funds | 53,199 | 1,549 | |
Certificates of deposit | 7,813 | 1,373 | |
Total assets measured and recorded at fair value | 61,012 | 2,922 | |
Embedded derivatives in connection with issuance of debt and equity instruments | |||
Freestanding derivative instruments in connection with issuance of equity instruments | |||
Cross-currency interest rate swap derivative liability(1) | [1] | ||
Total liabilities measured and recorded at fair value | |||
Fair Value, Inputs, Level 2 [Member] | |||
Money market funds | |||
Certificates of deposit | |||
Total assets measured and recorded at fair value | |||
Embedded derivatives in connection with issuance of debt and equity instruments | |||
Freestanding derivative instruments in connection with issuance of equity instruments | |||
Cross-currency interest rate swap derivative liability(1) | [1] | 3,343 | |
Total liabilities measured and recorded at fair value | 3,343 | ||
Fair Value, Inputs, Level 3 [Member] | |||
Money market funds | |||
Certificates of deposit | |||
Total assets measured and recorded at fair value | |||
Embedded derivatives in connection with issuance of debt and equity instruments | 4,203 | 2,283 | |
Freestanding derivative instruments in connection with issuance of equity instruments | 115,775 | 1,852 | |
Cross-currency interest rate swap derivative liability(1) | [1] | ||
Total liabilities measured and recorded at fair value | $ 119,978 | $ 4,135 | |
[1] | The cross-currency interest rate swap derivative was transferred to DSM in December 2017 as part of the Company's sale of Amyris Brasil Ltda; see Note 13, "Divestiture". |
Note 3 - Fair Value Measureme56
Note 3 - Fair Value Measurement - Reconciliation for Compound Embedded Derivative Liability (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | ||
(Gain) loss from change in fair value of derivative liabilities | [1] | $ 3,825 | ||
Fair Value, Inputs, Level 3 [Member] | Derivative Liability, Compound Embedded Derivatives [Member] | ||||
Balance, compound embedded derivative liabilities | 4,135 | 46,430 | ||
Additions | 130,957 | 2,050 | ||
(Gain) loss from change in fair value of derivative liabilities | 31,600 | (41,459) | ||
Derecognition upon conversion or extinguishment | (46,714) | (2,886) | ||
Balance, compound embedded derivative liabilities | $ 119,978 | $ 4,135 | $ 46,430 | |
[1] | The amount represents a net gain related to a change in the fair value of a liability classified common stock warrant included in the Company's consolidated statement of operations for the year ended December 31, 2015. The warrant has a nominal exercise price and shares issuable upon exercise of the warrant are considered equivalent to the Company's common shares for the purpose of computation of basic earnings per share and consequently losses are adjusted to exclude the gain. The warrant was exercised in 2015. |
Note 3 - Fair Value Measureme57
Note 3 - Fair Value Measurement - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details) - $ / shares | Jul. 29, 2015 | Dec. 31, 2017 | Dec. 31, 2016 |
Risk-free interest rate | 2.00% | ||
Risk-adjusted yields | |||
Expected volatility | 74.00% | 45.00% | |
Probability of change in control | 5.00% | 5.00% | |
Share Price | $ 3.75 | $ 10.95 | |
Credit spread | |||
Estimated conversion dates | |||
Expected dividend yield | |||
Risk-free interest rate | 2.00% | ||
Expected term (in years) (Year) | 10 years | ||
Expected volatility | 74.00% | 45.00% | |
Minimum [Member] | |||
Risk-free interest rate | 1.68% | 0.55% | |
Risk-adjusted yields | 18.40% | 12.80% | |
Expected volatility | 45.00% | ||
Credit spread | 16.63% | 11.59% | |
Estimated conversion dates | 2,018 | 2,017 | |
Expected dividend yield | 18.40% | 12.80% | |
Risk-free interest rate | 1.68% | 0.55% | |
Expected volatility | 45.00% | ||
Maximum [Member] | |||
Risk-free interest rate | 2.40% | 1.31% | |
Risk-adjusted yields | 28.53% | 22.93% | |
Expected volatility | 80.00% | ||
Credit spread | 26.70% | 21.64% | |
Estimated conversion dates | 2,025 | 2,019 | |
Expected dividend yield | 28.53% | 22.93% | |
Risk-free interest rate | 2.40% | 1.31% | |
Expected volatility | 80.00% |
Note 3 - Fair Value Measureme58
Note 3 - Fair Value Measurement - Derivative Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Derivative liabilities | $ 119,978 | $ 6,894 |
Derivative liabilities | 119,978 | 7,478 |
Interest Rate Swap [Member] | ||
Derivative liabilities, current | 584 | |
Derivative liabilities | 2,759 | |
Derivative liabilities | 3,343 | |
Embedded Derivative Financial Instruments [Member] | ||
Derivative liabilities | $ 119,978 | $ 4,135 |
Note 4 - Debt (Details Textual)
Note 4 - Debt (Details Textual) $ / shares in Units, R$ in Millions | May 31, 2018USD ($) | Dec. 28, 2017USD ($) | Feb. 15, 2016USD ($)shares | Jul. 29, 2015USD ($) | Mar. 31, 2018USD ($) | Jan. 31, 2018USD ($) | Dec. 31, 2017USD ($)$ / sharesshares | Jun. 30, 2017USD ($)$ / sharesshares | May 31, 2017USD ($) | Apr. 30, 2017USD ($) | Feb. 28, 2017USD ($) | Jan. 31, 2017USD ($)shares | Dec. 31, 2016USD ($) | Oct. 31, 2016USD ($) | Jun. 30, 2016USD ($) | Oct. 31, 2015USD ($) | Jul. 31, 2015USD ($)$ / shares | May 31, 2014USD ($) | Mar. 31, 2014USD ($) | Jan. 31, 2014USD ($) | Oct. 31, 2013USD ($) | May 31, 2018 | Sep. 30, 2017 | Dec. 31, 2017USD ($)$ / sharesshares | Dec. 31, 2017BRL (R$)shares | Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($) | Nov. 30, 2015USD ($) | Dec. 31, 2017BRL (R$) | Dec. 31, 2017BRL (R$) | Dec. 31, 2017BRL (R$)shares | Nov. 30, 2017USD ($) | Aug. 31, 2017USD ($) | Feb. 27, 2017 | Nov. 30, 2016USD ($) | Mar. 31, 2016USD ($) | Feb. 29, 2016USD ($) | Aug. 31, 2013USD ($) | Dec. 31, 2012USD ($)$ / shares | Jul. 31, 2012 | Jun. 30, 2012USD ($) | Dec. 31, 2011 | Nov. 30, 2010 | |
Gain (Loss) on Extinguishment of Debt | $ (1,900,000) | $ (1,521,000) | $ (4,146,000) | $ (1,141,000) | ||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | $ 40,200,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 30,400,000 | 30,400,000 | ||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 24,625,000 | |||||||||||||||||||||||||||||||||||||||||||
Letters of Credit Outstanding, Amount | $ 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Restricted Cash and Cash Equivalents, Noncurrent | 959,000 | $ 957,000 | 959,000 | 957,000 | ||||||||||||||||||||||||||||||||||||||||
Long-term Debt | 165,377,000 | 227,043,000 | 165,377,000 | 227,043,000 | ||||||||||||||||||||||||||||||||||||||||
The February 2016 Warrants [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 5 years | |||||||||||||||||||||||||||||||||||||||||||
FINEP Credit Facility [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | |||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | 1,900,000 | 1,900,000 | R$ 6.4 | |||||||||||||||||||||||||||||||||||||||||
Proceeds from Lines of Credit | R$ | R$ 6.4 | |||||||||||||||||||||||||||||||||||||||||||
BNDES Credit Facility [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 7.00% | |||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 6,800,000 | $ 6,800,000 | R$ 22.4 | |||||||||||||||||||||||||||||||||||||||||
Proceeds from Lines of Credit | R$ | R$ 19.1 | |||||||||||||||||||||||||||||||||||||||||||
DSM Credit Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | 10.00% | 10.00% | |||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 25,000,000 | $ 25,000,000 | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | 8,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Proceeds from Lines of Credit | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repayment Convenant, Percentage of Amount Being Repaid | 10.00% | |||||||||||||||||||||||||||||||||||||||||||
Letter of Credit [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Restricted Cash and Cash Equivalents, Noncurrent | $ 1,000,000 | 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||
Ginkgo Bioworks [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 333,334 | |||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 7.50 | |||||||||||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 13.50% | |||||||||||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | Stegodon [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount, Current | 425,000 | 425,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount, Noncurrent | 450,000 | 450,000 | ||||||||||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | Foris Ventures, LLC [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 152,381 | |||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 16,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | Naxyris S.A. [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 19,048 | |||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | Biolding Investment SA [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 19,048 | |||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 71,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 70,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Total and Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 34.50 | |||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Maximum [Member] | Prime Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 9.50% | |||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Minimum [Member] | Prime Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 6.25% | |||||||||||||||||||||||||||||||||||||||||||
Nossa Caixa and Banco Pine Agreements [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 15,700,000 | 15,700,000 | R$ 52.0 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.50% | |||||||||||||||||||||||||||||||||||||||||||
Certain Farnesene Production Assets Pledged as Collateral for Loans | 15,700,000 | 15,700,000 | R$ 52.0 | |||||||||||||||||||||||||||||||||||||||||
Collateral Provided by Company Certain Equipment and Other Tangible Assets, Amount | 20,600,000 | R$ 68.0 | ||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Future Minimum Payments Due | [1] | 80,394,000 | 80,394,000 | |||||||||||||||||||||||||||||||||||||||||
Long-term Debt | 57,915,000 | 78,923,000 | 57,915,000 | 78,923,000 | ||||||||||||||||||||||||||||||||||||||||
Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Future Minimum Payments Due | [1] | 56,073,000 | 56,073,000 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument Covenant Terms Minimum Amount Of Transactions Requiring Consent Of Noteholders | 20,000,000 | 20,000,000 | ||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | $ 47,211,000 | 42,759,000 | $ 47,211,000 | 42,759,000 | ||||||||||||||||||||||||||||||||||||||||
Related Party Convertible Notes [Member] | The Second Tranche [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Exchanged and Cancelled | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Unsecured Promissory Notes, 2016 [Member] | Private Placement February 2016 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 20,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 190,477 | 190,477 | 190,477 | |||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.15 | $ 0.15 | ||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 20,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Dividend Rate, Percentage | 17.38% | |||||||||||||||||||||||||||||||||||||||||||
Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | $ 3,700,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 70,000,000 | |||||||||||||||||||||||||||||||||||||||||||
The $5 Million Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Future Minimum Payments Due | $ 5,800,000 | $ 5,800,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 5,000,000 | $ 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 28.50 | $ 28.50 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Monthly Installments, Percent of Installment Amount | 118.00% | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Common Stock Payment, Maximum Percent of Aggregate Amount | 50.00% | 50.00% | 50.00% | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Threshold Amount of Dollar-weighted Volume of Common Stock | $ 200,000 | $ 200,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed | 118.00% | |||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Except Under Specified Conditions | 4.99% | 4.99% | 4.99% | |||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Under Specified Conditions | 9.99% | 9.99% | 9.99% | |||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage, Conditions, Number of Days After Written Notice | 61 days | |||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Maximum | shares | 3,645,118 | 3,645,118 | 3,645,118 | |||||||||||||||||||||||||||||||||||||||||
Tranche Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Future Minimum Payments Due | $ 25,000,000 | $ 25,000,000 | ||||||||||||||||||||||||||||||||||||||||||
Tranche Notes [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 21,800,000 | 21,800,000 | ||||||||||||||||||||||||||||||||||||||||||
Tranche Notes [Member] | Total and Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Covenant Terms, Maximum Debt | $ 200,000,000 | $ 200,000,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Covenant Terms, Maximum Debt, Percentage of Consolidated Assets | 50.00% | 50.00% | 50.00% | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Covenant Terms, Maximum Secured Debt | $ 125,000,000 | $ 125,000,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Covenant Terms, Maximum Secured Debt, Percentage of Consolidated Assets | 30.00% | 30.00% | 30.00% | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Covenant Terms, Minimum Amount Outstanding | $ 5,000,000 | $ 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||
Related Party and Non-Related Party Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 30,400,000 | $ 30,400,000 | ||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 57,600,000 | |||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 72,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Convertible Note Offering | $ 75,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Denominator [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Rate, Principle Amount | $ / shares | $ 1,000 | |||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Reverse Stock Split [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Ratio | 17.8073 | 17.8073 | ||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Convertible Debt Securities [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 6.50% | |||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Affiliated Entity [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.50% | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | $ 18,300,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchased Face Amount | $ 22,900,000 | |||||||||||||||||||||||||||||||||||||||||||
Amount of Convertible Debt Purchased by Affiliated Entities | $ 24,700,000 | |||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Decrease, Forgiveness | $ 9,700,000 | |||||||||||||||||||||||||||||||||||||||||||
Convertible Senior Notes, 9.5% [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.50% | |||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 54,400,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest, Payable in Common Stock, Percentage of Market-based Price | 92.50% | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Rate, Shares | shares | 58.2076 | 58.2076 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Rate, Principle Amount | $ / shares | $ 1,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 17.18 | $ 17.18 | ||||||||||||||||||||||||||||||||||||||||||
Convertible Note Substantial Change, Discount Rate Used in Calculate Value of Remaining Interest Payments | 0.75% | 0.75% | 0.75% | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible Percentage of Average Price Per Share the Stock will be Valued upon Early Conversion | 92.50% | 92.50% | ||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Additional Principal Amount Issued During Period | $ 19,100,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Decrease, Forgiveness | $ 15,300,000 | |||||||||||||||||||||||||||||||||||||||||||
Shares Issuable with Respect to Debt Instrument, Maximum Number of Shares of Common Stock Without Prior Approval | shares | 3,652,935 | |||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||
Conversion of All Outstanding Fidelity Notes for Aggregate Principal Amount of 2015 144A Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | (2,000,000) | |||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 3,700,000 | |||||||||||||||||||||||||||||||||||||||||||
March 2014 Letter Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | (1,800,000) | |||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 3,400,000 | |||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Notes [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 9,700,000 | 9,700,000 | ||||||||||||||||||||||||||||||||||||||||||
The December 2016 Convertible Note [Member] | Convertible Subordinated Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 | ||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | 9,900,000 | |||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | 0 | |||||||||||||||||||||||||||||||||||||||||||
The December 2016 Convertible Note [Member] | Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 7,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | 6,900,000 | |||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | 1,400,000 | |||||||||||||||||||||||||||||||||||||||||||
The December 2016 Convertible Note [Member] | Convertible Debt [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 15,000,000 | |||||||||||||||||||||||||||||||||||||||||||
The Second Tranche [Member] | Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 11,000,000 | $ 11,000,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 5.2977 | $ 5.2977 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Covenant Terms, Maximum Debt | $ 200,000,000 | $ 200,000,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Covenant Terms, Maximum Debt, Percentage of Consolidated Assets | 50.00% | 50.00% | 50.00% | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Covenant Terms, Maximum Secured Debt | $ 125,000,000 | $ 125,000,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Covenant Terms, Maximum Secured Debt, Percentage of Consolidated Assets | 30.00% | 30.00% | 30.00% | |||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Notes, Period After Which Notes Will Be Due | 5 years | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Accrued | 10.00% | |||||||||||||||||||||||||||||||||||||||||||
The Second Tranche [Member] | Related Party Convertible Notes [Member] | Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Purchased | $ 83,000,000 | |||||||||||||||||||||||||||||||||||||||||||
The Amended Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt Securities, Monthly Installment Discount | 20.00% | |||||||||||||||||||||||||||||||||||||||||||
Convertible Debt Securities, Price Floor Payment Discount Rate | 70.00% | |||||||||||||||||||||||||||||||||||||||||||
First Tranche [Member] | Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Cancellation of Convertible Debt | $ 0 | |||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Notes, Period After Which Notes Will Be Due | 5 years | |||||||||||||||||||||||||||||||||||||||||||
Plant Manufacturing Production, Product Sales, Percentage | 5.00% | |||||||||||||||||||||||||||||||||||||||||||
First Tranche [Member] | Temasek [Member] | Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | $ 500,000 | |||||||||||||||||||||||||||||||||||||||||||
The 3 Million Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 3,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount | $ 3,000,000 | |||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | $ 1,091,000 | 9,247,000 | $ 1,091,000 | 9,247,000 | ||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | 22,608,000 | 21,814,000 | 22,608,000 | 21,814,000 | ||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Total and Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 73,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Fidelity Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 57,600,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | 8,800,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchased Face Amount | $ 9,700,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 106.02 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Decrease, Forgiveness | $ 15,300,000 | |||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | 100,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 19,100,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Exchange Ratio of Converted Debt to Original Debt | 1.25 | |||||||||||||||||||||||||||||||||||||||||||
Fidelity Convertible Notes [Member] | Convertible Subordinated Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 3.00% | |||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Fidelity Convertible Notes [Member] | Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | 14,983,000 | 14,983,000 | ||||||||||||||||||||||||||||||||||||||||||
Total Purchase Agreement [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 105,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Replacement Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 46.20 | $ 46.20 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 12.00% | 1.50% | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Covenant Terms, Maximum Debt | $ 200,000,000 | $ 200,000,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Covenant Terms, Maximum Debt, Percentage of Consolidated Assets | 50.00% | 50.00% | 50.00% | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Covenant Terms, Maximum Secured Debt | $ 125,000,000 | $ 125,000,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Covenant Terms, Maximum Secured Debt, Percentage of Consolidated Assets | 30.00% | 30.00% | 30.00% | |||||||||||||||||||||||||||||||||||||||||
Loan and Security Agreement [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 31,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Proceeds from Long-term Lines of Credit | 16,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Payments of Financing Costs | $ 1,500,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Prepayment Price, Percentage of Principal Amount | 101.00% | 101.00% | 101.00% | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Prepayment, End of Term Charge | $ 3,300,000 | $ 3,300,000 | ||||||||||||||||||||||||||||||||||||||||||
Loan and Security Agreement [Member] | Stegodon [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | 0 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Requirement, Maximum Monthly Repayment, Using Proceeds from Collaboration Agreement | $ 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Monies Agreed to Apply Toward Repayment of Outstanding Loans, Maximum | $ 3,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Loan and Security Agreement [Member] | Stegodon [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Repayments of Lines of Credit | $ 1,300,000 | |||||||||||||||||||||||||||||||||||||||||||
Loan and Security Agreement [Member] | Scenario, Forecast [Member] | Stegodon [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Repayments of Lines of Credit | $ 5,500,000 | $ 5,500,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Increase (Decrease) | 5.00% | |||||||||||||||||||||||||||||||||||||||||||
Loan and Security Agreement [Member] | Scenario, Forecast [Member] | Stegodon [Member] | SMA [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Percent of Equity Interest Pledged for Collateral | 65.00% | |||||||||||||||||||||||||||||||||||||||||||
Loan and Security Agreement [Member] | Scenario, Forecast [Member] | Stegodon [Member] | Novvi LLC [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Percent of Equity Interest Pledged for Collateral | 100.00% | |||||||||||||||||||||||||||||||||||||||||||
Hercules Credit Additional Amount [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Maximum [Member] | Prime Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 8.50% | |||||||||||||||||||||||||||||||||||||||||||
Hercules Credit Additional Amount [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Minimum [Member] | Prime Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 5.25% | |||||||||||||||||||||||||||||||||||||||||||
Secured Promissory Note In Connection With Termination of Ginkgo Collaboration Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 12,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.50% | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fair Value Disclosure | $ 6,800,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 5,200,000 | |||||||||||||||||||||||||||||||||||||||||||
October 2016 Private Placement [Member] | Convertible Subordinated Debt [Member] | Ginkgo Bioworks [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,000,000 | $ 8,500,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 13.50% | |||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ 0 | |||||||||||||||||||||||||||||||||||||||||||
October 2016 Private Placement [Member] | Convertible Subordinated Debt [Member] | Foris Ventures, LLC [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 13.50% | |||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ 0 | |||||||||||||||||||||||||||||||||||||||||||
Salisbury Note [Member] | Salisbury Partners, LLC [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,500,000 | $ 3,500,000 | $ 3,500,000 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | 5.00% | ||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ 0 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 13 years | |||||||||||||||||||||||||||||||||||||||||||
Nikko Note [Member] | Nikko [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,900,000 | $ 3,900,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | 5.00% | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 13 years | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Percentage of Joint Venture Interests Owned By the Company Securing the Debt Instrument | 10.00% | 10.00% | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Payments Required in Four Monthly Installments | $ 400,000 | $ 400,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Equal Monthly Installments, Amount | 100,000 | |||||||||||||||||||||||||||||||||||||||||||
Aprinnova Notes [Member] | Unsecured Debt [Member] | Aprinnova JV [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 1,500,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Periodic Payment | $ 375,000 | |||||||||||||||||||||||||||||||||||||||||||
Aprinnova Notes [Member] | Unsecured Debt [Member] | Nikko [Member] | Aprinnova JV [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 2.75% | |||||||||||||||||||||||||||||||||||||||||||
Second Aprinnova Loan [Member] | Unsecured Debt [Member] | Nikko [Member] | Aprinnova JV [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 1,500,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 2.75% | |||||||||||||||||||||||||||||||||||||||||||
Guanfu Credit Agreement [Member] | Unsecured Debt [Member] | Guanfu Holding Co., Ltd [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | |||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 5 years | |||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | $ 25,000,000 | $ 25,000,000 | ||||||||||||||||||||||||||||||||||||||||||
[1] | Including $5.8 million in 2018 related to the $5 Million Note that, at the Company's election, may be settled in cash or shares, and $25.0 million in 2018 and 2019 related to the Tranche Notes that will be converted to common stock at maturity, subject to there being no default under the terms of the debt. |
Note 4 - Debt - Debt Components
Note 4 - Debt - Debt Components (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Debt, principal | $ 195,819 | $ 269,578 |
Unaccreted Debt (Discount) Premium | (30,442) | (42,535) |
Debt | 165,377 | 227,043 |
Debt, current | 56,943 | 59,155 |
Debt, noncurrent | 108,434 | 167,888 |
Convertible Debt [Member] | ||
Debt, principal | 70,900 | 107,017 |
Unaccreted Debt (Discount) Premium | (12,985) | (28,094) |
Debt | 57,915 | 78,923 |
Debt, noncurrent | 52,983 | |
Convertible Debt [Member] | The 2015 144A Notes [Member] | ||
Debt, principal | 37,887 | 40,478 |
Unaccreted Debt (Discount) Premium | (6,872) | (17,712) |
Debt | 31,015 | 22,766 |
Convertible Debt [Member] | The 2014 144A Notes [Member] | ||
Debt, principal | 24,004 | 27,404 |
Unaccreted Debt (Discount) Premium | (3,170) | (5,399) |
Debt | 20,834 | 22,005 |
Convertible Debt [Member] | December 2016, June 2017 and December 2017 Convertible Note [Member] | ||
Debt, principal | 5,000 | 10,000 |
Unaccreted Debt (Discount) Premium | (25) | (78) |
Debt | 4,975 | 9,922 |
Convertible Debt [Member] | August 2013 Convertible Notes [Member] | ||
Debt, principal | 4,009 | 13,826 |
Unaccreted Debt (Discount) Premium | (2,918) | (4,579) |
Debt | 1,091 | 9,247 |
Convertible Debt [Member] | Fidelity Convertible Notes [Member] | ||
Debt, principal | 15,309 | |
Unaccreted Debt (Discount) Premium | (326) | |
Debt | 14,983 | |
Related Party Convertible Notes [Member] | ||
Debt, principal | 50,116 | 48,186 |
Unaccreted Debt (Discount) Premium | (2,905) | (5,427) |
Debt | 47,211 | 42,759 |
Debt, noncurrent | 29,585 | |
Related Party Convertible Notes [Member] | The 2014 144A Notes [Member] | ||
Debt, principal | 24,705 | 24,705 |
Unaccreted Debt (Discount) Premium | (3,784) | (7,380) |
Debt | 20,921 | 17,325 |
Related Party Convertible Notes [Member] | August 2013 Convertible Notes [Member] | ||
Debt, principal | 21,711 | 19,781 |
Unaccreted Debt (Discount) Premium | 897 | 2,033 |
Debt | 22,608 | 21,814 |
Related Party Convertible Notes [Member] | Secured R&D Notes [Member] | ||
Debt, principal | 3,700 | 3,700 |
Unaccreted Debt (Discount) Premium | (18) | (80) |
Debt | 3,682 | 3,620 |
Loans Payable [Member] | ||
Debt, principal | 47,410 | 83,375 |
Unaccreted Debt (Discount) Premium | (6,513) | (7,705) |
Debt | 40,897 | 75,670 |
Debt, noncurrent | 8,905 | |
Loans Payable [Member] | Senior Secured Convertible Note [Member] | ||
Debt, principal | 28,566 | 28,566 |
Unaccreted Debt (Discount) Premium | (253) | (908) |
Debt | 28,313 | 27,658 |
Loans Payable [Member] | Ginkgo Collaboration Note [Member] | ||
Debt, principal | 12,000 | 8,500 |
Unaccreted Debt (Discount) Premium | (4,983) | |
Debt | 7,017 | 8,500 |
Loans Payable [Member] | Nossa Caixa [Member] | ||
Debt, principal | 11,135 | |
Unaccreted Debt (Discount) Premium | ||
Debt | 11,135 | |
Loans Payable [Member] | Other Loans Payable [Member] | ||
Debt, principal | 6,463 | 8,305 |
Unaccreted Debt (Discount) Premium | (1,277) | (1,361) |
Debt | 5,186 | 6,944 |
Loans Payable [Member] | Guanfu Credit Facility [Member] | ||
Debt, principal | 25,000 | |
Unaccreted Debt (Discount) Premium | (5,436) | |
Debt | 19,564 | |
Loans Payable [Member] | Other Credit Facilities [Member] | ||
Debt, principal | 381 | 1,869 |
Unaccreted Debt (Discount) Premium | ||
Debt | 381 | 1,869 |
Related Party Loan Payable [Member] | ||
Debt, principal | 27,393 | 31,000 |
Unaccreted Debt (Discount) Premium | (8,039) | (1,309) |
Debt | 19,354 | 29,691 |
Debt, noncurrent | 16,961 | |
Related Party Loan Payable [Member] | Other Loans Payable [Member] | ||
Debt, principal | 393 | |
Unaccreted Debt (Discount) Premium | ||
Debt | 393 | |
Related Party Loan Payable [Member] | DSM Note [Member] | ||
Debt, principal | 25,000 | |
Unaccreted Debt (Discount) Premium | (8,039) | |
Debt | 16,961 | |
Related Party Loan Payable [Member] | Private Placement February 2016 [Member] | ||
Debt, principal | 2,000 | 20,000 |
Unaccreted Debt (Discount) Premium | (1,309) | |
Debt | 2,000 | 18,691 |
Related Party Loan Payable [Member] | Loans Payable, June and October 2016 Private Placements [Member] | ||
Debt, principal | 11,000 | |
Unaccreted Debt (Discount) Premium | ||
Debt | $ 11,000 |
Note 4 - Debt - Long-term Debt
Note 4 - Debt - Long-term Debt Instruments (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 | |
Noncurrent portion of debt | $ 108,434 | $ 167,888 | |
Convertible Debt [Member] | |||
2,018 | 11,060 | ||
2,019 | 69,334 | ||
2,020 | |||
2,021 | |||
2,022 | |||
Thereafter | |||
Total future minimum payments(1) | [1] | 80,394 | |
Less: amount representing interest(2) | [2] | (22,479) | |
Present value of minimum debt payments | 57,915 | ||
Less: current portion | (4,932) | ||
Noncurrent portion of debt | 52,983 | ||
Related Party Convertible Notes [Member] | |||
2,018 | 20,835 | ||
2,019 | 35,238 | ||
2,020 | |||
2,021 | |||
2,022 | |||
Thereafter | |||
Total future minimum payments(1) | [1] | 56,073 | |
Less: amount representing interest(2) | [2] | (8,862) | |
Present value of minimum debt payments | 47,211 | ||
Less: current portion | (17,626) | ||
Noncurrent portion of debt | 29,585 | ||
Loans Payable [Member] | |||
2,018 | 36,465 | ||
2,019 | 1,704 | ||
2,020 | 1,627 | ||
2,021 | 1,627 | ||
2,022 | 13,417 | ||
Thereafter | 2,528 | ||
Total future minimum payments(1) | [1] | 57,368 | |
Less: amount representing interest(2) | [2] | (16,471) | |
Present value of minimum debt payments | 40,897 | ||
Less: current portion | (31,992) | ||
Noncurrent portion of debt | 8,905 | ||
Related Party Loan Payable [Member] | |||
2,018 | 5,423 | ||
2,019 | 2,500 | ||
2,020 | 2,500 | ||
2,021 | 27,500 | ||
2,022 | |||
Thereafter | |||
Total future minimum payments(1) | [1] | 37,923 | |
Less: amount representing interest(2) | [2] | (18,569) | |
Present value of minimum debt payments | 19,354 | ||
Less: current portion | (2,393) | ||
Noncurrent portion of debt | 16,961 | ||
Credit Facility [Member] | |||
2,018 | 73,783 | ||
2,019 | 108,776 | ||
2,020 | 4,127 | ||
2,021 | 29,127 | ||
2,022 | 13,417 | ||
Thereafter | 2,528 | ||
Total future minimum payments(1) | [1] | 231,758 | |
Less: amount representing interest(2) | [2] | (66,381) | |
Present value of minimum debt payments | 165,377 | ||
Less: current portion | (56,943) | ||
Noncurrent portion of debt | $ 108,434 | ||
[1] | Including $5.8 million in 2018 related to the $5 Million Note that, at the Company's election, may be settled in cash or shares, and $25.0 million in 2018 and 2019 related to the Tranche Notes that will be converted to common stock at maturity, subject to there being no default under the terms of the debt. | ||
[2] | Including net debt discount of $30.6 million that will be accreted to interest expense under the effective interest method over the term of the debt. |
Note 5 - Mezzanine Equity (Deta
Note 5 - Mezzanine Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | Apr. 08, 2016 | May 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Share Price | $ 3.75 | $ 10.95 | |||
Proceeds from Issuance of Private Placement | $ 24,625 | ||||
Gates Foundation Purchase Agreement [Member] | |||||
Stock Issued During Period, Shares, New Issues | 292,398 | ||||
Share Price | $ 17.10 | ||||
Proceeds from Issuance of Private Placement | $ 5,000 | ||||
Compound Annual Return | 10.00% |
Note 6 - Stockholders' Defici63
Note 6 - Stockholders' Deficit (Details Textual) - USD ($) | Oct. 28, 2017 | Aug. 07, 2017 | Aug. 03, 2017 | Mar. 08, 2016 | Jul. 29, 2015 | Dec. 31, 2017 | Aug. 31, 2017 | Aug. 30, 2017 | Jul. 31, 2017 | May 31, 2017 | Jan. 31, 2017 | Jul. 31, 2015 | Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Extinguishment of Debt, Amount | $ 40,200,000 | |||||||||||||||||||||||
Preferred Stock, Shares Outstanding | 22,171 | 22,171 | 0 | 22,171 | 22,171 | 0 | ||||||||||||||||||
Gain (Loss) on Derivative Instruments, Net, Pretax | $ (1,742,000) | $ 41,355,000 | $ 16,287,000 | |||||||||||||||||||||
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings | 8,600,000 | |||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | (1,900,000) | (1,521,000) | (4,146,000) | (1,141,000) | ||||||||||||||||||||
Adjustments to Additional Paid in Capital, Other | $ 600,000 | |||||||||||||||||||||||
Derivative Liability | $ 119,978,000 | $ 119,978,000 | $ 7,478,000 | $ 119,978,000 | 119,978,000 | $ 7,478,000 | ||||||||||||||||||
Derivative, Gain (Loss) on Derivative, Net | $ 26,700,000 | |||||||||||||||||||||||
Class of Warrants or Right, Issued in Period | 30,689,080 | |||||||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | (3,103,278) | |||||||||||||||||||||||
Share Price | $ 3.75 | $ 3.75 | $ 10.95 | $ 3.75 | $ 3.75 | $ 10.95 | ||||||||||||||||||
Preferred Stock, Value, Issued | ||||||||||||||||||||||||
Fair Value Inputs, Discount Rate | 8.60% | |||||||||||||||||||||||
Revenues | $ 80,588,000 | $ 24,197,000 | $ 25,680,000 | $ 12,980,000 | $ 22,238,000 | $ 26,544,000 | $ 9,599,000 | $ 8,811,000 | $ 143,445,000 | $ 67,192,000 | 34,153,000 | |||||||||||||
Preferred Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||||||||||||||
Class of Warrant or Right, Outstanding | 27,585,802 | 27,585,802 | 27,585,802 | 27,585,802 | ||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 24,626,000 | |||||||||||||||||||||||
Common Stock, Shares, Outstanding | 45,637,433 | 45,637,433 | 18,273,921 | 45,637,433 | 45,637,433 | 18,273,921 | ||||||||||||||||||
Equity Incentive Plan, 2010 [Member] | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | 548,214 | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage Increase of Common Stock Shares Outstanding | 3.00% | |||||||||||||||||||||||
Total [Member] | ||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 70,000,000 | |||||||||||||||||||||||
Temasek [Member] | ||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 71,000,000 | |||||||||||||||||||||||
Foris and Naxyris [Member] | ||||||||||||||||||||||||
Conversion of Stock, Shares Converted | 1,394,706 | |||||||||||||||||||||||
Affiliated Entity [Member] | ||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 1,068,379 | |||||||||||||||||||||||
DSM International B.V. [Member] | ||||||||||||||||||||||||
Preferred Stock, Shares Outstanding | 0 | 0 | 0 | 0 | ||||||||||||||||||||
Gain (Loss) on Derivative Instruments, Net, Pretax | $ 9,900,000 | |||||||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 0 | |||||||||||||||||||||||
Warrants and Rights Outstanding | $ 10,600,000 | |||||||||||||||||||||||
Designated Holder Maximum Common Stock Ownership | 33.00% | |||||||||||||||||||||||
Second Tranche Closing, Anniversary Payment | $ 5,000,000 | |||||||||||||||||||||||
Reserved Second Tranche Securities | $ 25,000,000 | |||||||||||||||||||||||
Licenses Revenue | $ 27,500,000 | $ 57,300,000 | ||||||||||||||||||||||
Credit Letter | 7,100,000 | |||||||||||||||||||||||
Consideration Transferred | 34,000,000 | |||||||||||||||||||||||
Equity Conversion Feature Embedded Derivative Liability Fair Value Disclosures | 9,900,000 | |||||||||||||||||||||||
DSM International B.V. [Member] | Intellectual Property License [Member] | ||||||||||||||||||||||||
Licenses Revenue | $ 9,000,000 | |||||||||||||||||||||||
Revenues | $ 700,000 | $ 700,000 | ||||||||||||||||||||||
Liability Reversal For The Consideration Recorded Related to Deferred Revenue Now Being Terminated | 7,300,000 | |||||||||||||||||||||||
DSM International B.V. [Member] | Designated Director One [Member] | ||||||||||||||||||||||||
Designated Director, Minimum Beneficial Ownership Level | 4.50% | |||||||||||||||||||||||
DSM International B.V. [Member] | Designated Director Two [Member] | ||||||||||||||||||||||||
Designated Director, Minimum Beneficial Ownership Level | 10.00% | |||||||||||||||||||||||
March 2014 Letter Agreement [Member] | ||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 3,400,000 | |||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | (1,800,000) | |||||||||||||||||||||||
Conversion of All Outstanding Fidelity Notes for Aggregate Principal Amount of 2015 144A Notes [Member] | ||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 3,700,000 | |||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ (2,000,000) | |||||||||||||||||||||||
Reclassification From Mezzanine to Permanent Equity [Member] | ||||||||||||||||||||||||
Reclassification of Equity | $ 12,800,000 | |||||||||||||||||||||||
Common Stock [Member] | ||||||||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 3,148,097 | 666,667 | 3,158,832 | |||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 2,826,711 | 1,068,377 | ||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | ||||||||||||||||||||||||
Preferred Stock [Member] | ||||||||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | ||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | ||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | ||||||||||||||||||||||||
Embedded Derivative Financial Instruments [Member] | ||||||||||||||||||||||||
Gain (Loss) on Derivative Instruments, Net, Pretax | $ 10,500,000 | |||||||||||||||||||||||
Derivative Liability | $ 119,978,000 | $ 119,978,000 | $ 4,135,000 | $ 119,978,000 | $ 119,978,000 | $ 4,135,000 | ||||||||||||||||||
Class of Warrant or Right, Securities Called by Warrants As Percentage of Shares Purchased By Investor | 100.00% | 100.00% | 100.00% | 100.00% | ||||||||||||||||||||
Series A Preferred Stock Converted Into Common Stock [Member] | ||||||||||||||||||||||||
Conversion of Stock, Shares Converted | 22,140 | |||||||||||||||||||||||
Minimum [Member] | DSM International B.V. [Member] | ||||||||||||||||||||||||
Credit Utilization Likelihood Percentage | 50.00% | |||||||||||||||||||||||
Minimum [Member] | The DSM Credit Letter [Member] | DSM International B.V. [Member] | ||||||||||||||||||||||||
Debt Instrument, Term | 1 year 180 days | |||||||||||||||||||||||
Maximum [Member] | DSM International B.V. [Member] | ||||||||||||||||||||||||
Credit Utilization Likelihood Percentage | 90.00% | |||||||||||||||||||||||
Maximum [Member] | The DSM Credit Letter [Member] | DSM International B.V. [Member] | ||||||||||||||||||||||||
Debt Instrument, Term | 4 years | |||||||||||||||||||||||
Due to Related Parties [Member] | ||||||||||||||||||||||||
Extinguishment of Debt, Amount | 33,100,000 | |||||||||||||||||||||||
Due to Related Parties [Member] | Foris Ventures, LLC [Member] | ||||||||||||||||||||||||
Extinguishment of Debt, Amount | 27 | |||||||||||||||||||||||
Due to Related Parties [Member] | Naxyris S.A. [Member] | ||||||||||||||||||||||||
Extinguishment of Debt, Amount | 2,000,000 | |||||||||||||||||||||||
May 2017 Offering Closing [Member] | ||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 50,700,000 | |||||||||||||||||||||||
Securities Purchase Agreement [Member] | Vivo Capital LLC [Member] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 5,575,118 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 6.39 | |||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 24,800,000 | |||||||||||||||||||||||
Class of Warrant or Right, Term | 5 years | |||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 2,826,711 | |||||||||||||||||||||||
Shares Issued, Price Per Share | $ 4.26 | |||||||||||||||||||||||
At the Market Offering [Member] | ||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 0 | $ 0 | ||||||||||||||||||||||
Common Stock, Value, Subscriptions | $ 50,000,000 | $ 50,000,000 | $ 50,000,000 | $ 50,000,000 | $ 50,000,000 | |||||||||||||||||||
Commission Rate | 3.00% | |||||||||||||||||||||||
May 2017 Warrants, Warrant 1 [Member] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 7,384,190 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 7.80 | |||||||||||||||||||||||
Class of Warrants or Right, Issued in Period | 14,768,380 | |||||||||||||||||||||||
Class of Warrant or Right, Dilution Period | 3 years | |||||||||||||||||||||||
May 2017 Warrants, Warrant 2 [Member] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 7,384,190 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 9.30 | |||||||||||||||||||||||
May 2017 Warrants [Member] | ||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 4.40 | $ 4.40 | $ 4.40 | $ 4.40 | ||||||||||||||||||||
Gain (Loss) on Derivative Instruments, Net, Pretax | $ (5,400,000) | |||||||||||||||||||||||
Derivative Liability | $ 39,500,000 | |||||||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 0 | |||||||||||||||||||||||
Class of Warrant or Right, Term | 5 years | |||||||||||||||||||||||
Warrants and Rights Outstanding | $ 34,100,000 | $ 34,100,000 | $ 34,100,000 | $ 34,100,000 | ||||||||||||||||||||
Dilution Warrants [Member] | ||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.0015 | $ 0.0015 | $ 0.0015 | $ 0.0015 | ||||||||||||||||||||
Gain (Loss) on Derivative Instruments, Net, Pretax | $ (45,700,000) | |||||||||||||||||||||||
Derivative Liability | $ 4,400,000 | |||||||||||||||||||||||
Class of Warrants or Right, Issued in Period | 6,377,466 | |||||||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 3,103,278 | |||||||||||||||||||||||
Preferred Stock Effective Conversion Price | $ 6.30 | $ 6.30 | $ 6.30 | $ 6.30 | ||||||||||||||||||||
Warrants and Rights Outstanding | $ 40,600,000 | $ 40,600,000 | $ 40,600,000 | $ 40,600,000 | ||||||||||||||||||||
Class of Warrant or Right, Outstanding | 3,274,188 | 3,274,188 | 3,274,188 | 3,274,188 | ||||||||||||||||||||
Class of Warrant or Right, Number Exercisable | 5,412,629 | 5,412,629 | 5,412,629 | 5,412,629 | ||||||||||||||||||||
DSM Warrants [Member] | DSM International B.V. [Member] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 3,968,116 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 6.30 | |||||||||||||||||||||||
Class of Warrant or Right, Term | 5 years | |||||||||||||||||||||||
DSM Dilution Warrant [Member] | DSM International B.V. [Member] | ||||||||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 0 | |||||||||||||||||||||||
Preferred Stock Effective Conversion Price | $ 6.30 | |||||||||||||||||||||||
Class of Warrant or Right, Term | 5 years | |||||||||||||||||||||||
Common Stock, Dividends, Per Share, Declared | $ 0.10 | |||||||||||||||||||||||
Vivo Cash Warrants [Member] | ||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 13,000,000 | $ 12,000,000 | $ 12,000,000 | $ 12,000,000 | $ 12,000,000 | |||||||||||||||||||
Vivo Cash Warrants [Member] | Common Stock [Member] | ||||||||||||||||||||||||
Warrants and Rights Outstanding | 5,500,000 | |||||||||||||||||||||||
Vivo Cash Warrants [Member] | Preferred Stock [Member] | ||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 6,200,000 | |||||||||||||||||||||||
August 2017 Vito Dilution Warrants [Member] | ||||||||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 0 | |||||||||||||||||||||||
Preferred Stock Effective Conversion Price | $ 4.26 | |||||||||||||||||||||||
Class of Warrant or Right, Term | 5 years | |||||||||||||||||||||||
Designated Holder Maximum Common Stock Ownership | 33.00% | |||||||||||||||||||||||
Minimum Beneficial Ownership Level to Designate a Director | 4.50% | |||||||||||||||||||||||
Total Funding Warrant [Member] | Total [Member] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,261,613 | |||||||||||||||||||||||
Total R&D Warrant [Member] | Total [Member] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 133,334 | |||||||||||||||||||||||
Temasek Warrant 1 [Member] | Total [Member] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 978,525 | |||||||||||||||||||||||
Temasek Warrant Three [Member] | Temasek [Member] | ||||||||||||||||||||||||
Class of Warrant or Right, Common Stock Shares Used In Calculation | 58,690 | |||||||||||||||||||||||
Class of Warrant or Right, Threshold Number of Securities | 133,334 | |||||||||||||||||||||||
Temasek Warrant 2 [Member] | Total [Member] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 133,334 | |||||||||||||||||||||||
Class of Warrant or Right, Numerator One | 30.60% | |||||||||||||||||||||||
Class of Warrant or Right, Denominator One | 69.40% | |||||||||||||||||||||||
Class of Warrant or Right, Numerator Two | 13.30% | |||||||||||||||||||||||
Class of Warrant or Right, Denominator Two | 86.70% | |||||||||||||||||||||||
The 2013 Warrant [Member] | Temasek [Member] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 66,667 | 846,683 | 846,683 | 846,683 | 846,683 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.15 | $ 0.15 | $ 0.15 | $ 0.15 | ||||||||||||||||||||
Class of Warrant or Right, Outstanding | 1,889,986 | 1,889,986 | 1,889,986 | 1,889,986 | ||||||||||||||||||||
July 2015 PIPE Warrants [Member] | Affiliated Entity [Member] | ||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.15 | $ 0.15 | $ 0.15 | $ 0.15 | ||||||||||||||||||||
Class of Warrant or Right, Securities Called by Warrants As Percentage of Shares Purchased By Investor | 10.00% | 10.00% | 10.00% | 10.00% | ||||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 25,643 | |||||||||||||||||||||||
Share Price | $ 23.40 | |||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 25,000,000 | |||||||||||||||||||||||
Common Stock, Shares, Outstanding | 81,197 | 81,197 | 81,197 | 81,197 | ||||||||||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||||||||||||
Preferred Stock, Capital Shares Reserved for Future Issuance | 22,140 | |||||||||||||||||||||||
Preferred Stock, Stated Value | $ 1,000 | |||||||||||||||||||||||
Preferred Stock, Conversion Price Per Share to Common Stock | $ 17.25 | |||||||||||||||||||||||
Preferred Stock, Dividend Rate, Percentage | 17.38% | |||||||||||||||||||||||
Preferred Stock, Anniversary Payment | $ 1,738 | |||||||||||||||||||||||
Preferred Stock, Shares Outstanding | 0 | 0 | 0 | 0 | ||||||||||||||||||||
Stock Issued During Period, Value, New Issues | ||||||||||||||||||||||||
Series A Preferred Stock [Member] | Common Stock [Member] | ||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | ||||||||||||||||||||||||
Series A Preferred Stock [Member] | Preferred Stock [Member] | ||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | ||||||||||||||||||||||||
Series A Preferred Stock [Member] | Minimum [Member] | ||||||||||||||||||||||||
Beneficiary Ownership, Conversion Percentage, Maximum | 4.99% | |||||||||||||||||||||||
Series A Preferred Stock [Member] | Maximum [Member] | ||||||||||||||||||||||||
Beneficiary Ownership, Conversion Percentage, Maximum | 9.99% | |||||||||||||||||||||||
Series B Preferred Stock [Member] | ||||||||||||||||||||||||
Preferred Stock, Capital Shares Reserved for Future Issuance | 70,904 | |||||||||||||||||||||||
Conversion of Stock, Shares Converted | 86,691 | |||||||||||||||||||||||
Preferred Stock, Shares Outstanding | 9,213 | 9,213 | 9,213 | 9,213 | ||||||||||||||||||||
Derivative Liability | $ 34,700,000 | $ 34,700,000 | $ 34,700,000 | $ 34,700,000 | ||||||||||||||||||||
Stock Issuance Costs Recognized | 1,200,000 | |||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | 5,476,000 | |||||||||||||||||||||||
Series B Preferred Stock [Member] | DSM International B.V. [Member] | ||||||||||||||||||||||||
Payments of Stock Issuance Costs | $ 200,000 | |||||||||||||||||||||||
Preferred Stock, Value, Issued | $ 5,500,000 | |||||||||||||||||||||||
Series B Preferred Stock [Member] | Foris Ventures, LLC [Member] | ||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | 30,729 | |||||||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued | 4,877,386 | |||||||||||||||||||||||
Series B Preferred Stock [Member] | Naxyris S.A. [Member] | ||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | 2,333 | |||||||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued | 370,404 | |||||||||||||||||||||||
Series B Preferred Stock [Member] | Common Stock [Member] | ||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | ||||||||||||||||||||||||
Series B Preferred Stock [Member] | Preferred Stock [Member] | ||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | ||||||||||||||||||||||||
Series A Preferred Stock and Warrants [Member] | May 2017 Offering Closing [Member] | ||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 22,100,000 | |||||||||||||||||||||||
Series B Preferred Stock and Warrants [Member] | May 2017 Offering Closing [Member] | ||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 30,700,000 | |||||||||||||||||||||||
Series A and Series B Preferred Stock [Member] | ||||||||||||||||||||||||
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Maximum | 3,792,778 | |||||||||||||||||||||||
Embedded Derivative, Fair Value of Embedded Derivative Liability | $ 11,000,000 | |||||||||||||||||||||||
Convertible Preferred Stock, Beneficial Conversion Feature, Proceeds Allocated to Preferred Stock | 600,000 | |||||||||||||||||||||||
Convertible Preferred Stock, Proceeds Allocated to Preferred Stock | $ 0 | |||||||||||||||||||||||
Series B Convertible Preferred Stock [Member] | DSM International B.V. [Member] | ||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 25,000 | |||||||||||||||||||||||
Share Price | $ 1,000 | |||||||||||||||||||||||
Proceeds from Issuance of Convertible Preferred Stock | $ 25,900,000 | |||||||||||||||||||||||
Series D Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member] | Vivo Capital LLC [Member] | ||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 12,958 | |||||||||||||||||||||||
Share Price | $ 1,000 | |||||||||||||||||||||||
Series D Preferred Stock [Member] | ||||||||||||||||||||||||
Preferred Stock, Stated Value | 1,000 | |||||||||||||||||||||||
Preferred Stock, Conversion Price Per Share to Common Stock | $ 4.26 | |||||||||||||||||||||||
Payments of Stock Issuance Costs | $ 200,000 | |||||||||||||||||||||||
Common Stock, Dividends, Per Share, Declared | $ 0.0001 | |||||||||||||||||||||||
Beneficiary Ownership, Conversion Percentage, Minimum | 9.99% | |||||||||||||||||||||||
Preferred Stock, Beneficial Conversion Feature | $ 5,800,000 | |||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | 6,197,000 | |||||||||||||||||||||||
Series D Preferred Stock [Member] | Common Stock [Member] | ||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | ||||||||||||||||||||||||
Series D Preferred Stock [Member] | Preferred Stock [Member] | ||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | ||||||||||||||||||||||||
Series C Preferred Stock [Member] | ||||||||||||||||||||||||
Preferred Stock, Stated Value | $ 1,000 | |||||||||||||||||||||||
Preferred Stock, Conversion Price Per Share to Common Stock | 15 | |||||||||||||||||||||||
Series C Preferred Stock [Member] | Foris and Naxyris [Member] | ||||||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share | $ 0.0001 | |||||||||||||||||||||||
Series C Preferred Stock [Member] | Conversion of Common Stock Into Series C Preferred Stock [Member] | Foris and Naxyris [Member] | ||||||||||||||||||||||||
Conversion of Stock, Shares Issued | 20,921 |
Note 6 - Stockholders' Defici64
Note 6 - Stockholders' Deficit - Warrant Activity (Details) | 12 Months Ended |
Dec. 31, 2017shares | |
Warrants issued (in shares) | 30,689,080 |
Warrants exercised (in shares) | 3,103,278 |
Warrants outstanding (in shares) | 27,585,802 |
Issuance of common stock upon exercise of warrants (in shares) | (3,103,278) |
May 2017 Cash Warrants [Member] | |
Warrants issued (in shares) | 14,768,380 |
Warrants exercised (in shares) | |
Warrants outstanding (in shares) | 14,768,380 |
Issuance of common stock upon exercise of warrants (in shares) | |
August 2017 Cash Warrants [Member] | |
Warrants issued (in shares) | 9,543,234 |
Warrants exercised (in shares) | |
Warrants outstanding (in shares) | 9,543,234 |
Issuance of common stock upon exercise of warrants (in shares) | |
Cash Warrants [Member] | |
Warrants issued (in shares) | 24,311,614 |
Warrants exercised (in shares) | |
Warrants outstanding (in shares) | 24,311,614 |
Issuance of common stock upon exercise of warrants (in shares) | |
May 2017 Dilution Warrants [Member] | |
Warrants issued (in shares) | 6,377,466 |
Warrants exercised (in shares) | (3,103,278) |
Warrants outstanding (in shares) | 3,274,188 |
Issuance of common stock upon exercise of warrants (in shares) | 3,103,278 |
August 2017 Dilution Warrants [Member] | |
Warrants issued (in shares) | |
Warrants exercised (in shares) | |
Warrants outstanding (in shares) | |
Issuance of common stock upon exercise of warrants (in shares) | |
Dilution Warrants [Member] | |
Warrants issued (in shares) | 6,377,466 |
Warrants exercised (in shares) | (3,103,278) |
Warrants outstanding (in shares) | 3,274,188 |
Issuance of common stock upon exercise of warrants (in shares) | 3,103,278 |
Note 7 - Variable-interest En65
Note 7 - Variable-interest Entities and Unconsolidated Investments (Details Textual) | Dec. 31, 2017USD ($) | Aug. 31, 2017 | Apr. 30, 2017USD ($)shares | Dec. 31, 2016USD ($) | Nov. 30, 2016USD ($) | Dec. 31, 2017EUR (€) | Oct. 31, 2017USD ($) | Jul. 31, 2016USD ($) |
Fair Value Inputs, Discount Rate | 8.60% | |||||||
Purchase of Leland Facility [Member] | ||||||||
Noncash or Part Noncash Acquisition, Value of Assets Acquired | $ 4,400,000 | |||||||
Nikko Note [Member] | Nikko [Member] | ||||||||
Debt Instrument, Face Amount | $ 3,900,000 | |||||||
Salisbury Note [Member] | Salisbury Partners, LLC [Member] | ||||||||
Debt Instrument, Face Amount | 3,500,000 | 3,500,000 | ||||||
Aprinnova JV [Member] | ||||||||
Loan Granted to Joint Venture | $ 500,000 | |||||||
Aprinnova JV [Member] | Nikko [Member] | ||||||||
Equity Method Investment, Ownership Percentage | 50.00% | |||||||
Cash Investment Joint Venture | $ 10 | |||||||
Joint Venture, Maximum Distributions | 10,000,000 | |||||||
Loan Granted to Joint Venture | 1,500,000 | |||||||
Novvi LLC [Member] | ||||||||
Equity Method Investment, Ownership Percentage | 24.39% | 24.39% | 24.39% | |||||
Obligation to Fund Agreement, Cash Portion | $ 10,000,000 | |||||||
Equity Method Investments | $ 0 | $ 0 | ||||||
Novvi LLC [Member] | American Refining Group [Member] | ||||||||
Obligation to Fund Agreement, Cash Portion | $ 10,000,000 | |||||||
Novvi LLC [Member] | Chevron U.S.A. [Member] | ||||||||
Obligation to Fund Agreement, Cash Portion | $ 1,000,000 | |||||||
Joint Venture, Ownership Stake | 2.44% | 3.00% | ||||||
Joint Venture, Additional Ownership Stake | 25.00% | |||||||
JVCO Joint Venture [Member] | ||||||||
Capitalization, Long-term Debt and Equity | € | € 0 | |||||||
SweeGen Common Stock [Member] | ||||||||
Equity Method Investment, Aggregate Cost | $ 3,200,000 | |||||||
Fair Value Inputs, Discount Rate | 40.00% | |||||||
SweeGen Common Stock [Member] | Blue California [Member] | Intellectual Property License and Strain Access Agreement [Member] | ||||||||
Shares Received in Satisfaction of Payment Obligation | shares | 850,115 |
Note 7 - Variable-interest En66
Note 7 - Variable-interest Entities and Unconsolidated Investments - Variable Interest Entities (Details) - Variable Interest Entity, Primary Beneficiary [Member] - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Assets | $ 36,781 | $ 30,778 |
Liabilities | $ 3,187 | $ 333 |
Note 7 - Variable-interest En67
Note 7 - Variable-interest Entities and Unconsolidated Investments - Noncontrolling Interest (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Balance, noncontrolling interest | $ 937 | ||
Net loss attributable to noncontrolling interest | $ 100 | ||
Balance, noncontrolling interest | 937 | 937 | |
Noncontrolling Interest [Member] | |||
Balance, noncontrolling interest | (937) | 391 | |
Net loss attributable to noncontrolling interest | (1,328) | ||
Balance, noncontrolling interest | $ (937) | $ (937) | $ 391 |
Note 8 - Net Loss Per Share A68
Note 8 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | ||||||||||
Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | ||
Net income (loss) attributable to Amyris, Inc. | $ (72,329) | $ (97,334) | $ (217,952) | |||||||||
Less deemed dividend on capital distribution to related parties | (8,648) | |||||||||||
Less deemed dividend related to beneficial conversion feature on Series A preferred stock | (562) | |||||||||||
Less deemed dividend related to beneficial conversion feature on Series B preferred stock | (634) | |||||||||||
Less deemed dividend related to beneficial conversion feature on Series D preferred stock | (5,757) | |||||||||||
Less cumulative dividends on Series A and Series B preferred stock | (5,439) | |||||||||||
Net loss attributable to Amyris, Inc. common stockholders, basic | $ (2,914) | $ (42,819) | $ (10,265) | $ (37,371) | $ (48,755) | $ (19,705) | $ (13,566) | $ (15,308) | (93,369) | (97,334) | (217,952) | |
Adjustment to exclude fair value gain on liability classified warrants(1) | [1] | (3,825) | ||||||||||
Net loss attributable to Amyris, Inc. common stockholders for basic net loss per share | (93,369) | (97,334) | (221,777) | |||||||||
Interest on convertible debt | 4,428 | |||||||||||
Accretion of debt discount | 2,889 | |||||||||||
Gain from change in fair value of derivative instruments | (25,630) | |||||||||||
Net loss attributable to Amyris, Inc. common stockholders, diluted | $ (2,914) | $ (42,819) | $ (10,265) | $ (37,371) | $ (48,755) | $ (19,705) | $ (29,245) | $ (30,273) | $ (93,369) | $ (115,647) | $ (221,777) | |
Basic (in shares) | 47,895,238 | 37,529,694 | 23,155,874 | 19,335,948 | 18,227,100 | 16,612,690 | 14,874,135 | 13,813,305 | 32,253,570 | 15,896,014 | 8,464,106 | |
Basic (in dollars per share) | $ (0.06) | $ (1.14) | $ (0.44) | $ (1.93) | $ (2.67) | $ (1.19) | $ (0.91) | $ (1.11) | $ (2.89) | $ (6.12) | $ (26.20) | |
Effective of dilutive convertible promissory notes (in shares) | 1,746,951 | |||||||||||
Weighted-average common stock equivalents used in computing net loss per share of common stock, diluted (in shares) | 32,253,570 | 17,642,965 | 8,464,106 | |||||||||
Diluted (in dollars per share) | $ (0.06) | $ (1.14) | $ (0.44) | $ (1.93) | $ (2.67) | $ (1.19) | $ (1.67) | $ (1.74) | $ (2.89) | $ (6.55) | $ (26.20) | |
[1] | The amount represents a net gain related to a change in the fair value of a liability classified common stock warrant included in the Company's consolidated statement of operations for the year ended December 31, 2015. The warrant has a nominal exercise price and shares issuable upon exercise of the warrant are considered equivalent to the Company's common shares for the purpose of computation of basic earnings per share and consequently losses are adjusted to exclude the gain. The warrant was exercised in 2015. |
Note 8 - Net Loss Per Share A69
Note 8 - Net Loss Per Share Attributable to Common Stockholders - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares | 12 Months Ended | |||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | ||
Period-end common stock warrants (in shares) | 39,986,046 | 4,095,591 | 6,261,614 | |
Stock Options to Purchase Common Stock [Member] | ||||
Period-end common stock warrants (in shares) | 29,921,844 | 334,740 | 193,462 | |
Convertible Promissory Notes [Member] | ||||
Period-end common stock warrants (in shares) | [1] | 8,040,828 | 2,395,596 | 4,835,821 |
Common Stock Subject to Repurchase [Member] | ||||
Period-end common stock warrants (in shares) | 1,338,367 | 899,179 | 862,008 | |
Restricted Stock Units (RSUs) [Member] | ||||
Period-end common stock warrants (in shares) | 685,007 | 466,076 | 370,323 | |
[1] | The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of December 31, 2017. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding. |
Note 9 - Commitments and Cont70
Note 9 - Commitments and Contingencies (Details Textual) R$ in Millions, $ in Millions | 12 Months Ended | |||
Dec. 31, 2017USD ($) | Dec. 31, 2017BRL (R$) | Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($) | |
Operating Leases, Rent Expense | $ 5.1 | $ 5.3 | $ 5.5 | |
Operating Leases, Future Minimum Payments Receivable | 0.4 | |||
Contractual Obligation | 18.3 | |||
Purchase Obligation | $ 9 | |||
Equity Interest of Aprinnova JV Pledge as Collateral [Member] | ||||
Collateral, Percentage of Equity Interest in VIE | 10.00% | 10.00% | ||
Financing Agreement with Banco Safra [Member] | ||||
Financing Agreement, Amount Commited to Fund | $ 1 | |||
Financing Agreement, Term | 1 year | 1 year | ||
Nossa Caixa and Banco Pine Agreements [Member] | ||||
Collateral Provided by Company Certain Equipment and Other Tangible Assets, Amount | $ 15.7 | R$ 52.0 | ||
FINEP Credit Facility [Member] | Chattel Mortgage [Member] | ||||
Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired | 1.8 | 6 | ||
BNDES Credit Facility [Member] | BNDES [Member] | ||||
Collateral Provided by Company Certain Equipment and Other Tangible Assets, Amount | $ 7.5 | R$ 24.9 |
Note 9 - Commitments and Cont71
Note 9 - Commitments and Contingencies - Future Minimum Payments for Lease Obligations (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Capital leases 2018 | $ 755 | |
Operating leases 2018 | 10,127 | |
Total lease obligations 2018 | 10,882 | |
Capital leases 2019 | 185 | |
Operating leases 2019 | 8,760 | |
Total lease obligations 2019 | 8,945 | |
Capital leases 2020 | 39 | |
Operating leases 2020 | 7,018 | |
Total lease obligations 2020 | 7,057 | |
Capital leases 2021 | 0 | |
Operating leases 2021 | 7,242 | |
Total lease obligations 2021 | 7,242 | |
Capital leases 2022 | ||
Operating leases 2022 | 7,415 | |
Total lease obligations 2022 | 7,415 | |
Capital leases thereafter | 0 | |
Operating leases thereafter | 3,545 | |
Total lease obligations thereafter | 3,545 | |
Total future minimum capital lease payments | 979 | |
Total future minimum operating lease payments | 44,107 | |
Total future minimum lease payments | 45,086 | |
Less: amount representing interest | (38) | |
Present value of minimum lease payments | 941 | |
Less: current portion | (724) | |
Capital lease obligation, net of current portion | $ 217 | $ 334 |
Note 10 - Significant Revenue72
Note 10 - Significant Revenue Agreements (Details Textual) - USD ($) | Oct. 28, 2017 | Dec. 31, 2017 | Nov. 30, 2017 | Aug. 31, 2017 | Jul. 31, 2017 | May 31, 2017 | Jun. 30, 2016 | Apr. 30, 2016 | Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Sep. 30, 2015 |
Revenues | $ 80,588,000 | $ 24,197,000 | $ 25,680,000 | $ 12,980,000 | $ 22,238,000 | $ 26,544,000 | $ 9,599,000 | $ 8,811,000 | $ 143,445,000 | $ 67,192,000 | $ 34,153,000 | ||||||||||||
Technology Investment Agreement with DARPA [Member] | |||||||||||||||||||||||
Maximum DARPA Funding to be Received if all Milestones are Achieved | $ 35,000,000 | ||||||||||||||||||||||
Collective Obligation Due | $ 15,500,000 | ||||||||||||||||||||||
Firmenich [Member] | Master Collaboration Agreement [Member] | Flavors and Fragrances Compounds [Member] | |||||||||||||||||||||||
Sales Margin Company Percentage Split | 30.00% | ||||||||||||||||||||||
Sales Margin Collaborator Percentage Split | 70.00% | ||||||||||||||||||||||
Return Required for Collaboration Partner Before Adjusting Split on Sales Margin | $ 15,000,000 | ||||||||||||||||||||||
Sales Margin Company Percentage Split Following Return Requirements | 50.00% | ||||||||||||||||||||||
Success Bonus | $ 2,500,000 | ||||||||||||||||||||||
Contingent Consideration Liability | $ 300,000 | 300,000 | $ 300,000 | 300,000 | |||||||||||||||||||
Nenter & Co., Inc. [Member] | Supply Agreements [Member] | |||||||||||||||||||||||
Supply Agreement, Renewable Terms | 5 years | ||||||||||||||||||||||
Loss on Contract Termination | $ 2,500,000 | ||||||||||||||||||||||
DSM International B.V. [Member] | |||||||||||||||||||||||
Credit Letter | $ 7,100,000 | ||||||||||||||||||||||
Consideration Transferred | 34,000,000 | ||||||||||||||||||||||
Warrants and Rights Outstanding | 10,600,000 | ||||||||||||||||||||||
Deferred Revenue | 7,100,000 | 7,100,000 | 7,100,000 | 7,100,000 | |||||||||||||||||||
Performance Agreement, Contingent Obligation | 1,800,000 | $ 1,800,000 | 1,800,000 | 1,800,000 | |||||||||||||||||||
Licenses Revenue | $ 27,500,000 | $ 57,300,000 | |||||||||||||||||||||
DSM International B.V. [Member] | Cash Warrants [Member] | |||||||||||||||||||||||
Warrants and Rights Outstanding | 33,300,000 | ||||||||||||||||||||||
DSM International B.V. [Member] | Collaborative Arrangement [Member] | |||||||||||||||||||||||
Receivable from Collaborators | 9,000,000 | ||||||||||||||||||||||
Credit to Collaboration Agreements | 12,000,000 | ||||||||||||||||||||||
DSM International B.V. [Member] | Collaborative Arrangement [Member] | Maximum [Member] | |||||||||||||||||||||||
Credit to Collaboration Agreements | $ 6,000,000 | ||||||||||||||||||||||
DSM International B.V. [Member] | Intellectual Property License [Member] | |||||||||||||||||||||||
Revenues | $ 700,000 | $ 700,000 | |||||||||||||||||||||
Licenses Revenue | $ 9,000,000 | ||||||||||||||||||||||
Ginkgo Bioworks [Member] | |||||||||||||||||||||||
Licenses Revenue | $ 5,000,000 | 15,000,000 | |||||||||||||||||||||
Proceeds from Collaborators | $ 20,000,000 | $ 5,000,000 | $ 5,000,000 | $ 15,000,000 | |||||||||||||||||||
Royalty Percentage | 10.00% | 10.00% | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 333,334 | 333,334 | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 7.50 | $ 7.50 | |||||||||||||||||||||
Collaboration Agreement Period | 3 years | ||||||||||||||||||||||
Ginkgo Bioworks, Inc. [Member] | Partnership Agreement [Member] | |||||||||||||||||||||||
Sales Margin Company Percentage Split | 50.00% | ||||||||||||||||||||||
Collaboration Agreement Period | 2 years | ||||||||||||||||||||||
Partnership Payments, Quarterly Fees | $ 800,000 | ||||||||||||||||||||||
Payments for Other Fees | $ 500,000 | ||||||||||||||||||||||
Collaboration Agreement, Automatic Renewal Term | 1 year |
Note 10 - Significant Revenue73
Note 10 - Significant Revenue Agreements - Revenue in Connection With Significant Revenue Agreement (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
DSM (related party) | $ 80,588 | $ 24,197 | $ 25,680 | $ 12,980 | $ 22,238 | $ 26,544 | $ 9,599 | $ 8,811 | $ 143,445 | $ 67,192 | $ 34,153 |
Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | 103,297 | 48,851 | 12,764 | ||||||||
DSM International B.V. [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | 59,651 | ||||||||||
Firmenich [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | 16,623 | 17,918 | 12,684 | ||||||||
Nenter & Co., Inc. [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | 14,690 | 6,236 | |||||||||
DARPA [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | 12,333 | 9,697 | 80 | ||||||||
Ginkgo Bioworks, Inc. [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | 15,000 | ||||||||||
All Other Customers [Member] | |||||||||||
DSM (related party) | 40,148 | 18,341 | 21,389 | ||||||||
Renewable Products [Member] | |||||||||||
DSM (related party) | 42,370 | 25,510 | 14,506 | ||||||||
Renewable Products [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | 21,678 | 15,896 | 1,425 | ||||||||
Renewable Products [Member] | DSM International B.V. [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | |||||||||||
Renewable Products [Member] | Firmenich [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | 9,621 | 9,660 | 1,425 | ||||||||
Renewable Products [Member] | Nenter & Co., Inc. [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | 12,057 | 6,236 | |||||||||
Renewable Products [Member] | DARPA [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | |||||||||||
Renewable Products [Member] | Ginkgo Bioworks, Inc. [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | |||||||||||
Renewable Products [Member] | All Other Customers [Member] | |||||||||||
DSM (related party) | 20,692 | 9,614 | 13,081 | ||||||||
Licenses and Royalties [Member] | |||||||||||
DSM (related party) | 64,477 | 15,839 | 390 | ||||||||
Licenses and Royalties [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | 61,804 | 15,745 | 259 | ||||||||
Licenses and Royalties [Member] | DSM International B.V. [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | 57,972 | ||||||||||
Licenses and Royalties [Member] | Firmenich [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | 1,199 | 745 | 259 | ||||||||
Licenses and Royalties [Member] | Nenter & Co., Inc. [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | 2,633 | ||||||||||
Licenses and Royalties [Member] | DARPA [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | |||||||||||
Licenses and Royalties [Member] | Ginkgo Bioworks, Inc. [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | 15,000 | ||||||||||
Licenses and Royalties [Member] | All Other Customers [Member] | |||||||||||
DSM (related party) | 2,673 | 94 | 131 | ||||||||
Grants and Collaborations [Member] | |||||||||||
DSM (related party) | 36,598 | 25,843 | 19,257 | ||||||||
Grants and Collaborations [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | 19,815 | 17,210 | 11,080 | ||||||||
Grants and Collaborations [Member] | DSM International B.V. [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | 1,679 | ||||||||||
Grants and Collaborations [Member] | Firmenich [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | 5,803 | 7,513 | 11,000 | ||||||||
Grants and Collaborations [Member] | Nenter & Co., Inc. [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | |||||||||||
Grants and Collaborations [Member] | DARPA [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | 12,333 | 9,697 | 80 | ||||||||
Grants and Collaborations [Member] | Ginkgo Bioworks, Inc. [Member] | Significant Revenue Agreement [Member] | |||||||||||
DSM (related party) | |||||||||||
Grants and Collaborations [Member] | All Other Customers [Member] | |||||||||||
DSM (related party) | $ 16,783 | $ 8,633 | $ 8,177 |
Note 11 - Related Party Trans74
Note 11 - Related Party Transactions (Details Textual) - USD ($) | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Derivative Liability | $ 119,978,000 | $ 7,478,000 | |
Derivative, Gain (Loss) on Derivative, Net | 26,700,000 | ||
Research and Development Expense | 56,956,000 | 51,412,000 | $ 44,636,000 |
Accounts Receivable, Related Parties | 14,668,000 | 805,000 | |
Operating Leases, Rent Expense, Sublease Rentals | 500,000 | 400,000 | 700,000 |
Operating Leases, Rent Expense, Net | 400,000 | ||
Related Party Convertible Notes [Member] | |||
Derivative Liability | 200,000 | 800,000 | |
Derivative, Gain (Loss) on Derivative, Net | 600,000 | 7,600,000 | 10,500,000 |
Total [Member] | |||
Accounts Receivable, Related Parties | 238,000 | 805,000 | |
Total [Member] | Pilot Plant Agreements [Member] | |||
Related Party Transaction, Amounts of Transaction | 400,000 | 400,000 | 900,000 |
Research and Development Expense | 800,000 | $ 900,000 | |
Accounts Receivable, Related Parties | $ 1,400,000 | $ 2,200,000 |
Note 11 - Related Party Trans75
Note 11 - Related Party Transactions - Related Party Debt (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Related party debt, gross | $ 195,819 | $ 269,578 |
Unamortized debt (discount) premium | (30,442) | (42,535) |
Due to related parties, net | 165,377 | 227,043 |
Unaccreted Debt (Discount) Premium | (30,442) | (42,535) |
Related Party Debt [Member] | ||
Related party debt, gross | 77,509 | 79,186 |
Unamortized debt (discount) premium | (10,944) | (6,736) |
Due to related parties, net | 66,565 | 72,450 |
Unaccreted Debt (Discount) Premium | (10,944) | (6,736) |
Related Party Debt [Member] | Total [Member] | ||
Related party debt, gross | 35,116 | 33,186 |
Unamortized debt (discount) premium | (659) | (1,033) |
Due to related parties, net | 34,457 | 32,153 |
Unaccreted Debt (Discount) Premium | (659) | (1,033) |
Related Party Debt [Member] | DSM International B.V. [Member] | ||
Related party debt, gross | 25,393 | |
Unamortized debt (discount) premium | (8,039) | |
Due to related parties, net | 17,354 | |
Unaccreted Debt (Discount) Premium | (8,039) | |
Related Party Debt [Member] | Foris Ventures, LLC [Member] | ||
Related party debt, gross | 5,000 | 32,000 |
Unamortized debt (discount) premium | (660) | (2,363) |
Due to related parties, net | 4,340 | 29,637 |
Unaccreted Debt (Discount) Premium | (660) | (2,363) |
Related Party Debt [Member] | R&D Note [Member] | Total [Member] | ||
Related party debt, gross | 3,700 | 3,700 |
Unamortized debt (discount) premium | (18) | (80) |
Due to related parties, net | 3,682 | 3,620 |
Unaccreted Debt (Discount) Premium | (18) | (80) |
Related Party Debt [Member] | August 2013 Convertible Notes [Member] | Total [Member] | ||
Related party debt, gross | 21,711 | 19,781 |
Unamortized debt (discount) premium | 897 | 2,033 |
Due to related parties, net | 22,608 | 21,814 |
Unaccreted Debt (Discount) Premium | 897 | 2,033 |
Related Party Debt [Member] | The 2014 144A Notes [Member] | Total [Member] | ||
Related party debt, gross | 9,705 | 9,705 |
Unamortized debt (discount) premium | (1,538) | (2,986) |
Due to related parties, net | 8,167 | 6,719 |
Unaccreted Debt (Discount) Premium | (1,538) | (2,986) |
Related Party Debt [Member] | DSM Note [Member] | ||
Due to related parties, net | ||
Related Party Debt [Member] | DSM Note [Member] | DSM International B.V. [Member] | ||
Related party debt, gross | 25,000 | |
Unamortized debt (discount) premium | (8,039) | |
Due to related parties, net | 16,961 | |
Unaccreted Debt (Discount) Premium | (8,039) | |
Related Party Debt [Member] | Other Loans Payable [Member] | DSM International B.V. [Member] | ||
Related party debt, gross | 393 | |
Unamortized debt (discount) premium | ||
Due to related parties, net | 393 | |
Unaccreted Debt (Discount) Premium | ||
Related Party Debt [Member] | Private Placement February 2016 [Member] | Biolding Investment SA [Member] | ||
Related party debt, gross | 2,000 | 2,000 |
Unamortized debt (discount) premium | (131) | |
Due to related parties, net | 2,000 | 1,869 |
Unaccreted Debt (Discount) Premium | (131) | |
Related Party Debt [Member] | Private Placement February 2016 [Member] | Foris Ventures, LLC [Member] | ||
Related party debt, gross | 16,000 | |
Unamortized debt (discount) premium | (1,047) | |
Due to related parties, net | 14,953 | |
Unaccreted Debt (Discount) Premium | (1,047) | |
Related Party Debt [Member] | Private Placement February 2016 [Member] | Naxyris S.A. [Member] | ||
Related party debt, gross | 2,000 | |
Unamortized debt (discount) premium | (131) | |
Due to related parties, net | 1,869 | |
Unaccreted Debt (Discount) Premium | (131) | |
Related Party Debt [Member] | Related Party 2014 144A Convertible Notes [Member] | Foris Ventures, LLC [Member] | ||
Related party debt, gross | 5,000 | 5,000 |
Unamortized debt (discount) premium | (660) | (1,316) |
Due to related parties, net | 4,340 | 3,684 |
Unaccreted Debt (Discount) Premium | (660) | (1,316) |
Related Party Debt [Member] | Related Party 2014 144A Convertible Notes [Member] | Temasek [Member] | ||
Related party debt, gross | 10,000 | 10,000 |
Unamortized debt (discount) premium | (1,586) | (3,078) |
Due to related parties, net | 8,414 | 6,922 |
Unaccreted Debt (Discount) Premium | (1,586) | (3,078) |
Related Party Debt [Member] | Loans Payable, June and October 2016 Private Placements [Member] | Foris Ventures, LLC [Member] | ||
Related party debt, gross | 11,000 | |
Unamortized debt (discount) premium | ||
Due to related parties, net | 11,000 | |
Unaccreted Debt (Discount) Premium |
Note 11 - Related Party Trans76
Note 11 - Related Party Transactions - Related Party Revenues (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
DSM (related party) | $ 80,588 | $ 24,197 | $ 25,680 | $ 12,980 | $ 22,238 | $ 26,544 | $ 9,599 | $ 8,811 | $ 143,445 | $ 67,192 | $ 34,153 |
Customers Other Than Related Parties [Member] | |||||||||||
DSM (related party) | 82,503 | 65,630 | 33,288 | ||||||||
DSM International B.V. [Member] | |||||||||||
DSM (related party) | 59,651 | ||||||||||
Novvi LLC [Member] | |||||||||||
DSM (related party) | 1,491 | 1,390 | |||||||||
Total [Member] | |||||||||||
DSM (related party) | (200) | 172 | 865 | ||||||||
Related Parties [Member] | |||||||||||
DSM (related party) | 60,942 | 1,562 | 865 | ||||||||
Renewable Products [Member] | |||||||||||
DSM (related party) | 42,370 | 25,510 | 14,506 | ||||||||
Renewable Products [Member] | Customers Other Than Related Parties [Member] | |||||||||||
DSM (related party) | 41,079 | 23,948 | 13,641 | ||||||||
Renewable Products [Member] | DSM International B.V. [Member] | |||||||||||
DSM (related party) | |||||||||||
Renewable Products [Member] | Novvi LLC [Member] | |||||||||||
DSM (related party) | 1,491 | 1,390 | |||||||||
Renewable Products [Member] | Total [Member] | |||||||||||
DSM (related party) | (200) | 172 | 865 | ||||||||
Renewable Products [Member] | Related Parties [Member] | |||||||||||
DSM (related party) | 1,291 | 1,562 | 865 | ||||||||
Licenses and Royalties [Member] | |||||||||||
DSM (related party) | 64,477 | 15,839 | 390 | ||||||||
Licenses and Royalties [Member] | Customers Other Than Related Parties [Member] | |||||||||||
DSM (related party) | 6,505 | 15,839 | 390 | ||||||||
Licenses and Royalties [Member] | DSM International B.V. [Member] | |||||||||||
DSM (related party) | 57,972 | ||||||||||
Licenses and Royalties [Member] | Novvi LLC [Member] | |||||||||||
DSM (related party) | |||||||||||
Licenses and Royalties [Member] | Total [Member] | |||||||||||
DSM (related party) | |||||||||||
Licenses and Royalties [Member] | Related Parties [Member] | |||||||||||
DSM (related party) | 57,972 | ||||||||||
Grants and Collaborations [Member] | |||||||||||
DSM (related party) | 36,598 | 25,843 | 19,257 | ||||||||
Grants and Collaborations [Member] | Customers Other Than Related Parties [Member] | |||||||||||
DSM (related party) | 34,919 | 25,843 | 19,257 | ||||||||
Grants and Collaborations [Member] | DSM International B.V. [Member] | |||||||||||
DSM (related party) | 1,679 | ||||||||||
Grants and Collaborations [Member] | Novvi LLC [Member] | |||||||||||
DSM (related party) | |||||||||||
Grants and Collaborations [Member] | Total [Member] | |||||||||||
DSM (related party) | |||||||||||
Grants and Collaborations [Member] | Related Parties [Member] | |||||||||||
DSM (related party) | $ 1,679 |
Note 11 - Related Party Trans77
Note 11 - Related Party Transactions - Related Party Accounts Receivable (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Related party accounts receivable, net | $ 14,668 | $ 805 |
DSM International B.V. [Member] | ||
Related party accounts receivable, net | 12,823 | |
Novvi LLC [Member] | ||
Related party accounts receivable, net | 1,607 | |
Total [Member] | ||
Related party accounts receivable, net | $ 238 | $ 805 |
Note 12 - Stock-based Compens78
Note 12 - Stock-based Compensation (Details Textual) - USD ($) | Sep. 28, 2010 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2005 |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 12 years | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | 1,338,367 | 875,021 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ 33.40 | $ 55.20 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $ 0 | $ 0 | $ 0 | ||
Allocated Share-based Compensation Expense | $ 6,265,000 | 7,325,000 | 9,134,000 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | |||||
Employee Stock Option [Member] | |||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 2 years 182 days | ||||
Allocated Share-based Compensation Expense | $ 3,300,000 | 3,500,000 | $ 6,000,000 | ||
Restricted Stock Units (RSUs) [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 523,167 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $ 523,167 | $ 326,523 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 5.51 | $ 9.15 | $ 27.30 | ||
Allocated Share-based Compensation Expense | $ 2,800,000 | $ 3,600,000 | $ 2,800,000 | ||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $ 5,000,000 | $ 5,400,000 | |||
Equity Incentive Plan, 2010 [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 2,000,000 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Period Available to Grant | 10 years | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Execrise Price to Fair Market Value on Grant Date | 100.00% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Shareholder Triggering Higher Exercise Price | 10.00% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Execrise Price to Fair Market Value on Grant Date of Ten Percent or Greater Shareholder of Company | 110.00% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | 1,255,045 | 770,761 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ 26.29 | $ 45.76 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 252,107 | 552,392 | |||
Equity Incentive Plan, 2010 [Member] | Restricted Stock [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 683,554 | 454,923 | |||
Equity Incentive Plan, 2010 [Member] | Minimum [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 4 years | ||||
Equity Incentive Plan, 2010 [Member] | Maximum [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 5 years | ||||
Stock Options and Stock Issuance Plans, 2005 [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Period Available to Grant | 10 years | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Execrise Price to Fair Market Value on Grant Date | 100.00% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Shareholder Triggering Higher Exercise Price | 10.00% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Execrise Price to Fair Market Value on Grant Date of Ten Percent or Greater Shareholder of Company | 110.00% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 5 years | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | 79,322 | 100,260 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ 144.58 | $ 127.58 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 0 | 0 | |||
Employee Stock Purchase Plan, 2010 [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 666,666 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 11,241 | 80,594 | 127,669 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | 85.00% | ||||
Shares Available for Issuance, Percentage of Total Outstanding Shares | 1.00% | ||||
Allocated Share-based Compensation Expense | $ 100,000 | $ 100,000 | $ 300,000 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 47,045 | 22,405 |
Note 12 - Stock-based Compens79
Note 12 - Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Allocated share-based compensation expense | $ 6,265 | $ 7,325 | $ 9,134 |
Research and Development Expense [Member] | |||
Allocated share-based compensation expense | 2,204 | 1,948 | 2,306 |
Selling, General and Administrative Expenses [Member] | |||
Allocated share-based compensation expense | $ 4,061 | $ 5,377 | $ 6,828 |
Note 12 - Stock-based Compens80
Note 12 - Stock-based Compensation - Options Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Options granted (in shares) | 661,094 | 239,012 | 314,686 |
Weighted-average grant-date fair value per share (in dollars per share) | $ 3.26 | $ 8.85 | $ 18.15 |
Allocated share-based compensation expense | $ 6,265 | $ 7,325 | $ 9,134 |
Unrecognized compensation costs as of December 31 (in millions) | 2,700 | 4,400 | 8,000 |
Employee Stock Option [Member] | |||
Allocated share-based compensation expense | $ 3,300 | $ 3,500 | $ 6,000 |
Note 12 - Stock-based Compens81
Note 12 - Stock-based Compensation - Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - Employee Stock Option [Member] | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Expected dividend yield | |||
Risk-free interest rate | 2.10% | 1.40% | 1.80% |
Expected term (in years) (Year) | 6 years 43 days | 6 years 58 days | 6 years 29 days |
Expected volatility | 84.00% | 73.00% | 74.00% |
Note 12 - Stock-based Compens82
Note 12 - Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Outstanding (in shares) | 875,021 | ||
Outstanding, weighted average exercise price (in dollars per share) | $ 55.20 | ||
Outstanding, weighted average remaining contractual life (Year) | 7 years 259 days | 6 years 255 days | |
Outstanding, aggregate intrinsic value | $ 97 | $ 443 | |
Options granted (in shares) | 661,094 | 239,012 | 314,686 |
Options granted, weighted average exercise price (in dollars per share) | $ 4.56 | ||
Options exercised (in shares) | |||
Options exercised, weighted average exercise price (in dollars per share) | |||
Options forfeited or expired (in shares) | (197,748) | ||
Options forfeited or expired (in dollars per share) | $ 33.46 | ||
Outstanding (in shares) | 1,338,367 | 875,021 | |
Outstanding, weighted average exercise price (in dollars per share) | $ 33.40 | $ 55.20 | |
Vested or expected to vest after December 31, 2017 (in shares) | 1,257,439 | ||
Vested and expected to vest after December 31, 2016, weighted average exercise price (in dollars per share) | $ 33.40 | ||
Vested and expected to vest after December 31, 2016, weighted average remaining contractual life (Year) | 7 years 226 days | ||
Vested and expected to vest after December 31, 2016, aggregate intrinsic value | $ 81 | ||
Exercisable at December 31, 2017 (in shares) | 925,778 | ||
Exercisable at December 31, 2016, weighted average exercise price (in dollars per share) | $ 43.48 | ||
Exercisable at December 31, 2016, weighted average remaining contractual life (Year) | 7 years 65 days | ||
Exercisable at December 31, 2016, aggregate intrinsic value | $ 27 |
Note 12 - Stock-based Compens83
Note 12 - Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Outstanding, RSUs (in shares) | 454,923 | ||
Outstanding, weighted average grant-date fair value (in dollars per share) | $ 17.48 | ||
Outstanding, weighted average remaining contractual life (Year) | 1 year 146 days | 1 year 146 days | |
Awarded (in shares) | 523,167 | ||
Awarded (in dollars per share) | $ 5.51 | $ 9.15 | $ 27.30 |
Vested (in shares) | (191,844) | ||
Vested (in dollars per share) | $ 18.71 | ||
Forfeited (in shares) | (102,692) | ||
Forfeited (in dollars per share) | $ 13 | ||
Outstanding, RSUs (in shares) | 683,554 | 454,923 | |
Outstanding, weighted average grant-date fair value (in dollars per share) | $ 8.66 | $ 17.48 | |
Vested or expected to vest after December 31, 2017 (in shares) | 533,670 | ||
Vested or expected to vest after December 31, 2017 (in dollars per share) | $ 8.92 | ||
Vested or expected to vest after December 31, 2017 (Year) | 1 year 109 days |
Note 13 - Divestiture (Details
Note 13 - Divestiture (Details Textual) - USD ($) | Dec. 28, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal | $ 5,732,000 | |||
DSM International B.V. [Member] | ||||
Licenses Revenue | 57,300,000 | |||
Deferred Revenue | 2,100,000 | |||
DSM Credit Agreement [Member] | ||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 25,000,000 | $ 25,000,000 | ||
DSM [Member] | ||||
Disposal Group, Including Discontinued Operation, Consideration | 17,800,000 | |||
License and Services Revenue | 27,500,000 | |||
Royalty Revenue | 15,000,000 | |||
Line of Credit Facility, Maximum Borrowing Capacity | 25,000,000 | |||
Amyris Brasil [Member] | ||||
Disposal Group, Including Discontinued Operation, Consideration | 56,900,000 | |||
Repayments of Debt | 12,600,000 | |||
Divestiture of Business, Consideration Transferred | 56,900,000 | |||
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal | 5,700,000 | |||
Amyris Brasil [Member] | Disposal Group, Not Discontinued Operations [Member] | ||||
Disposal Group, Including Discontinued Operation, Consideration | 33,000,000 | |||
Repayments of Debt | $ 12,600,000 |
Note 14 - Goodwill (Details Tex
Note 14 - Goodwill (Details Textual) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Goodwill | $ 560 | $ 560 |
Other Assets [Member] | ||
Goodwill | $ 600 | $ 600 |
Note 15 - Income Taxes (Details
Note 15 - Income Taxes (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | ||||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | $ 291,000 | $ 26,700 | $ 47,900 | ||
Deferred Tax Assets, Gross | $ 102,519 | $ 398,803 | $ 364,591 | ||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 34.00% | 34.00% | 34.00% | ||
Provisional Amount Due to Remeasurement of Deferred Tax Assets and Liabilities, Before Valuation Allowance | $ 37,700 | ||||
Unrecognized Tax Benefits | 17,180 | $ 9,101 | $ 8,634 | $ 17,081 | |
Unrecognized Tax Benefits, Decrease Resulting from IRC Section 382 Limitation | 120,000 | ||||
Remeasurement of Deferred Tax Assets Liabilities [Member] | |||||
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | (43,600) | ||||
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | |||||
Operating Loss Carryforwards | $ 136,500 | ||||
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Earliest Tax Year [Member] | |||||
Open Tax Year | 2,005 | ||||
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | |||||
Tax Credit Carryforward, Write-offs | $ 14,200 | ||||
Tax Credit Carryforward, Amount | 700 | ||||
State and Local Jurisdiction [Member] | |||||
Operating Loss Carryforwards | 111,700 | ||||
State and Local Jurisdiction [Member] | California Franchise Tax Board [Member] | Research Tax Credit Carryforward [Member] | |||||
Tax Credit Carryforward, Amount | $ 12,700 | ||||
Foreign Tax Authority [Member] | Secretariat of the Federal Revenue Bureau of Brazil [Member] | Earliest Tax Year [Member] | |||||
Open Tax Year | 2,010 | ||||
Scenario, Forecast [Member] | |||||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21.00% | ||||
Accounting Standards Update 2016-09 [Member] | |||||
Deferred Tax Assets, Gross | $ 40,100 |
Note 15 - Income Taxes - Compon
Note 15 - Income Taxes - Components of Income Loss (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
United States | $ (68,777) | $ (101,210) | $ (188,943) |
Foreign | (3,257) | 4,429 | (24,457) |
Loss before income taxes and loss from investments in affiliates | $ (72,034) | $ (96,781) | $ (213,400) |
Note 15 - Income Taxes - Comp88
Note 15 - Income Taxes - Components of Benefit (Provision) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Current: | |||
Federal | |||
State | |||
Foreign | 964 | 553 | 468 |
Total current provision | 964 | 553 | 468 |
Deferred: | |||
Federal | (669) | ||
State | |||
Foreign | |||
Total deferred provision (benefit) | (669) | ||
Total provision for income taxes | $ 295 | $ 553 | $ 468 |
Note 15 - Income Taxes - Effect
Note 15 - Income Taxes - Effective Tax Rate Reconciliation (Details) | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Statutory tax rate | (34.00%) | (34.00%) | (34.00%) |
State taxes, net of federal tax benefit | (0.30%) | ||
Stock-based compensation | 0.10% | 0.10% | |
Federal R&D credit | (1.00%) | (0.80%) | (0.60%) |
Derivative liabilities | 1.70% | 1.40% | 3.60% |
Nondeductible interest | 6.20% | 5.00% | 5.50% |
Other | (0.40%) | (3.20%) | 0.10% |
Foreign losses | 17.60% | 0.50% | (1.20%) |
Change in U.S. federal tax rate | 57.00% | ||
IRC Section 382 limitation | 5.00% | ||
Change in valuation allowance | (51.90%) | 31.70% | 27.10% |
Effective income tax rate | 0.30% | 0.60% | 0.30% |
Note 15 - Income Taxes - Deferr
Note 15 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Net operating loss carryforwards | $ 23,877 | $ 236,741 | $ 207,241 |
Property, plant and equipment | 4,195 | 12,917 | 10,519 |
Research and development credits | 10,702 | 17,348 | 16,612 |
Foreign tax credit | 2,669 | 2,452 | 1,899 |
Accruals and reserves | 10,754 | 30,303 | 26,366 |
Stock-based compensation | 11,417 | 17,184 | 19,048 |
Capitalized start-up costs | 9,182 | 9,568 | |
Capitalized research and development costs | 34,973 | 65,962 | 63,339 |
Intangible and others | 3,932 | 6,714 | 9,999 |
Total deferred tax assets | 102,519 | 398,803 | 364,591 |
Debt discount and derivative | (6,616) | (11,936) | (4,402) |
Total deferred tax liabilities | (6,616) | (11,936) | (4,402) |
Net deferred tax assets prior to valuation allowance | 95,903 | 386,867 | 360,189 |
Less: valuation allowance | (95,903) | (386,867) | (360,189) |
Net deferred tax assets |
Note 15 - Income Taxes - Uncert
Note 15 - Income Taxes - Uncertain Tax Benefits (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Balance | $ 9,101 | $ 8,634 | $ 17,081 |
Decreases in tax positions for prior period | (50) | (314) | (9,404) |
Increases in tax positions during current period | 8,029 | 781 | 957 |
Increases in tax positions for prior period | 50 | 314 | 9,404 |
Balance | $ 17,180 | $ 9,101 | $ 8,634 |
Note 16 - Geographical Inform92
Note 16 - Geographical Information - Revenues by Geography (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Revenues | $ 80,588 | $ 24,197 | $ 25,680 | $ 12,980 | $ 22,238 | $ 26,544 | $ 9,599 | $ 8,811 | $ 143,445 | $ 67,192 | $ 34,153 |
UNITED STATES | |||||||||||
Revenues | 94,060 | 30,942 | 7,122 | ||||||||
Europe [Member] | |||||||||||
Revenues | 23,823 | 23,612 | 16,049 | ||||||||
Asia [Member] | |||||||||||
Revenues | 23,290 | 12,055 | 5,907 | ||||||||
BRAZIL | |||||||||||
Revenues | 2,159 | 488 | 5,004 | ||||||||
Other Area [Member] | |||||||||||
Revenues | $ 113 | $ 95 | $ 71 |
Note 16 - Geographical Inform93
Note 16 - Geographical Information - Long-lived Assets by Geography (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Long-Lived Assets | $ 13,892 | $ 53,735 | $ 59,797 |
UNITED STATES | |||
Long-Lived Assets | 10,357 | 9,342 | 18,401 |
BRAZIL | |||
Long-Lived Assets | 3,357 | 44,153 | 41,093 |
Europe [Member] | |||
Long-Lived Assets | $ 178 | $ 240 | $ 303 |
Note 17 - Quarterly Results o94
Note 17 - Quarterly Results of Operations Data (Unaudited)* - Quarterly Results of Operations Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Renewable products (includes related party revenue of $1,291, $1,562 and $865, respectively) | $ 13,445 | $ 10,996 | $ 9,892 | $ 8,037 | $ 11,215 | $ 6,619 | $ 4,711 | $ 2,965 | $ 42,370 | $ 25,510 | $ 14,506 |
Licenses and royalties (includes related party revenue of $57,972, $0 and $0, respectively) | 57,703 | 1,022 | 5,497 | 255 | 252 | 15,201 | 211 | 175 | 64,477 | 15,839 | 390 |
Grants and collaborations (includes related party revenue of $1,679, $0 and $0, respectively) | 9,440 | 12,179 | 10,291 | 4,688 | 10,771 | 4,724 | 4,677 | 5,671 | 36,598 | 25,843 | 19,257 |
Total revenue | 80,588 | 24,197 | 25,680 | 12,980 | 22,238 | 26,544 | 9,599 | 8,811 | 143,445 | 67,192 | 34,153 |
Gross profit (loss) from product sales | (1,584) | (6,641) | (7,387) | (4,731) | (11,290) | (8,056) | (2,969) | (8,038) | |||
Net loss | (1,717) | (33,861) | 620 | (37,371) | (48,755) | (19,705) | (13,566) | (15,308) | (72,329) | (97,334) | (218,052) |
For basic loss per share | (2,914) | (42,819) | (10,265) | (37,371) | (48,755) | (19,705) | (13,566) | (15,308) | (93,369) | (97,334) | (217,952) |
For diluted loss per share | $ (2,914) | $ (42,819) | $ (10,265) | $ (37,371) | $ (48,755) | $ (19,705) | $ (29,245) | $ (30,273) | $ (93,369) | $ (115,647) | $ (221,777) |
Basic (in dollars per share) | $ (0.06) | $ (1.14) | $ (0.44) | $ (1.93) | $ (2.67) | $ (1.19) | $ (0.91) | $ (1.11) | $ (2.89) | $ (6.12) | $ (26.20) |
Diluted (in dollars per share) | $ (0.06) | $ (1.14) | $ (0.44) | $ (1.93) | $ (2.67) | $ (1.19) | $ (1.67) | $ (1.74) | $ (2.89) | $ (6.55) | $ (26.20) |
Basic (in shares) | 47,895,238 | 37,529,694 | 23,155,874 | 19,335,948 | 18,227,100 | 16,612,690 | 14,874,135 | 13,813,305 | 32,253,570 | 15,896,014 | 8,464,106 |
Diluted (in shares) | 47,895,238 | 37,529,694 | 23,155,874 | 19,335,948 | 18,227,100 | 16,612,690 | 17,526,410 | 17,395,474 | 32,253,570 | 17,642,965 | 8,464,106 |
Note 18 - Subsequent Events (De
Note 18 - Subsequent Events (Details Textual) - USD ($) | May 31, 2018 | Apr. 12, 2018 | Mar. 31, 2018 | Jan. 31, 2018 | May 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Class of Warrants or Right, Issued in Period | 30,689,080 | |||||||
Proceeds from Warrant Exercises | $ 5,000,000 | $ 285,000 | ||||||
May 2017 Warrants [Member] | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 4.40 | |||||||
Class of Warrant or Right, Term | 5 years | |||||||
Subsequent Event [Member] | May 2017 Warrants [Member] | ||||||||
Class of Warrants or Right, Issued in Period | 3,616,174 | |||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 7 | |||||||
Class of Warrant or Right, Term | 1 year 90 days | |||||||
Proceeds from Warrant Exercises | $ 15,900,000 | |||||||
Stegodon [Member] | Loan and Security Agreement [Member] | Subsequent Event [Member] | ||||||||
Repayments of Lines of Credit | $ 1,300,000 | |||||||
Scenario, Forecast [Member] | Stegodon [Member] | Loan and Security Agreement [Member] | ||||||||
Repayments of Lines of Credit | $ 5,500,000 | $ 5,500,000 | ||||||
Debt Instrument, Interest Rate, Increase (Decrease) | 5.00% |
Schedule II - Valuation and Q96
Schedule II - Valuation and Qualifying Accounts - Schedule II Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Valuation Allowance of Deferred Tax Assets [Member] | |||
Balance at Beginning of Period | $ 386,867 | $ 360,189 | $ 312,323 |
Additions | 13,567 | 26,678 | 47,866 |
Write-off Adjustments | (294,877) | ||
Balance at End of Period | 105,557 | 386,867 | 360,189 |
Allowance for Doubtful Accounts [Member] | |||
Balance at Beginning of Period | 501 | 969 | 479 |
Additions | 141 | 490 | |
Write-off Adjustments | (468) | ||
Balance at End of Period | $ 642 | $ 501 | $ 969 |